First International Convention IMMUNOPHARMACOLOGY - VACCIPHARMA 2015 III International Congress on Immunopharmacology (IMMUNOPHARMACOLOGY 2015) III International Congress on Pharmacology of Vaccines (VACCIPHARMA 2015) SCIENTIFIC PROGRAM Cuban Society of Pharmacology Meliá Marina Varadero, Varadero Beach, Cuba June 14-19, 2015 http://www .imm uno vaccipharmacuba.com http://www.imm .immuno unov The International Union of Basic and Clinical Pharmacology (IUPHAR), The IUPHAR Section of Immunopharmacology and the Cuban Society of Pharmacology are organizing the First International Convention IMMUNOPHARMACOLOGY–VACCIPHARMA 2015, scheduled for June 14-19, 2015 at the Meliá Marina Varadero Hotel, in Varadero beach, Cuba. This Convention is the fusion of the 3rd International Congress on Immunopharmacology (IMMUNOPHARMACOLOGY 2015) and the 3rd International Congress on Pharmacology of Vaccines (VACCIPHARMA 2015) The key objectives of the Convention are: ♦ To provide a progressive state-of-the-art report for scientists, manufacturers, regulators and healthcare workers in the fields of immunological research and the development and research on vaccines. ♦ To promote the experience exchange, the presentation of results and the discussion on topics related with the activities scheduled, as well as creating a suitable framework for collaboration. ♦ To contribute to the acceptance of new products, methods and technologies. Convention Organizers Main Organizers: International Union of Basic and Clinical Pharmacology (IUPHAR) IUPHAR Section of Immunopharmacology Latin-American Association of Pharmacology (ALF) Cuban Society of Pharmacology (SCF) Local co-organizers: Cuban National Council of Health Scientific Societies Cuban Society of Parasitology and Microbiology Finlay Institute Centre for Genetic Engineering and Biotechnology (CIGB) Centre of Molecular Immunology (CIM) International Center for Neurological Restoration (CIREN) Finlay Editions State Centre for Control of Drugs, Equipment and Medical Devices (CECMED) LABIOFAM Tropical Medicine Institute (IPK) CIDEM CEBIMAR CENSA BioCEN Centre for the Research and Rehabilitation of Hereditary Ataxias (CIRAH) Convention sponsors: Pan-American Health Organization (PAHO) PNUD IBRO ROCHE MERCK SARTORIUS RS-IMEX IBS SEPPIC BDC ABIVAX NUOVA OMPI KARL STORZ IBADECAM BRAUN DIAGNOVUM BLANC-LABO COPA AIRLINES CONFITERÍA Y DERIVADOS DE LA HARINA Or ganizing Committee Org President: Mario Landys Chovel Cuervo Finlay Institute / SCF Silvio E. Perea CIGB Idania Rodeiro CEBIMAR Reinaldo Acevedo Finlay Institute Ana María Vázquez CIM Néstor Expósito CIGB Ana María Hernández CIM Miladys Limonta CIGB Daniel Cardoso Finlay Institute Giset Jiménez CECMED Mabel Izquierdo CIGB René Delgado CIDEM/President, SCF María de los Ángeles Robinson CIREN Rolando Ochoa Finlay Institute Diadelis Remírez CECMED Eduardo Martínez CIGB Adamelis Avilés CECMED Luis García Finlay Institute Nadine Álvarez Finlay Institute Gillian Martínez CIGB Yanet Hechavarría CECMED Carmen Portuondo CECMED Sonia Resik IPK Giselle Pentón CIGB Shirley González LABIOFAM María Cristina Lara MINSAP Lizet Gil IPK Vilcy Reyes CIGB Liván Delgado CEBIMAR Dionisio Zaldívar BIOMAT Nely Rodríguez Zhurbenko CIM Narjara González CIM Vivian Kourí IPK Roberto Rodríguez CIRAH Beatriz Garrido CIDEM Alexis Labrada BioCEN Indira Utria CQB Scientif ic Ad visor y Committee Scientific Advisor visory Presidents: Silvio E. Perea (CIGB) and Deybis Orta (CECMED ) Agustín Lage CIM, Cuba Angus Dagleish John Hopkins Hospital, UK Francesca Levi-Schaffer The Hebrew University of Jerusalem, Israel Dorothea Sesardic NIBSC, UK Coenraad Hendriksen Intravacc, The Netherlands Micheline Piquette Toronto University, Canada Gustavo Sierra OSDE, Cuba Luis Herrera CIGB, Cuba Rafael Pérez Cristiá CECMED, Cuba Rolando Ochoa Finlay Institute, Cuba Ali Harandi University of Gottemnburg, Sweden Adrian Llerena Extremadura University, Spain Idania Rodeiro CEBIMAR, Cuba Dr. Uwe Gottschalk Sartorius Stedim Biotech, Germany John Hiscott McGill University, Montreal, Canada Wilson Savino International Society of Neuroimmunomodulation (ISNIM), Brazil Liliana Francis Turner, Tolima University, Colombia Dario Siniscalco University of Naples, Italy Hartmut Wekerle ISNI, Germany Carlos Alberto Gonçalvez UFRGS, Bra zil Gianvito Martino Italy Rachel Tyndale Canada Valerie A. Ferro University of Strahclyde, Scotland, UK Bruce Levy Harvard Medical School, USA Alberto Mantovani Institute Mario Neri, Milán, Italy Jorge Pérez IPK, Cuba Herve Bercovier Hebrew University of Jerusalem, Israel María Guadalupe Guzmán IPK, Cuba Vicente Vérez CQB, Cuba Rino Rappuoli Novartis, Italy José Vicente Castell Spain Javier Espinosa UNAM , Mexico Carlo Riccardi University of Perugia, Italy Mauro Teixeira University of Minas Gerais, Brazil Luis Velázquez Pérez CIRAH, Cuba Christopher Gomez University of Chicago, USA Ray Borrow UK Einar Rosenqvist NIPH, Norway Abraham Assefa AHRI, Ethiopia IMMUNOPHARMACOLOGY - VACCIPHARMA 2015 GENERAL PROGRAM / IMMUNOVACCIPHARMA 2015 Day / Hour Sunday 14 / 09:00-14:00 Sunday 14 / 18:00-20:00 Monday 15 / 09:00-13:00 Monday 15 / 15:00-18:00 Tuesday 16 / 09:00-13:00 Tuesday 16 / 15:00-18:00 Wednesday 17 / 09:00-13:00 Wednesday 17 / 15:00-18:00 Room 1 Room 2 Room 3 Room 4 Room 5 Room 6 Room 7 Registration Opening Ceremony and Plenary Lectures WIP VPL SCP WNI SK SIP WIP SMV SCP WNI STBV SVetV WIP SMV WTV (1) WNI SAT SBP WIP SEV SCV (1) WNI SCTO SPNV WRS WHIV SAT SBP SPNV (RT) WRS SCV (3) CPS SBP SHA SBP Wednesday 17 / 15:00-17:00 Poster presentations (Vaccines, Bioproc esses, Veterinary, AIDS and Regulatory System) / Commercial Fair Thursday 18 / 09:00-13:00 WTV (2) (Ca ncer) Poster presentations (Immunopharmacology, Pharmacology of Cytochrome P 450 , Neuroimmunology, Kinases, Inflammation and Pain , Atherosclerosis, Clinical and Translational Oncology, Hereditary Ataxias ) / Commercial Fair Thursday 18 / 15:00-17:00 Thursday 18 / 18:00-19:30 Thursday 18 / 20:00-01:00 Friday 19 / 9:00-12:00 SCTO SVV SCV (2) Closing Ceremony Dinner and Farewell Party Exchanging among delegates Legend: WIP: Workshop Immunopharmacology; SCTO:Symposium Clinical and Translational Oncology; VPL: Vaccine Plenary Lectures; SMV: Symposium Meningococcal Vaccines; SEV: Symposium Enteric Vaccines SPNV: Symposium Pneumococcal Vaccines; SVV: Symposium Viral Vaccines; SCP: Symposium Pharmacology of Cytochrome P 450, Transporters and OMICS; WTV: Workshop Therapeutic Vaccines (1. Infectious diseases); SCV: Symposium Combined Vaccines (1. Polio Vaccines); WRS: Workshop Regulatory System; SVC: Symposium Combined Vaccines (2. Pertussis Vaccines); WNI: Workshop Neuroimmunology; WVIH: Workshop VIH-AIDS; SCV: Symposium Combined Vaccines (3. D-T-P-IPV-HB-Hib); WTV: Workshop Therapeutic Vaccines (2. Cancer) SK: Symposium Kinases; STBV: Symposium Tuberculosis Vaccines; SAT: Symposium Atherosclerosis; CPS: Commercial Presentations Session SIP: Symposium Inflammation and Pain SVetV:Symposium Veterinary Vaccines SBP: Symposium Bioprocesses; SHA: Symposium Hereditary Ataxias Other activities: Room 7, Tuesday 16, 18:00-20:00: IUPHAR-ALF-Cuban Society of Pharmacology Meeting. Note 1: Coffe Breaks will be into the rooms during the morning time. Note 2: Lunches will be held from Monday to Friday, 13:00-15:00 hours. 6 IMMUNOPHARMACOLOGY - VACCIPHARMA 2015 GENERAL PROGRAM PLENARY LECTURES SESSION (PLENARY ROOM) SUNDAY 14 (18:00-20:30) 18:45-19:25 CHANGING VIEWS IN THE IMMUNOLOGY OF VACCINATION AND THE CHALLENGES AHEAD (Shiv Pillai, Harvard Medical School Cambridge, PA. USA) 19:30-20:10 IMMUNOTHERAPY AS AN EMERGING PARADIGM IN ADVANCED CERVICAL CANCER (Tewari Krishnansu, Todd cancer Pavilion, Long Beach, CA, USA) IMMUNOPHARMACOLOGY SYMPOSIUM (ROOM 1) MONDAY 15 (09:00-13:05) Topic: B cell function and regulation: impact of aging Chairs: Thomas Rothstein (USA)/Ana M Hernández (CUBA) 09:00-09:30 B LYMPHOCYTE SELECTION AND HOMEOSTASIS (Michael Cancro, University of Pennsylvania, PA, USA) 09:35-10:05 THE HUMAN COUNTERPART OF MOUSE B-1 CELLS (Thomas Rothstein, The Feinstein Institute for Medical Research, NY, USA) 10:10-10:30 HUMAN B-1 AND B-2 CELLS ARE GENERATED FROM A COMMON UMBILICAL CORD BLOOD PROGENITOR CD34+CD38LO/INT CELL POPULATION (Tam D Quach, The Feinstein Institute for Medical Research, NY, USA) 10:35-11:05 PROTECTIVE NATURAL AUTOANTIBODIES TO APOPTOTIC CELLS: EVIDENCES OF CONVERGENT SELECTION OF RECURRENT INNATE-LIKE CLONES (Gregg Silverman, NY Univ School of Medicine, NY, USA) 11:10-11:30 CHARACTERIZATION OF B AND T CELLS INVOLVED IN IMMUNOGENIC PROPERTIES OF ANTI-IDIOTYPIC ANTIBODY (Darel Martinez, Center of Molecular Immunology, Havana, Cuba) 11:30-11:45 COFFEE BREAK Chairs: Bonnie B Blomberg (USA)/ Gregg Silverman (USA) 11:45-12:15 BIOMARKERS FOR HUMAN VACCINE RESPONSE WHICH CHANGE WITH AGE: B CELL SUBSETS, AID, MIRS, INFLAMMATION, AND CMV (Bonnie B Blomberg, Univ of Miami, FLA, USA) 12:20-12:40 NATURAL CYTOTOXIC ANTIBODIES AGAINST TUMOR NEUGCGM3 GANGLIOSIDE DECREASE WITH AGE AND ARE ABSENT IN NSCLC PATIENTS (Nely Rodriguez-Zhurbenko, Center of Molecular Immunology, Cuba) 7 IMMUNOPHARMACOLOGY - VACCIPHARMA 2015 12:45-13:05 AGE-RELATED DECLINE IN NATURAL IGM FUNCTION: DIVERSIFICATION AND SELECTION OF THE B-1A CELL POOL WITH AGE (Nichole Holodick, The Feinstein Institute for Medical Research, NY, USA) IMMUNOPHARMACOLOGY SYMPOSIUM (ROOM 1) MONDAY 15 (15:00-17:35) Topic: Immunomodulation Chairs: Dirk Homann (USA)/Tania Carmenate (CUBA) 15:00-15:30 HOW AGING CAN IMPROVE IMMUNE PROTECTION: AN INTEGRATED PERSPECTIVE ON THE TEMPORAL ORGANIZATION OF CD8+T CELL MEMORY (Dirk Homann, Mount Sinai Sch of Medicine, NY, USA) 15:35-15:55 CELLULAR MECHANISMS INVOLVED IN MACROPHAGE ACTIVATION INDUCED BY THE MUCOSAL ADJUVANT PROTOXIN CRY1AC (Damarys Ilhuicatzi, Universidad Nacional Autónoma de México, Estado de Mexico, Mexico) 16:00-16:20 IMMUNOSTIMULATING EFFECTS OF CRY1AC TOXIN AND IDENTIFICATION OF PUTATIVE RECEPTORS IN MURINE MACROPHAGES (Nestor Rubio-Infante, Laboratorio de Inmunidad en Mucosas, México) 16:25-16:45 IN VITRO AND IN VIVO COMPARISON OF CD40, DEC-205, OR CD11C FOR TARGETING OF NANOPARTICLES ON DENDRITIC CELLS FOR EFFICIENT INDUCTION OF CD8+ T CELL RESPONSE (Luis J Cruz, Leiden University Medical Center, Leiden, The Netherlands) 16:50-17:10 TOWARDS A BETTER THERAPY BASED ON IL-2, AVOIDING TREG CELL EXPANSION (Tania Carmenate, Center of Molecular Immunology, Havana, Cuba) 17:15-17:35 APL-1, A PEPTIDE AS IMMUNOMODULATOR FOR THE TREATMENT OF JUVENILE IDIOPATHIC ARTHRITIS (Norailys Lorenzo, Center for Genetic Engineering & Biotechnology, Havana, CUBA) IMMUNOPHARMACOLOGY SYMPOSIUM (ROOM 1) TUESDAY 16 (09:00-13:15) Topic: Relevant targets & translational research on inflammation Chairs: Shiv Pillai (USA)/Patricia Hernandez (CUBA) 09:00-09:30 METABOLIC INHIBITORS TO TREAT LUPUS (LAURENCE M. MOREL, DEP OF MEDICINE UNIVERSITY OF FLORIDA, GAINESVILLE, FL, USA) 8 IMMUNOPHARMACOLOGY - VACCIPHARMA 2015 09:35-09:55 TARGETING CD6 MODULATES INFLAMMATORY-MEDIATED PATHWAYS AND ACHIEVES THERAPEUTIC RESPONSE IN AUTOIMMUNITY SETTING (Patricia Hernandez, Center of Molecular Immunology, Havana, Cuba) 10:00-10:20 NOVEL IL15 ANTAGONISTS FOR THE TREATMENT OF INFLAMMATORY DISEASES (Jacques Yannick, CRCNA, University of Nantes, Nantes, France) 10:25-10:45 VERY SMALL SIZE PROTEOLIPOSOMES ABROGATE CROSS-PRESENTATION OF TUMOR ANTIGENS BY MYELOID-DERIVED SUPPRESSOR CELLS AND INDUCE THEIR DIFFERENTIATION TO DENDRITIC CELLS (Odrey Fernandez, Center of Molecular Immunology, Havana, Cuba) 10:50-11:10 NEOPLASTIC TRANSFORMATION CAN CONCERTS IMMUNE EVASION AND INFLAMMATION IN THE ABSENCE OF EXTRINSIC IMMUNE PRESSURE: LESSONS FROM A MODEL BASED ON MESENCHYMAL STEM CELLS (Alex Miranda, Center of Molecular Immunology, Havana, Cuba) 11:15-11:30 COFFEE BREAK Chairs: Jacques Yannick (France)/Alicia Santos (CUBA) 11:30-12:00 CD4+ CYTOLYTIC T CELLS: DRIVERS OF INFLAMMATORY FIBROSIS AND A LAYER OF HUMAN ANTI-VIRAL PROTECTION (Shiv S. Pillai, Harvard Medical School Cambridge, MA, USA) 12:05-12:25 NO-HYBRIDIZED PROTEASE INHIBITORS AS NOVEL DRUGS FOR THE TREATMENT OF CANCER AND AUTOIMMUNE DISEASES (Ferdinando Nicoletti, Dep of Biomedical and Biotechnological Sciences, University of Catania, Italy) 12:30-12:50 ANTI-INFLAMMATORY ACTION OF GLUCOCORTICOIDS: ROLE OF GILZ (Carlo Riccardi, Department of Medicine, University of Perugia, Perugia, Italy) 12:55-13:15 A NOVEL PEPTIDE SELECTED FROM AN ALA-SCANNING REGULATES THE ONCOGENICINFLAMMATORY ACTIVITY OF NFKB IN CANCER CELLS (BRIZAIDA OLIVA, CENTER FOR GENETIC ENGINEERING AND BIOTECHNOLOGY, HAVANA, CUBA) IMMUNOPHARMACOLOGY SYMPOSIUM (ROOM 1) TUESDAY 16 (15:00-18:00) Topic: Immunopharmacology and Allergy Chairs: Francesca Levi-Schaffer (Scotland) / Carlo Riccardi (Italy) 15:00-15:30 GLIAL CONTROL OF NEUROINFLAMMATION IN TRAUMATIC CENTRAL NERVOUS SYSTEM INJURIES: ROLE OF FATTY ACID ETHANOL AMIDES (Salvatore Cuzzocrea, University of Messina, Italy) 15:35-16:05 ACTIVATION OF INHIBITORY RECEPTORS BY SPECIFIC ANTIBODIES AS A TREATMENT FOR ALLERGIC DISEASES (Francesca Levi-Schaffer, Hebrew University of Jerusalem, Israel) 16:10-16:40 ANTI-INFLAMMATORY ACTION OF GLUCOCORTICOIDS: ROLE OF GILZ (Carlo Riccardi, Department of Medicine, University of Perugia, Perugia, Italy) 9 IMMUNOPHARMACOLOGY - VACCIPHARMA 2015 16:45-17:15 HUMAN MONOCYTES AND MACROPHAGES FOR THE SENSITIVE AND ROBUST IN VITRO EVALUATION OF IMMUNOMODULATORY AND IMMUNOTOXIC EFFECTS (Diana Boraschi, National Research Council, Napoli, Italy) 17:20-17:50 SEEKING FOR IMMUNOLOGICAL MARKERS PREDICTING THE EFFICACY AND SAFETY OF NOVEL ALLERGEN-SPECIFIC IMMUNOTHERAPY PRODUCTS (Alexis Labrada, BioCEN, Cuba) IMMUNOPHARMACOLOGY SYMPOSIUM (ROOM 1) WEDNESDAY 17 (09:00-13:25) Topic: Translational & Clinical Oncology (I) Chairs: Lesley A Stark (Scotland/ Kalet Leon (Cuba) 09:00-9:30 CK2 AS A CANCER BIOMARKER (Isabel Dominguez, Boston University School of Medicine, Boston, MA, USA) 09:35-09:55 COMMD1 IN COLORECTAL CANCER PROGRESSION AND THE CHEMOPREVENTATIVE EFFECTS OF ASPIRIN (Lesly A Stark, Edinburgh Cancer Research Centre, Institute of Genetics and Molecular Medicine, Edinburgh, Scotland, UK) 10:00-10:20 RATIONAL DESIGN OF A TGFB1 MUTANT USEFUL FOR CANCER IMMUNOTHERAPY (Kalet Leon, Center of Molecular Immunology, Havana, Cuba) 10:25-10:45 HUMAN THERAPEUTIC ENZYME SPECIFICALLY SABOTAGES TUMOR METABOLISM BY AN ENGINEERED CYSTINE/CYSTEINE DEGRADING ACTIVITY (Shira Cramer, Dep of Biomedical and Chemical Engineering, The Univ of Texas, Austin, TX, USA) 10:50-11:10 ECTOPIC MICRORNA-150-5P TRANSCRIPTION MIMICKS GLUCOCORTICOID THERAPY RESPONSE IN MM1S MULTIPLE MYELOMA CELLS BUT FAILS TO OVERCOME HORMONE THERAPY RESISTANCE IN MM1R CELLS (Wim Vanden Berghe, 2. Lab of Eukaryotic Gene Expression and Signal Transduction (LEGEST), Ghent University, Belgium) 11:15-11:30 COFFEE BREAK Chairs: Wim Vanden Berghe (Belgium)/ Circe Mesa (Cuba) 11:30-12:00 NATURAL KILLER CELL LINE GENETICALLY MODIFIED WITH A CHIMERIC ANTIGEN RECEPTOR (CAR) WITH SPECIFICITY AGAINST MALIGNANT TUMORS (Gabriele Percher, Charité – University Medicine of Berlin, Berlin, Germany) 12:05-12.35 GENERATION AND FUNCTION OF ENGINEERED HUMAN REGULATORY T CELLS FOR AUTOIMMUNITY: LESSONS FROM CAR THERAPY (David Scott, Dep of Med, Uniformed Services Univ of the Health Sciences, Bethesda, MD, USA) 10 IMMUNOPHARMACOLOGY - VACCIPHARMA 2015 12:40-13:00 GANGLIOSIDE CONTAINING NANO-PROTEOLIPOSOME REDUCES NUMBER OF MYELOIDDERIVED SUPPRESSOR CELLS: FIRST CLINICAL EVIDENCES IN METASTATIC RENAL CANCER PATIENTS (Circe Mesa, Center of Molecular Immunology, Havana, Cuba) 13:05-13:25 ANTITUMOR AND CYTOTOXIC PROPERTIES OF A HUMANIZED ANTIBODY SPECIFIC FOR THE GM3 (NEU5GC) GANGLIOSIDE (Denise Dorvignit, Center of Molecular Immunology, Havana, Cuba). IMMUNOPHARMACOLOGY SYMPOSIUM (ROOM 1) THURSDAY 18 (09:00-13:10) Topic: Translational & Clinical Oncology (II) Chairs: Rubén A Mesa (USA)/Leonardo Lami (Cuba) 09:00-09:20 FERTILITY PRESERVATION IN EARLY CERVICAL CANCER (Concepcion Diaz-Arrastia, BCM Department of Ob/GynHouston, TX, USA) 09:25-09:45 SIGNIFICANT INCREASE OF OVERALL SURVIVAL AND CLINICAL IMMUNOLOGICAL RESPONSE IN CANCER PATIENTS WITH CIGB-247 THERAPEUTIC VACCINE PREPARATION (Katty-Hind SelmanHousein, CIMEQ Hospital, Havana, CUBA) 09:50-10:10 EVOLVING TARGETED THERAPY FOR MYELOPROLIFERATIVE NEOPLASMS (Ruben A Mesa, Mayo Clinic Cancer Center, AZ, USA) 10:15-10:35 NIMOTUZUMAB FOR THE TREATMENT OF CHILDREN WITH NEWLY DIAGNOSED DIFFUSE INTRINSIC PONTINE GLIOMA (Camilo Rodriguez, Center of Molecular Immunology, Havana, CUBA) 10:40-11:00 EMERGING TARGETED THERAPIES AND THE ROLE OF IMMUNOTHERAPY IN CHRONIC LYMPHOCYTIC LEUKEMIA (Jose F Leis, Mayo Clinic, AZ, USA) 11:00-11:15 COFFEE BREAK Chairs: David Steensma (USA)/Jorge L Soriano (Cuba) 11:15-11:35 CIGB-128, NOVEL FORMULATION OF INTERFERONS (IFNS) WITH IMPROVED PHARMACODYNAMICS FOR CANCER TREATMENT (Iraldo Bello, Center for Genetic Engineering and Biotechnology, Havana, CUBA) 11:40-12:00 TREATMENT OF MYELODYSPLASTIC SYNDROMES (MDS) IN 2015 (David P. Steensma, DanaFarber Cancer Institute and Harvard Medical School, Boston, USA) 12:05-12:25 CURRENT BIOLOGICAL TARGETED AGENTS IN THE THERAPEUTIC OF COLORECTAL CANCER (Leonardo Lami, National Institute of Oncology & Radiobiology, Havana, CUBA) 11 IMMUNOPHARMACOLOGY - VACCIPHARMA 2015 12:30-12:50 IDENTIFICATION AND CHARACTERIZATION OF LONG-TERM SURVIVAL POPULATION IN NONSMALL CELL LUNG CANCER PATIENTS TREATED WITH IMMUNOTHERAPIES (Patricia Lorenzo-Luaces, Center of Molecular Immunology, Havana, CUBA) 12:50-13:10 RACOTUMOMAB-ALUM, NIMOTUZUMAB OR DOCETAXEL AS SWITCH MAINTENANCE THERAPY FOR ADVANCED NSCLC: RANIDO TRIAL PRELIMINAR RESULTS (Maurenis Hernandez, Center of Molecular Immunology, Cuba) SYMPOSIUM ON PHARMACOLOGY OF CYTOCHROME P450, TRANSPORTERS AND OMICS (ROOM 3) MONDAY 15 (9:00-13:20) Topics: Pharmacogenetic Chairs: Adrián Llerena (Spain) / Howard L. McLeod (USA) 09:00-09:25 PHARMACOGENETICS IN IBERO AND LATIN-AMERICAN POPULATIONS (Adrián Llerena Ruiz, Spain) 09:30-09:55 CLINICAL IMPLEMENTATION OF GENETIC TESTING IN MEDICINE (Lawrence Lesko, EU) 10:00-10:25 PERSONALIZED CANCER TREATMENT: SELECTING FROM A BASKET OF POTENTIAL THERAPIES (Howard L. McLeod, USA) 10:30-10:45 FROM PHARMACOGENETICS TO PERSONALIZED MEDICINE: REGULATORY PERSPECTIVES AND IMPLICATIONS FOR LATIN-AMERICAN COUNTRIES (Diadelis Remirez, Cuba) 10:50-11:05 FREQUENCY OF CYP2D6 POOR METABOLIZERS IN A SAMPLE OF CUBAN PATIENTS WITH SCHIZOPHRENIA (Hilda Roblejo, Cuba) 11:10-11:35 Coffee break Topics: OMICS Chairs: Wim Vanden (Belgium) / Idania Rodeiro (Cuba) 11:35–12:00 EPIGENETIC RESPONSE OF DIETARY FLAVANOLS AND STEROIDAL WITH ANOLIDES IN CHEMOPREVENTION OF CANCER-INFLAMMATION: FINDING THE NEEDLE IN THE HAYSTACK FOR PERSONALIZED NUTRITIONAL RECOMMENDATIONS (Wim Vanden, Belgium) 12:05–12:30 FLAVONOIDS AS POTENTIAL CHEMOPREVENTIVE AGENTS (Javier Espinosa-Aguirre, México) 12:35–12:50 IDENTIFICATION OF GENES REGULATED BY THE CO-FORMULATION OF INTERFERON-ALPHA AND GAMMA CIGB28-A IN GLIOBLASTOMA CELL LINE U87MG BY ILLUMINA MICROARRAY ANALYSIS (Dania Vázquez-Blomquist, Cuba) 12 IMMUNOPHARMACOLOGY - VACCIPHARMA 2015 12:55–13:10 GENETIC FACTORS FOR MULTIPLE SCLEROSIS AND NEUROMYELITIS OPTICA IN CUBAN PATIENTS. (Dr. María Elena Fernández Cossio, CIGB, La Habana, Cuba) SYMPOSIUM ON PHARMACOLOGY OF CYTOCHROME P450, TRANSPORTERS AND OMICS (ROOM 3) MONDAY 15 (15:00- 17:00) Topics: Pharmacogenomic Chairs: Lawrence J. Lesko (USA) / Javier Espinosa (México) 15:00–15:30 CIGB-522 MODULATES THE IMMUNE RESPONSE OF TUMOR CELL LINES (Julio Raúl Fernández, Cuba) 15:30–15:50 GENE EXPRESSION REGULATION OF A SET OF GENES BY THE ANTITUMOR PEPTIDE CIGB300- IN AML CELL LINES (Dania Vázquez-Blomquist, Cuba) 15:50–16:10 DNA ANALYSIS OF MICROBES IN THE COLON OF RAT MODEL OF ULCERATIVE COLITIS (Isabel Guillén, Cuba) 16:10–16:30 A WEBSITE TO PROMOTE CONTENTS AND RESOURCES ABOUT THE CLINICAL APPLICATIONS OF THE OMICS TECHNOLOGIES (Orlando Serrano-Barrera, Cuba) 16:30–17:00 GENERAL DISCUSSION WORKSHOP OF NEUROIMMUNOLOGY (ROOM 4) MONDAY 15 (09:00-13:00) Topics: Neuroimmune Interaction and repair of brain damage Chairs: Carlos Alberto Goncalves (Brazil) / Alina González Q (Cuba) 09:00-09:25 NEUROPLASTICITY: PRESENT AND FUTURE (Jorge Bergado Rosado, CIREN, Cuba) 09:30-09:50 ASTROCYTE SIGNALING IN NEUROINFLAMMATION (Cinthia Farina, San Raffaele Scientific Institute, Italy) 09:55-10:20 MARKERS OF ASTROGLIAL ACTIVITY IN ALZHEIMER´S DISEASE (Carlos Alberto Gonçalves, UFRGS,Brazil) 10:25-10:45 IL-12/IL-23 SIGNALING AND GLIAL ACTIVATION IN ALZHEIMER’S DISEASE. (Ileana Lopategui, ISCM-H, Cuba) 10:50-11:05 S100 BETA AND BDNF IN PATIENTS WITH LUPUS AND PSYCHIATRIC DISORDERS. (Elena Noris Garcia, Nephrology Institute, Cuba) 11:10-11:25 Coffee break 13 IMMUNOPHARMACOLOGY - VACCIPHARMA 2015 11:25-11:50 NEUROBIOLOGICAL MECHANISMS IMPLICATED IN THE IMPAIRMENT INDUCED BY THE PRO-INFLAMMATORY CYTOKINE IL-1Â ON FEAR MEMORY PROCESSES (Patricia Gonzalez, Faculty of Chemical Science - UNC, Argentina) 11:55-12:15 NEUREGULIN 1 REGULATES EXCITABILITY OF FAST-SPIKING NEURONS THROUGH KV1.1 AND ACTS IN EPILEPSY (Xiao-Ming Li. Zhejiang, Zhejiang University China) 12:20-12:45 IMPACT OF PLANT DERIVED FLAVONOIDS ON GLIA MODULATION AND NEURODEGENERATIVE DISEASES. (Silvia Lima Costa, Universidade Federal da Bahia, Brazil) WORKSHOP OF NEUROIMMUNOLOGY (ROOM 4) MONDAY 15 (15:00-18:00) Topic: Modulating functions in neurological diseases Chairs: Salvatore Cuzzocrea (Italy) / René Delgado (Cuba) 15:00-15:25 NEUROPROTECTION IS A PENDING TASK OF THE NEUROSCIENCES OF THE XXI CENTURY (Julio Cesar García, Havana University, Cuba) 15:30-15:45 NEUROPROTECTION BY LONG-CHAIN FATTY ACIDS IN TRAUMA: THE CONTROL OF NEUROINFLAMMATION (Salvatore Cuzzocrea, University of Messina, Italy) 15:50-16:10 FUMARIC ACID ESTERS ATTENUATE SECONDARY DEGENERATION AND PROMOTE FUNCTIONAL RECOVERY FOLLOWING EXPERIMENTAL SPINAL CORD INJURY (Emanuela Esposito, University of Messina, Italy) 16:15-16:30 INFLAMMATORY AND NEUROTROPHIC RESPONSE TO GLUTATHIONE DEPLETION IN THE SUBSTANTIA NIGRA PARS COMPACT OF RATS. (Mei-Li Díaz Hung, CIREN, Cuba) 16:35-16:55 MITOCHONDRIA: A TARGET FOR NEUROPROTECTIVE INTERVENTIONS IN CEREBRAL ISCHEMIA-REPERFUSION (Gilberto L Pardo- Andreu, CIDEM, Cuba) 17:00− −17:20 ANTIPARKINSONIAN ANTIDYSKINETIC EFFECT OF PHYTODRUG MUCUNAPRURIENS IN RAT MODEL OF PARKINSON DISEASE (Liliana Francis Turner, Ibague University, Colombia) 17:25-17:40 NEUROPROTECTIVE EFFECT OF JM-20, A NOVEL MULTI-TARGET LIGAND, IN DIFFERENT EXPERIMENTAL MODELS RELATED TO CEREBRAL ISCHEMIA (Yanier Núñez, CIDEM, Cuba) 17:40-18:00 NEUROPHARMACOLOGICAL STUDIES OF NEW NEUROPROTECTIVES COMPOUNDS IN CUBA. TODAY BASIC AND APPLIED SCIENCE: TOMORROW NEW DRUGS AGAINST CEREBROVASCULAR DISORDERS AND NEURODEGENERATIVE DISEASES (Rene Delgado, CIDEM, Cuba) 14 IMMUNOPHARMACOLOGY - VACCIPHARMA 2015 WORKSHOP OF NEUROIMMUNOLOGY (ROOM 4) TUESDAY 16 (9.00-13.40) Topic: Molecular mechanisms in genetic and neurodevelopmental disorder Chairs: Margaret Fahnestock (Canada) / Maria Robinson (Cuba) 09:00-9:25 MOLECULAR REGULATION OF STEM CELLS IN DOWN’S SYNDROME AND NEURODEGENERATION (Michael Clarke, Stanford Institute, USA) 09:30-9:50 ANTINEURONAL ANTIBODIES AGAINST NEUROTRANSMITTER RECEPTORS AND SYNAPTIC PROTEINS IN SCHIZOPHRENIA: CURRENT KNOWLEDGE AND CLINICAL IMPLICATION (Johann Steiner, Magdeburg University, Germany) 09:55-10:20 GENE EXPRESSION CHANGES IN AUTISM: EVIDENCE FOR NEUROINFLAMMATION (Dario Siniscalco, Second University of Naples,Italy) 10:25-10:50 DECREASED TRKB AND MTOR SIGNALING PATHWAYS IN HUMAN IDIOPATHIC AUTISM AND IN A RODENT MODEL OF AUTISM (Margaret Fahnestock, Ontario University, Canada) 10:55-11:10 Coffee break 11:15-11:30 HLA ANTIGENS IN AUTISTIC CUBAN PATIENTS (Arturo Chang, CICEL, Cuba) 11:35-11:55 CYTOKINE PROFILE AND CLINICAL DATA IN AUTISM CUBAN PATIENTS (Maria Robinson, CIREN, Cuba) 12:00-12:25 ELECTROPHYSIOLOGICAL EVENTS IN ASD CUBAN PATIENTS (Lilia Morales Chacón, CIREN, Cuba) 12:30-13:00 TRANSCRANIAL MAGNETIC STIMULATION AND ADHD (Lázaro Gomez, CIREN, Cuba) WORKSHOP OF NEUROIMMUNOLOGY (ROOM 4) TUESDAY 16 (15:00-17:40) Topic: First Symposia on Multiple Sclerosis and related disorders Chairs: Harmut Wekerle (Germany)// Giselle Pentón (Cuba) 15:00-15:25 MULTIPLE SCLEROSIS AND THE GUT FLORA: A BACTERIAL BIOREACTOR FUELS BRAIN AUTOIMMUNITY (Harmut Wekerle, Max Planck Institute, Germany) 15:30-15:55 MICROPARTICLES IN THE CEREBROSPINAL FLUID REFLECT MICROGLIA/MACROPHAGE ACTIVATION IN RODENT AND HUMAN NEUROLOGICAL DISORDER (Roberto Furlan, San Raffaele Scientific Institute, Italy) 16:00-16:25 NEUROINFLAMMATION AND NEURODEGENERATION: INDEPENDENT NEUROPATHOLOGICAL TARGETS OF EAE? (J Carvalho Tavares, Minas de Gerais University, Brazil) 15 IMMUNOPHARMACOLOGY - VACCIPHARMA 2015 16:30− −16:45 IFN-B AND C-PHYCOCYANIN COMBINATION IN VITRO IMMUNOMODULATORY RESPONSES (Majel Cervantes, CIGB, Cuba) − 17:15 THALAMIC ATROPHY CORRELATES WITH COGNITIVE DYSFUNCTION IN RELAPSING16:50− REMITTING MULTIPLE SCLEROSIS PATIENTS TREATED WITH NATALIZUMAB (Jacqueline Bernard. Chicago University, USA) 17:20-17:45 MULTIPLE SCLEROSIS: GREATER EXPECTATIONS ON NOVEL COMBINED THERAPY (Giselle Pentón, CIGB, Cuba) SATELLITE MEETING: PROTEIN KINASES AS DRUGGABLE PHARMACOLOGICAL TARGET. FOCUS ON PROTEIN KINASE CK2 (ROOM 5) MONDAY 15 (09:00-13:25) Chairs: Olaf-Georg Issinger (Denmark)/Silvio E Perea (Cuba) 09:00-09:10 OPENING REMARKS: TOWARDS VALIDATION OF CK2 AS A CLINICAL CANCER TARGET? (Silvio E Perea, Dept of Cancer, Center for Genetic Engineering and Biotechnology, Havana, Cuba) 09:15-09:40 CIGB-300 IMPAIRS THE CK2 BETA-DEPENDENT PHOSPHORYLATION (Teresa Núñez, Dept of Systems Biology, Center for Genetic Engineering and Biotechnology, Havana, Cuba) 09:45-10:10 SMALL COMPOUND INHIBITORS OF PROTEIN KINASE CK2: STUDIES IN TUMOR CELLS AND CARDIOMYOCYTES (Olaf-Georg Issinger, Dept Biochem & Mol Biology, Univ Southern Denmark, Odense, Denmark) 10:15-10:40 PROTEIN KINASE CK2: LESSONS FROM KNOCKOUT MICE (Brigitte Boldyreff, KinaseDetect ApS, R&D, Odense, Denmark) 10:45-11:10 CK2: INTERSECTIONS WITHIN THE REGULATORY POST-TRANSLATIONAL MODIFICATION NETWORKS (David Litchfield, Dept of Biochem, Univ of Western Ontario, London Ontario, Canada) 11:15-11:30 COFFEE BREAK Chairs: David Litchfield (Canada)/ Isabel Domínguez (USA) 11:30-11:55 ABROGATION OF CASEIN KINASE 2 (CK2)-MEDIATED SIGNALING USING A PEPTIDE INHIBITOR IMPAIRS VIABILITY AND PROLIFERATION OF T-CELL ACUTE LYMPHOBLASTIC LEUKEMIA CELLS (Yasser Perera, Center for Genetic Engineering and Biotechnology, Havana, Cuba) 12:00-12:25 MINING CK2 IN CANCER (Isabel Dominguez, Boston University School of Medicine, Boston, MA, USA) 12:30-12:55 THE MAPK SIGNALING PATHWAY PMK1P AND MAINTENANCE OF CELL INTEGRITY IN SCHIZOSACCHAROMYCES POMBE (Sandra Cruz, Universidad Nacional de Chimborazo, Ecuador) 16 IMMUNOPHARMACOLOGY - VACCIPHARMA 2015 13:00-13:25 INHIBITION OF PROTEIN TYROSINE PHOSPHATASE 1B (PTP1B) OF CUBAN PLANTS EXTRACTS AS PROMISING TYPE 2 ANTI-DIABETES AGENTS (Eva Marrero, Dept of Biopharmaceutical Development, CENSA, Havana, Cuba) SYMPOSIUM OF ATHEROSCLEROSIS (ROOM 5) TUESDAY 16 (9.00-13.00) Chairs: Proctor Spencer (Canada)/Ana María Vázquez (Cuba) 09:00-09:30 THE EFFECTS OF TOBACCO ON THE DEVELOPMENT OF ATHEROSCLEROTIC LESIONS. AN AUTOPSY-BASED STUDY (Emilio Fernández-Britto, Center for Research and References of Atherosclerosis of Havana (CIRAH), University of Medical Science of Havana, Cuba) 09:35-10:05 CONTRIBUTIONS OF INTESTINAL APOB LIPOPROTEINS TO PLAQUE CHOLESTEROL: EVIDENCE FROM BENCH TO BEDSIDE DURING CHILDHOOD OBESITY (Proctor Spencer, Metabolic and Cardiovascular Disease Laboratory, Alberta Diabetes and Mazankowski Heart Institutes, University of Alberta, Canada) 10:10-10:40 NON-ALCOHOLIC FATTY LIVER DISEASE, FRAMINGHAM RISK SCORE AND FLOW-MEDIATED DILATION IN PATIENTS WITH CARDIO-METABOLIC RISK FACTORS (Francesco Angelico, Departments of Internal Medicine and Medical Specialties and Department of Public Health and Infectious Diseases, Sapienza University, Rome, Italy) 10:45-11:15 COMBINED SUB-OPTIMAL DOSES OF ROSUVASTATIN AND BEXAROTENE IMPAIRS ANGIOTENSIN II-INDUCED ARTERIAL MONONUCLEAR CELL ADHESION AND ATHEROSCLEROSIS LESION FORMATION (María Jesús Sanz, Department of Pharmacology, Faculty of Medicine, University of Valencia. Institute of Health Research INCLIVA, University Clinic Hospital of Valencia, Spain) 11.15-11.30 COFFEE BREAK 11.30-12.00 VISFATIN/NAMPT, VASCULAR INFLAMMATION AND ENDOTHELIAL SENESCENCE: A ROLE IN ATHEROSCLEROSIS? (Concha Peiro, Department of Pharmacology, School of Medicine, Universidad Autónoma de Madrid, Madrid, Spain) 12.05-12.35 ANTI-ATHEROSCLEROTIC EFFECT OF ACTIVE IMMUNIZATION WITH AN ANTIPROTEOGLYCAN ANTIBODY IN THERAPEUTIC SETTINGS. (Ana María Vázquez, Center of Molecular Immunology, Havana, Cuba) 12.40-12:55 GENERAL DISCUSSION 17 IMMUNOPHARMACOLOGY - VACCIPHARMA 2015 SYMPOSIUM OF ATHEROSCLEROSIS SYMPOSIUM (ROOM 5) WEDNESDAY 17 (09:00-13:00) Chairs: Francesco Violi (Italy)/Livan Delgado-Roche (Cuba) 09:00-09:30 NADPH OXIDASE AND CARDIOVASCULAR DISEASES (Francesco Violi, Sapienza University, I Clinica Medica, Rome, Italy) 09:35-10:05 OXIDATIVE STRESS AND PLATELET ACTIVATION IN OBESITY (Giovanni Daví, «G. d’ Annunzio» University Foundation, Center of Excellence on Aging, University of Chieti, Italy) 10:10-10:40 DIAGNOSTIC AND THERAPEUTIC POTENTIAL OF STAT1 AND IRF8 IN CARDIOVASCULAR DISEASE (Hans Bluyssen, Department of Human Molecular Genetics, Institute of Molecular Biology and Biotechnology, Faculty of Biology, Adam Mickiewicz University, Poznan Poland) 10:45-11:15 EFFECTS OF OBEX® IN OVERWEIGHT AND OBESE SUBJECTS WITH IMPAIRED FASTING GLUCOSE: A PILOT STUDY (Eduardo Cabrera, National Institute of Endocrinology, Havana, Cuba) 11:15-11:30 COFFEE BREAK 11:30-12:00 HYPOCHOLESTEROLEMIC AND ANTI-ATHEROSCLEROTIC EFFECTS OF CRUDE LEAF EXTRACT OF MORINGA OLEIFERA IN APOE KO MICE (Dasha Fuentes, National Center for Laboratory Animal Breeding, Mayabeque, Cuba) 12:05-12:35 REDOX REGULATION AND ANTI-INFLAMMATORY EFFECTS OF AN ANTI-PROTEOGLYCAN ANTIBODY IN ANIMAL MODELS OF ATHEROSCLEROSIS. (Livan Delgado-Roche, Center of Marine Bioproducts, Havana, Cuba) 12:40-12:55 GENERAL DISCUSSION SYMPOSIUM OF PAIN AND INFLAMMATION (ROOM 6) MONDAY 15 (09:00-13:00) Topic: Inflammation and Pain Chairs: Marcelo Kreiner (Uruguay)/Beatriz Garrido (Cuba) 09:00-09:30 TARGETING NEUROINFLAMMATION WITH NOVEL SYNTHETIC AND NATURAL NEUROPROTECTIVE COMPOUNDS. A NEW APPROACH TO DEVELOPMENT THERAPIES FOR NEUROPATHIC PAIN (Beatriz Garrido, Laboratory of Pharmacology and Toxicology, Center of Research and Drug Development, Havana, Cuba) 09:35-10:05 ANTINOCICEPTION PRODUCED BY THALASSIA TESTUDINUM EXTRACT BM-21 IS MEDIATED BY THE INHIBITION OF ACID SENSING IONIC CHANNELS (ASIC) BY THE PHENOLIC COMPOUND THALASSIOLIN B (Roberto Menéndez, Department of Pharmacology, Center of Marine Bioproducts, Havana, Cuba) 18 IMMUNOPHARMACOLOGY - VACCIPHARMA 2015 10:10-10:40 EFFECTS OF PALMITOYLETHANOLAMIDE AND SILYMARIN COMBINATION THERAPY IN AN ANIMAL MODEL OF KIDNEY ISCHEMIA AND REPERFUSION (Irene Paterniti, Department of Biological and Environmental Sciences, University of Messina, Italy) 10:45-11:15 ANTI-INFLAMMATORY AND ANTI-HYPERNOCICEPTIVE EFFECTS OF C-PHYCOCYANIN ON MBSA-INDUCED ARTHRITIS IN MICE (Javier Marín, Center for Research and Biological Evaluations, Institute of Pharmacy and Food, University of Havana, Cuba) 11:15-11:30 COFFEE BREAK Chairs: Marcelo Kreiner (Uruguay)/Beatriz Garrido (Cuba) 11:35-12:05 IMPACT OF CHRONIC SOCIAL STRESS ON THE IMMUNE MECHANISMS OF PROINFLAMMATORY SIGNALING ACTIVATION IN THE SMALL INTESTINE OF RATS (Inna Topol, Department of Microbiology, Virology and Immunology Zaporozhye State Medical University, Zaporozhye, Ukraine) 12:10-12:40 CLINICAL AND NEUROPHYSIOLOGICAL CONSIDERATIONS IN FACIAL PAIN WITH EMPHASIS IN VISCERAL REFERRED PAIN AND TRIGEMINAL NEURALGIA (Marcelo Kreiner, Department of General and Oral Physiology, University of Republic, Uruguay) SYMPOSIUM OF HEREDITARY ATAXIAS (ROOM 7) TUESDAY 16 (09:00-13:00) Chairs: Georg Auburger (Germany) / Luis Velázquez (Cuba) 09:00-9:30 MOLECULES BEHIND SCA2 (Georg Auburger, Universidad de Frankfurt, Frankfurt, Germany) 9:30-10:00 PRODROMAL BIOMARKERS FOR SPINOCEREBELLAR ATAXIA TYPE 2 (Luis Velázquez, CIRAH, Holguín, Cuba) 10:00-10:30 EXPANDING THE ROLE OF RNA-BINDING PROTEINS IN NEURODEGENERATIVE DISEASE: TDP-43, ATAXIN 2, C9ORF72 AND BEYOND (Aaron Gitler, Stanford University School of Medicine, Stanford, USA) 10:30-11:00 BIOMARKERS IN SCAS (Christopher Gómez, University of Chicago School of Medicine, Chicago, USA) 11:00-11:30 SPINOCEREBELLAR ATAXIA TYPE 2: PROGRESSION OF SACCADIC EYE MOVEMENT ABNORMALITIES OVER 5 YEARS (Roberto Rodríguez, CIRAH, Holguín, Cuba) 11:30-11:45 COFFEE BREAK 11:45-12:15 ELECTROPHYSIOLOGICAL FEATURES OF SPINOCEREBELLAR ATAXIA TYPE 7 (Rigoberto González, Instituto Nacional de Rehabilitación, México DF, México) 12:15-12:45 CLINICAL AND GENETIC CHARACTERIZATION OF SPINOCEREBELLAR ATAXIA TYPE 7 IN MEXICAN POPULATION (Cesar Ceredo-Zapata, Centro de Rehabilitación Veracruz, México) 19 IMMUNOPHARMACOLOGY - VACCIPHARMA 2015 12:45-13:15 ELECTRONEUROGRAPHIC ALTERATIONS OF TRIGEMINAL AND FACIAL NERVES IN SCA2: FACIAL MORPHOLOGY RELATION (Jacqueline Medrano, CIRAH, Holguín, Cuba) 13:15-13:45 SCA2 PREDICTIVE TESTING IN CUBA: CHALLENGING CONCEPTS AND PROTOCOL EVOLUTION (Yaimeé Vázquez, CIRAH, Holguín, Cuba) 13:45-14:30 LUNCH 14:30-14:50 NEUROREHABILITATIVE THERAPY IN SPINOCEREBELLAR ATAXIA TYPE 2: EXPERIENCES FROM THE CUBAN PROGRAM. (Julio Cesar Rodríguez, CIRAH, Holguín, Cuba) 14:50-15:10 AUDITORY VERBAL MEMORY AND LEARNING CURVES IN PATIENTS WITH SPINOCEREBELLAR ATAXIA TYPE 7 (Michelle Rodríguez-Trejo, Universidad de las Américas, México DF, México) 15:10-15:30 NEUROPROTECTIVE EFFECT OF MAGNETIC FIELDS IN BIOMODELS OF ATAXIA SCA2 (Consuelo Gonzalez, CENPALAB, Artemisa, Cuba) 15:30-15:50 PROCESO PSICOLÓGICO Y AFRONTAMIENTO EN EL NÚCLEO FAMILIAR PRIMARIO Y PACIENTE CON ATAXIA HEREDITARIA (Víctor Manuel González, Centro de Rehabilitación Integral, Zimapán, Mexico) . 15:50-16:10 HIGHER SUPEROXIDE DISMUTASE AND CATALASE ACTIVITIES ARE ASSOCIATED WITH A LESS SEVERE CLINIC EXPRESSION OF SPINOCEREBELLAR ATAXIA TYPE 2. (Dennis Almaguer, CIRAH, Holguín Cuba). 16:10-16:30 REHABILITACION COGNITVA: UNA PROPUESTA EN LA ENFERMEDAD VASCULAR CEREBRAL. (Daniel Alfredo Landínez, Instituto Nacional de Rehabilitación, México DF). 16:30-16:50 EFECTO DE LA INTERVENCIÓN SENSORIOMOTRIZ EN LOS NIVELES DE NORADRENALINA HIPOCAMPALES Y PONTINOS Y EN LA MORFOLOGÍA SINÁPTICA EN RATAS ADULTAS CON ABLACIÓN CORTICAL. (Laura E. Ramos, Instituto Nacional de Neurología y Neurocirugía, México DF, México). 16:50-17:10 CUBAN FAMILIES WITH SPINOCEREBELLAR ATAXIA TYPE 7. (Yanetza González Zaldívar, CIRAH, Holguín, Cuba). COMMERCIAL PRESENTATION SESSION (Room 5) WEDNESDAY 17 (15:00-17:00) 15:00-15:20 MEDIA, SERA AND AUXILIARY PRODUCTS FOR CELL CULTURE AND MOLECULAR BIOLOGY. Hofmann, M. Seafront Biotech GmbH Logistics & Management, Franz-Jacob-Str. 4A, 10369 Berlin, featuring Biological Industries Israel Beit Haemek Ltd., Beit Haemek, Israel 15:30-15:50 HIGH-PERFORMANCE PRECISION ANALYTICAL SYSTEMS. Hofmann, M. Seafront Biotech GmbH Logistics & Management, Franz-Jacob-Str. 4A, 10369 Berlin, featuring Analytik Jena AG, Analytical Instrumentation, Konrad-Zuse-Straße 1, 07745 Jena Germany 20 IMMUNOPHARMACOLOGY - VACCIPHARMA 2015 16:00-16:20 SPECIALIZING IN CHO|360-HCP ELISA. Hofmann, M. Seafront Biotech GmbH Logistics & Management, Franz-Jacob-Str. 4A, 10369 Berlin, featuring BioGenes GmbH, Köpenicker Straße 325, D-12555 Berlin, Germany VACCINE PLENARY SESSION (Room 2) MONDAY 15 (09:00-13:00) Chairs: Dr. Sonia Pagliusi (WHO) / Dr. Rolando Ochoa (Cuba) 09:00-09:05 OPENING SESSION 09:05-09:45 THE EXPANDED IMMUNIZATION PROGRAM IN AMERICA (Nancy Vasconez, PAHO-WHO, Nicaragua) 09:35-10:05 VACCINATION STRATEGIES: THE CUBAN EXPERIENCE (Rolando Ochoa, Finlay Institute Cuba) 10:05-10:35 DCVMN INTERNATIONAL UPDATES (Sonia Pagliusi, DCVMN-WHO, Brazil) 10:35-11:05 SURROGATES OF PROTECTION, PAST, PRESENT AND FUTURE (Jamie Findlow, Public Health England, UK) 11:05-11:35 MONOCLONAL ANTIBODIES: AN ANALYTICAL TOOL IN VACCINE DEVELOPMENT (Elizabeth González, Finlay Institute. Cuba) 11:35-12:05 RETHINKING TECHNOLOGY TRANSFER FOR A FASTER ACCESS TO INNOVATIVE VACCINES (Aldo Tagliabue, Siena, Italy) 12:05-12:35 ETHICAL ISSUES AND VACCINES (Glenn Ellis, Strategies for Well-Being, Philadelphia, USA) 12:35-13:00 DISCUSSION SYMPOSIUM MENINGOCOCCAL VACCINES (Room 2) MONDAY 15 (15.00-18.00) Chairs: Dr Ray Borrow (UK) / Dr. Reinaldo Acevedo (Cuba) 15:00-15:05 OPENING SESSION 15:05-15:30 EVOLVING STRATEGIES FOR MENINGOCOCCAL CONJUGATE VACCINATION (Ray Borrow, Vaccine Evaluation Unit, Public Health England, PHE. UK) 15:30-15:55 A NEW THERMOSTABLE PENTAVALENT (A/C/Y/W/X) MENINGOCOCCAL CONJUGATE VACCINE FOR AFRICA (Marc LaForce, Serum Institute of India and PATH, Seattle. USA) 15:55-16:20 NOVEL MENINGOCOCCAL VACCINES: QUANTITATIVE APPROACHES FOR EFFECTIVENESS PREDICTION AND POST-IMPLEMENTATION SURVEILLANCE (Duccio Medini, GSK. Italy) 21 IMMUNOPHARMACOLOGY - VACCIPHARMA 2015 16:20-16:45 UNVEILING THE TRUE COMPLEXITY OF THE MENINGOCOCCAL ST-11 COMPLEX (Jay Lucidarme, Vaccine Evaluation Unit, Public Health England, PHE. UK) 16:45-17:05 OBTAINING AND APPLICABILITY OF MONOCLONAL ANTIBODIES TO CAPSULAR POLYSACCHARIDE SEROGROUPS A, C, W, Y AND X OF NEISSERIA MENINGITIDIS (Fidel Ramirez, Finlay Institute. Cuba) 17:05-17:25 ANALYTICAL TRANSFERENCE PROCESS OF AN ELISA FOR DETERMINING CONTENT OF POLYSACCHARIDES A,C,Y,W IN MULTIVALENT VACCINES (Mario Landys Chovel, Finlay Institute. Cuba) 17:25-17:35 DISCUSSION 17:35-17:55 UNIQUE ASPECTS OF MENINGOCOCCAL PORB IMMUNE STIMULATION AND USE AS A VACCINE ADJUVANTE (Lee Wetzler, Boston University School of Medicine. USA) 17:55-18:15 AFPL1®: A NEW VACCINE ADJUVANT BASED ON NEISSERIAL MENINGITIDES OMV (Julio Balboa, Finlay Institute. Cuba) 18:15-18:25 DISCUSSION SYMPOSIUM MENINGOCOCCAL VACCINES (Room 2) TUESDAY 16 (09.00-13.30) Chairs: Dr Johan Holst (Norway) / Dr. Luis García (Cuba) 09:00-09:10 OPENING SESSION 09:10-09:35 LEARNING-POINTS FROM THE DEVELOPMENT OF PROTEIN-BASED MENB VACCINES WITH BROAD STRAIN COVERAGE (Johan Holst, Norwegian Institute of Public Health NIPH. Norway) 09:35-10:00 FACTOR H-BINDING PROTEIN DISTRIBUTION AMONG CULTURE AND NON CULTURE MENINGOCOCCI IN ENGLAND AND WALES: 2011-2013 (Stephen Clark, Vaccine Evaluation Unit, Public Health England, PHE. UK) 10:00-10:25 GLOBAL EXPRESSION PROFILING OF NEISSERIA MENINGITIDIS FACTOR H BINDING PROTEIN (FHBP) BY AN ANTIBODY-INDEPENDENT MASS SPECTROMETRY BASED METHODOLOGY (Marcia Giuliani, Novartis. Italy) 10:25-10:45 POOLED HSBA TITRES PREDICT SERORESPONSE RATES OF INFANTS AND TODDLERS VACCINATED WITH 4CMENB (Sonia Budroni, GSK. Italy) 10:45-11:05 UPDATE OF THE SAFETY PROFILE OF MENINGOCOCCAL B&C VACCINE VA MENGOC BC (Ivan Cuevas, Finlay Institute. Cuba) 11:05-11:20 EFFECT OF THE ECULIZUMAB (SOLIRIS®), ON THE MENINGOCOCCAL SEROGROUP B (MENB) SERUM BACTERICIDAL ANTIBODY (SBA) ASSAY (Xillian Bai, Public Health England, PHE.UK) 11:20-11:35 DISCUSSION 22 IMMUNOPHARMACOLOGY - VACCIPHARMA 2015 11:35-12:00 OVERVIEW OF THE PROJECT-AW OMV VACCINE-FROM MICE TO MEN (Einar Rosenqvist, Norwegian Institute of Public Health NIPH. Norway) 12:00-12:25 PHASE I CLINICAL STUDY-DESIGN AND SAFETY OF AW OMV CANDIDATE (Luis Garcia, Finlay Institute. Cuba) 12:25-12:50 IMMUNE RESPONSES IN HUMANS AFTER VACCINATION WITH A NOVEL OUTER MEMBRANE VESICLE VACCINE AGAINST SEROGROUP A AND W MENINGOCOCCAL DISEASE (Lisbeth Naess, Norwegian Institute of Public Health NIPH. Norway) 12:50-13:10 NEW VACCINE STRATEGIES AGAINST NESISSERIA MENINGITIDIS SEROGROUP X (Reinaldo Acevedo, Finlay Institute. Cuba) 13:10-13:25 DISCUSSION SYMPOSIUM ENTERIC VACCINE (Room 2) TUESDAY 16 (15.00-18.00) Chairs: Imran Khan (USA) / Thomas Wierzba (USA) 15:00-15:05 OPENING SESSION 15:05-15:25 GLOBAL BURDEN OF TYPHOID AND PARATYPHOID AND STRATEGIES FOR ITS CONTROL (Sushant Sahastrabuddhe, International Vaccine Institute. Republic of Korea) 15:25-15:45 TYPHOID VACCINE DEVELOPMENT AND THE POTENTIAL FOR CONTROL OF ENTERIC FEVER (Imran Khan, Coalition against Typhoid Sabin Institute. USA) 15:45-16:05 DEVELOPMENT OF VI CONJUGATE VACCINE AGAINST TYPHOID (Sonsire Fernández, Finlay Institute. Cuba) 16:05-16:20 DISCUSSION 16:20-16:40 ENTERIC DISEASE VACCINE DEVELOPMENT FOR CHILDREN LESS THAN 2 YEARS OF AGE (Khalid Ali Syed, International Vaccine Institute. Republic of Korea) 16:40-17:00 ETEC VACCINES (Thomas Wierzba, Enteric Vaccine Initiative PATH. USA) 17:00-17:20 CLINICAL PROOF-OF-CONCEPT OF SBVGH SHIGELLA SONNEI GENERAL MODULES FOR MEMBRANE ANTIGENS (GMMA) VACCINE ADMINISTERED BY INTRAMUSCULAR ROUTE (Audino Podda, SBVGH, Sienna, Italy) 17:20-17:40 PRELIMINARY SAFETY PROFILE OF THE CHOLERA 638 VACCINE CANDIDATE (Rodrigo Valera, Finlay Institute. Cuba) 17:40-17:55 DISCUSSION 23 IMMUNOPHARMACOLOGY - VACCIPHARMA 2015 SYMPOSIUM PNEUMOCOCCAL VACCINES (Room 2) WEDNESDAY 17 (09:00-13:00) Chairs: David Goldblatt (UK) / Vicente Vérez (Cuba) 09:00-09:15 OPENING SESSION 09:15-09:45 GLOBAL IMPACT OF PCV‘S AND LESSON LEARNED/ EPIDEMIOLOGY OF PNEUMOCOCCAL SEROTYPES IN 2015, IMPLICATIONS FOR NEW CONJUGATE VACCINES (Katherine O‘Brien, Center for American Indian Health/International Vaccine Access Center. USA) 09:45-10:15 PCVS-FROM IMMUNOGENICITY THROUGH CARRIAGE TO PUBLIC HEALTH IMPACT (Ron Dagan, Soroka University Medical Center. Israel) 10:15-10:45 CHANGES IN PNEUMOCOCCAL DISEASE IN THE VACCINE ERA/PNEUMOCOCCAL EXPERIENCES IN LATIN AMERICA UNIVERSAL VACCINATION (María Catalina Pírez, Centro Hospitalario Pereira Rosell. Uruguay) 10:45-11:15 NEXT GENERATION PNEUMOCOCCAL VACCINES, CHALLENGES INCLUDING EFFECTIVENESS (David Goldblatt, Institute of Child Health of University College London/WHO Reference Laboratory for Pneumococcal Serology. UK) 11:15-11:45 SURVEILLANCE/IMPACT ASSESSMENT OF PCV INTRODUCTION IN GAVI COUNTRIES: OPPORTUNITIES FOR LOWERING COST BY INTRODUCING NEW VACCINES AND/OR REDUCED SCHEDULES. (Gail Rodgers, The Bill and Melinda Gates Foundation. USA) 11:45-12:00 DISCUSSION 12:00-12:30 CHANGES IN PNEUMOCOCCAL DISEASE IN THE VACCINE ERA/PNEUMOCOCCAL EXPERIENCES IN LATIN AMERICA UNIVERSAL VACCINATION (Maria Catalina Pírez, Centro Hospitalario Pereira Rosell. Uruguay) 12:30-13:00 CUBAN PNEUMOCOCCAL CONJUGATE VACCINE: A NEW MORE COST-EFFECTIVE PCV7 IN PCV13 ERA (Vicente Vérez, Finlay Institute. Cuba) 13:00-13:30 STRATEGY FOR CLINICAL AND IMPACT EVALUATION OF A NEW CUBAN PNEUMOCOCCAL CONJUGATE VACCINE (Nivaldo Linares, Finlay Institute. Cuba) SYMPOSIUM VIRAL VACCINES (Room 2) THURSDAY 18 (09:00-13:00) Topic: Viral Vaccines Chairs: María Guadalupe Guzmán (IPK, Cuba) / Laureano Mestra (Colombia) 09:00-09:05 OPENING SESSION 09:05-09:35 VIRUS-LIKE PARTICLES AND NUCLEOPARTICLES AS VACCINE CANDIDATES (Gerardo Guillén, CIGB. Cuba) 24 IMMUNOPHARMACOLOGY - VACCIPHARMA 2015 09:35-10:05 DENGUE VACCINE, ADVANCES AND CHALLENGES (María Guadalupe Guzmán, IPK. Cuba) 10:05-10:25 EVALUATION OF THE IMMUNOGENICITY AND PROTECTIVE EFFICACY OF A TETRAVALENT SUBUNIT VACCINE CANDIDATE AGAINST DENGUE VIRUS (Laura Lazo, CIGB Cuba) 10:25-10:45 RECOMBINANT DENGUE 2 VIRUS NS3 PROTEIN CONSERVES STRUCTURAL ANTIGENIC AND IMMUNOLOGICAL PROPERTIES RELEVANT FOR DENGUE VACCINE DESIGN (Rosa Ramirez, IPK. CUBA) 10:45-11:05 HBV AND HCV MUTANTS ASSOCIATE WITH VACCINE ESCAPE AND ANTIVIRAL RESISTANCE (Licel Rodríguez, IPK. CUBA) 11:05-11:25 MOLECULAR EPIDEMIOLOGY OF HPV IN WOMAN FROM COAST REGION OF ECUADOR (Cesar Bedoya, INSPI. ECUADOR) 11:25-11:45 MOLECULAR EPIDEMIOLOGY OF HPV IN CUBAN POPULATION (Celia María Limia, IPK. CUBA) 11:45-12:05 MEASLES, RUBELLA AND MUMPS ANTIBODIES DETECTION AFTER PRIMARY MMR VACCINATION IN CHILDREN BETWEEN 14 TO 17 YEARS OLD (María de los Angeles Ribas, IPK. CUBA) 12:05-12:25 ETHIC CONSIDERATIONS IN VACCINE DEVELOPMENT (Laureano Mestra, PAHO. COLOMBIA) 12:25-12:55 DISCUSSION WORKSHOP THERAPEUTIC VACCINE (infectious disease) Room 3 TUESDAY 16 (09.00-13.30) Topic1: Human Papillomavirus Chairs: Dr. Rosella Franconi (Italy) / Dr. Isis Torrens (Cuba) 09.00-09.05 OPENING SESSION 09.05-09.30 DEVELOPMENTS ABOUT PLANT-BASED VACCINES FOR THE IMMUNOTHERAPY OF HUMAN PAPILLOMAVIRUS-RELATED CANCERS (Dr. Rosella Franconi, Italian National Agency for New Technologies, ENEA. Italy) 09.35-10.00 A NOVEL STRATEGY TO IMPROVING ANTIGEN PRESENTATION FOR ACTIVE IMMUNOTHERAPY IN HUMAN PAPILLOMAVIRUS RELATED CANCER BY LINKING OF THE HPV TYPE 16 E7 ANTIGEN TO A CELL PENETRATING PEPTIDE (Isis Torrens, Center for Genetic Engineering and Biotechnology. Cuba) 10.05-10.30 NEW IMMUNOTHERAPIES AND NEW ORTHOTOPIC MOUSE MODELS (Dr. Aldo Venuti, Laboratory of Virology HPV-UNIT, National Cancer Institute, Rome. Italy) 25 IMMUNOPHARMACOLOGY - VACCIPHARMA 2015 Topic 2: Hepatitis B Therapeutic vaccine Chairs: Dr. Marie-Louise Michel (France) and Dr. Eduardo Pentón (Cuba) 10.35-10.40 OPENING SESSION 10.40-11.05 THERAPEUTIC VACCINES IN TREATING CHRONIC HEPATITIS B: FROM BENCH TO BEDSIDE AND BACK (Dr. Marie-Louise Michel, Institute Pasteur. France) 11.10-11.30 IN VITRO STIMULATION WITH HBV THERAPEUTIC VACCINE CANDIDATE NASVAC ACTIVATES B AND T CELLS FROM CHRONIC HEPATITIS B PATIENTS AND HEALTHY DONORS (Dr. Yadira Lobaina, CIGB. Cuba) 11.35-12.00 NASVAC, A CUBAN HEPATITIS B THERAPEUTIC VACCINE CANDIDATE: PRINCIPLES, UPDATE OF COMPLETED CLINICAL TRIALS (CT) AND ONGOING AND PLANNED CTS IN SEVERAL COUNTRIES (Dr. Eduardo Pentón, CIGB. Cuba) Topic 3: Adjuvants 12.05-12.10 OPENING NEW SESSION 12.10-12.35 ANTIVIRAL AND ADJUVANT PROPERTIES OF RIG-I AGONISTS (John Hiscott, Vaccine & Gene Therapy Institute of Florida. USA) 12.40-13.05 INFLUENCE OF THE HAPTEN AND THE CONJUGATE DOSE ON THE CARRIER-INDUCED HAPTEN-SPECIFIC SUPPRESSION ELICITED BY P64K IN MICE (Dr. Sonia Gonzalez, CIGB. Cuba) SYMPOSIUM COMBINED VACCINE (Room 3) TUESDAY 16 (15:00-18:00) Topic: Inactivated Polio Vaccine Chairs: Sonia Resik (IPK, Cuba) / Javier Martin (NIBSC, UK) 15.00-15.05 OPENING SESSION (Sonia Resik, Cuba) 15.05-15.35 THE ROLE OF INACTIVATED POLIO VACCINES IN THE POST-ERADICATION ERA (Javier Martin, NIBSC. UK) 15.35-16.05 ASSESSMENT ON POLIO VACCINES NEEDED TO ASSURE ERADICATION (Robyn Iqbal, BMGF. USA) 16.05-16.35 CUBAN CONTRIBUTIONS TO THE POLIO GLOBAL ERADICATION PROGRAM (Sonia Resik, IPK, Cuba) 16.35-16.55 SABIN-IPV PROCESS DEVELOPMENT AND PRODUCTION PROCESS (Wilfried Bakker, INTRAVAC. The Netherlands) 16.55-17.20 SAFETY AND IMMUNOGENICITY OF INACTIVATED POLIOVIRUS VACCINE BASED ON SABIN STRAINS, WITH AND WITHOUT ALUMINUM HYDROXIDE (Yenisleidys Martínez, IPK. Cuba) 26 IMMUNOPHARMACOLOGY - VACCIPHARMA 2015 17.20-17.45 SABIN-IPV DEVELOPMENT TO SUPPORT POLIO ERADICATION GOALS: CLINICAL TRIALS AND TECHNOLOGY TRANSFER (Wilfried Bakker, INTRAVAC. The Netherlands) 17.45-18.00 DISCUSSION WORKSHOP REGULATORY SYSTEM (Room3) WEDNESDAY 17 (09.00-17.30) Topic: Biologic/Biotech Products Chairs: Bradley Scott (Canada) and Yanet Hechavarría Núñez (Cuba) 09.00-09.05 OPENING SESSION (Yanet Hechavarría, Cuba) 09.05-09.30 SUBSEQUENT ENTRY BIOLOGICS (BIOSIMILARS) IN CANADA: A REVIEW OF KEY REGULATORY ISSUES AND LESSONS LEARNT (Bradley Scott, Health Canada. Canada) 09.30-09.55 CHARACTERIZATION REGULATIONS TO MAKE POSSIBLE AN ABBREVIATED MECHANISM OF APPROVAL OF CLINICAL TRIALS AND MARKETING OF PHARMACEUTICALS PRODUCTS FOR CANCER INDICATION (Violeta Pérez, CECMED. Cuba) 09.55-10.15 GUIDELINES FOR BIOLOGICS/BIOSIMILARS PRODUCTS IN BRAZIL (Caroline Blades, ANVISA. Brazil) 10.15-10.35 DEVELOPMENT AND EVALUATION OF BIOSIMILARS (Gilberto Castañeda-Hernández, Roche. México) 10.35-11.00 BIOSIMILAR CLINICAL DEVELOPMENT: PATIENT ACCESSIBILITY AND AFFORDABILITY OF LIFE-SAVING MEDICINES (Camilo Rodríguez, CENTER OF MOLECULAR IMMUNOLOGY, CUBA. Cuba) 11.00-11.25 EVALUATION OF REGULATORY CONVERGENCE FOR SIMILAR BIOLOGICAL MEDICINAL PRODUCTS IN LATIN AMERICA (Celeste Sanchez, CECMED. Cuba) 11.25-11.45 DISCUSSION 11.45-12.00 REGULATORY DOCUMENTS FOR CELL THERAPY AND TISSUE ENGINEERING PRODUCTS (Diana Patricia Hermida Vitar, CECMED. Cuba) 12.00-12.15 SURVEILLANCE AND TRACEABILITY OF CELLS AND TISSUES FOR CELL THERAPY (Lara Alonso, ANVISA. Brazil) 12.15-12.30 CELL THERAPY IN CUBA: INTRODUCTION, DEVELOPMENT AND PERSPECTIVES (José A Galván, IHI. Cuba) Chairs: Gilberto Castañeda-Hernández (México) and Biorkys Yáñez (Cuba) 15.00-15.15 CURRENT APPROACH ON POST-APPROVAL CHANGES AND PROCESS CHANGES DURING CLINICAL PHASE: INDUSTRY PERSPECTIVES (Gilberto Castañeda-Hernández, Mexico) 27 IMMUNOPHARMACOLOGY - VACCIPHARMA 2015 15.15-15.30 IMPACT OF THE NATIONAL INSPECTION PROGRAM ON QUALITY IMPROVEMENT OF CLINICAL TRIALS (2001-2015) (Judith Cartaya, CECMED. Cuba) 15.30-15.45 THE QUALITY RISK MANAGEMENT APPROACH INTO THE REGULATORY INSPECTIONS PROCESS (Biorkys Yáñez, CECMED. Cuba) 15.45-16.00 QUALITY RISK MANAGEMENT REGULATORY STANDPOINT AND IMPLEMENTATION (Yanelis Martínez, CECMED. Cuba) 16.00-16.15 MANAGEMENT OF QUALITY SYSTEMS FOR VACCINES PRODUCTION: CIGB AS CASE STUDY (Yair Quiñones, CIGB. Cuba) 16.15-16.30 CERTIFICATION IN GOOD CLINICAL PRACTICE. IMPLEMENTATION IN PRIMARY HEALTH CARE (Lidice Fernández, CECMED. Cuba) 16.30-17.00 DISCUSSION SYMPOSIUM COMBINED VACCINES (Room 3) THURSDAY 18 (09:00-13:00) Topic: Pertussis Vaccine Chairs: Coenraad Hendriksen (Intravacc, The Netherlands) / Mario Landys Chovel (Finlay Institute, Cuba) 09:00-09:05 OPENING SESSION 09:05-09:35 WHOLE-CELL AND ACELULAR PERTUSSIS COMPONENTS AND INTERACTIONS WITH OTHER ANTIGENS IN VACCINES COMBINATIONS (Waldely O. Dias, Butantan, Brazil) / 09:35-10:05 ACELULAR VERSUS WHOLE-CELL PERTUSSIS VACCINES: CLINICAL ISSUES (Joseph Mathew. India) 10:05-10:30 THE CONSISTENCY APPROACH IN LOT RELEASE TESTING OF VACCINES (Coenraad Hendriksen, Intravacc. The Netherlands) 10:30-10:55 PRODUCT CHARACTERIZATION AND IMMUNOPROTEOMIC PROFILING ARE VALUABLE TOOLS IN THE DEVELOPMENT AND PRODUCTION OF PERTUSSIS WHOLE CELL AND OMV VACCINES (Arno van der Ark, Intravacc. The Netherlands) 10:55-11:20 ASSESSMENT OF THE BORDETELLA PERTUSSIS BPCNIC0311 AS PRODUCING STRAIN FOR GENETICALLY DETOXIFIED TOXOID (PTG), FILAMENTOUS HEMAGGLUTININ (FHA) AND PERTACTIN TYPE 2 (PRN2) (Anabel Álvarez, CIGB. Cuba) 11:35-12:00 NEW RECOMBINANT HYBRID PROTEINS FROM PERTACTIN TYPE 1 AND 2 OF BORDETELLA PERTUSSIS (Diógenes Quintana, CIGB. Cuba) 28 IMMUNOPHARMACOLOGY - VACCIPHARMA 2015 12:00-12:30 DETECTION AND LOCALIZATION OF THE SURFACE-ASSOCIATED ADHESIN FILAMENTOUS HAEMAGGLUTIN ON BORDETELLA PERTUSSIS LIVING CELLS USING ATOMIC FORCE MICROSCOPY (Osvaldo Yantorno, Universidad Nacional de La Plata. Argentina) 12:30-13:00 DISCUSSION WORKSHOP THERAPEUTIC VACCINES (Cancer, Room 4) THURSDAY 18 (09:00-13:00) Topic: Pre-clinic approaches in the design of cancer therapies Chairs: James Hodge (USA) / Belinda Sánchez (Cuba) 09:00-09:05 OPENING SESSION 09:05-09:35 ATTACKING TUMOR CELLS THAT SURVIVE THERAPY: EXPLOITING IMMUNOGENIC MODULATION (James Hodge, National Cancer Institute, Maryland. USA) 09:35-10:00 ONGENE ADDICTION: A GOOD REASON FOR DESIGNING THERAPIES BASED ON HER1 AND HER2 (Belinda Sanchez, CENTER OF MOLECULAR IMMUNOLOGY, CUBA. Cuba) 10:00-10:25 PRE-CLINICAL DEVELOPMENT OF SVX-1: A NOVEL THERAPEUTIC CANCER VACCINE (Ahmed Bouzidi, Vaxeal. Switzerland) 10:25-10:50 EFFECT OF CYCLOOXYGENASE INHIBITION ON THE IMMUNE RESPONSE TO VACCINATION (Giselle Hevia, Center of Molecular Immunology, Cuba) 10:50-11:15 STATE OF THE ART OF DOWNSTREAM BIOPROCESSING OF PROTEIN BASED BIOLOGICAL PRODUCTS (Steve Cramer, RPI. USA) 11:15-11:40 DRUGS AGAINST LUNG CÁNCER (Katharine Christine Carter, University of Strathclyde. UK) 11:40-11:55 DISCUSSION Topic: A close look into the clinic Chairs: Marta Ayala (Cuba) / Camilo Rodríguez (Cuba) 11:55-12:20 DECIPHERING THE THERAPEUTIC EFFECT OF NGCGM3/VSSP VACCINE USING A RELEVANT SPONTANEOUS METASTASIS TUMOR MODEL (Mayrel Labrada, CENTER OF MOLECULAR IMMUNOLOGY. Cuba) 12:20-12:45 IMMUNOGENICITY OF CIMAVAX-EGF AFTER COMBINATION WITH DIFFERENT CHEMOTHERAPY SCHEDULES IN ADVANCED NON SMALL CELL LUNG CANCER (Camilo Rodríguez, Center of Molecular Immunology, Cuba) 12:45-13:10 IMMUNE RESPONSE IN HUMAN AFTER VACCINATION WITH A MODIFIED VARIANT OF HUMAN VEGF (Marta Ayala, CIGB. Cuba) 29 IMMUNOPHARMACOLOGY - VACCIPHARMA 2015 13:10-13:35 RESULTS OF A RANDOMIZED, MULTICENTER AND PLACEBO-CONTROLLED CLINICAL TRIAL WITH RACOTUMUMAB-ALUM AS SWITCH MAINTENANCE THERAPY IN ADVANCED NON SMALL CELL LUNG CANCER (Annet Valdes, Center of Molecular Immunology, Cuba) WHIV: WORKSHOP HIV-AIDS (Room 7) TUESDAY 16 (09:00-13:30) Topic: HIV/AIDS Chairs: José Alcamí, Instituto de Salud Carlos III (Spain) / Vivian Kourí, IPK (Cuba) 09.00-09.05 OPENING SESSION (Vivian Kourí, Cuba) 09.05-09.45 PHARMACOLOGICAL STRATEGIES TO TACKLE THE HIV RESERVOIRS: TO ACTIVATE OR TO DEACTIVATE (José Alcamí, Instituto de Salud Carlos III. Spain) 09.50-10.10 RESULTS OF CUBAN RESPONSE TO HIV/AIDS EPIDEMIC 28 YEARS AFTER. WERE WE IN THE RIGHT PATH? (José Joanes, MINSAP. Cuba) 10.15-10.35 PREVENTION OF HIV WITH THE ART TREATMENT IS POSSIBLE. NATIONAL RESPONSE OF HIV EPIDEMICS IN CUBA (Jorge Pérez, IPK. Cuba) 10.40-11.00 HIGH FREQUENCY OF ANTIVIRAL DRUG RESISTANCE AND NON-B HIV-1 SUBTYPES IN CUBA (Vivian Kourí, IPK. Cuba) 11.05-11.25 HIV RESISTANCE TO ANTIRETROVIRALS IN ECUADOR (Manuel González, INSPI. Ecuador) 11.30-11.50 HIV VIF AS TARGET FOR ANTI-RETROVIRAL THERAPY. GENERATION OF SINGLE CHAIN ANTIBODY FRAGMENTS DERIVED FROM A NOVEL MONOCLONAL ANTIBODY AGAINST RECOMBINANT VIF (Carlos A. Duarte, CIGB, Cuba) 11.55-12.15 CIGB-210: A NOVEL APPROACH TO TREAT HIV INFECTION (Celia Fernández-Ortega, CIGB, Cuba) 12.20-12.40 DETERMINANTS OF ADHERENCE TO HIGHLY ACTIVE ANTIRETROVIRAL THERAPY AMONG PEOPLE ATTENDING A PUBLIC HIV CLINIC IN GHANA (Nora Katende-Kyenda, South Africa) 12:45-13:05 OXIDANT /ANTIOXIDANT STATUS AND PROGRESSION MARKERS IN HIV/AIDS PATIENT’S BLOOD SAMPLES IN DIFFERENT CLINICAL CONDITIONS AND ANTIRETROVIRAL COMBINATION (Lizette Gil, IPK, Cuba) SYMPOSIUM COMBINED VACCINES (Room 4) WEDNESDAY 17 (15:00-18:00) Chairs: Dorothea Sesardic (UK) / Verena Muzio (Cuba) 15:00-15:30 BIOASSAYS FOR EVALUATION OF MEDICAL PRODUCTS DERIVED FROM BACTERIAL TOXINS (Dorothea Sesardic, NIBSC. UK) 30 IMMUNOPHARMACOLOGY - VACCIPHARMA 2015 15:35-15:55 INACTIVATED POLIO VACCINE COMPONENT AND INTERACTIONS WITH OTHER ANTIGENS IN VACCINES COMBINATIONS (Javier Martin, NIBSC. UK) 16:00-16:20 CUBAN PENTAVALENT VACCINE: CLINICAL ISSUES (Verena Muzio, CIGB. Cuba) 16:25-16:45 COMPARISON BETWEEN WHO AND FDA POTENCY METHODS FOR DIPHTHERIA AND TETANUS COMPONENTS IN THE CUBAN PENTAVALENT VACCINE (Mabel Izquierdo, CIGB. Cuba) 16:50-17:10 EFFICIENT MEANS TO DETERMINE THE HIB COMPONENT IN LIQUID FORMULATION VACCINE COMBINATIONS (Ute Rosskopf, WHO. Germany) 17:10-17:30 DISCUSSION SYMPOSIUM TB VACCINES (Room 5) MONDAY 15 (15.00-18.00) Topic: Tuberculosis Vaccine and Research Chairs: Dr. Willem Hanekom (South Africa) / Prof. Herve Bercovier (Israel) 15:00-15:10 OPENING SESSION 15:10-15:35 DEVELOPING NEW VACCINES FOR TUBERCULOSIS CHALLENGES AND STRATEGIES (Lewis Schrager, AERAS. USA) 15:35-16:00 TB VACCINES: WHAT IS NEW? (Willem Hanekom, Bill and Melinda Gates Fundation. South Africa) 16:00-16:25 BACILLE CALMETTE- GUERIN (BCG): A VACCINE GOOD FOR ONLY TB? (Prof. Hervé Bercovier, Hebrew University of Jerusalem. Israel) 16:25-16:50 TUBERCULOSIS AND SOCIAL INEQUALITIES IN HEALTH (Edilberto González Ochoa, Tropical Medicine Institute IPK, Cuba) 16:50-17:15 IMMUNOGENICITY AND PROTECTION INDUCED BY A MYCOBACTERIUM TUBERCULOSIS SIGE/FADD26 DOUBLE MUTANT IN A BALB/C MOUSE MODEL OF PROGRESSIVE PULMONARY TUBERCULOSIS (Rogelio Hernández-Pando, INCMNSZ, Mexico) 17:15-17:25 MYCOBACTERIUM SMEGMATIS: A PROPHYLACTIC PROTECTIVE CANDIDATE AGAINST TB IN AN EXPERIMENTAL MODEL OF INFECTION (Nadine Alvarez, Finlay Institute. Cuba) 17:25-17:35 THE DEVELOPMENT OF FERMENTATION AND PURIFICATION PROCESSES FOR THE RECOMBINANT PROTEIN RV2626C OF MYCOBACTERIUM TUBERCULOSIS EXPRESSED IN STREPTOMYCES LIVIDANS (Emmanuel N. King-Batsios, PhD student. Ghana) 17:35-17:45 PROTECTIVE CAPACITY OF PROTEOLIPOSOMES FROM MYCOBACTERIUM BOVIS BCG IN A MOUSE MODEL OF TUBERCULOSIS (Yanely Tirado, Finlay Institute. Cuba) 31 IMMUNOPHARMACOLOGY - VACCIPHARMA 2015 17:45-17:55 RELEVANT ASPECTS OF THE USE OF MYCOBACTERIUM ´HABANA´ AS TUBERCULOSIS VACCINAL CANDIDATE (Iliana Valdes, Tropical Medicine Institute IPK. Cuba) 17.55-18.10 DISCUSSION SYMPOSIUM VETERINARY VACCINES (Room 6) MONDAY 15 (15:00-18:00) Chairs: Ángel Hilario Álvarez (México) / Octavio Fernández Lima (Cuba) 15:00-15:05 OPENING SESSION 15:05-15:25 LONG-TERM VIABILITY MB2054C, MB2057C, AND MB2660C PROTEINS FROM MYCOBACTERIUM BOVIS INDUCE HUMORAL AND CELLULAR IMMUNE RESPONSES IN VIVO AND IN VITRO (Ángel Hilario Álvarez, Centro de Investigación y Asistencia en Tecnología y diseño del Estado de Jalisco. México) 15:25-15:45 INFLUENCE OF ENROFLOXACIN GIVEN IN THERAPEUTIC DOSES ON THE POSTVACCINAL IMMUNE RESPONSE IN PIGS (Malgorzata Pomorska, National Veterinary Research Institute. Poland) 15:45-16:05 IDENTIFICATION OF IMMUNOGENIC PROTEINS FROM OVARIAN TISSUES OF THE CATTLE TICK RHIPICEPHALUS (BOOPHILUS) MICROPLUS BY AN IMMUNOPROTEOMIC APPROACH (Patricia Ramírez, Centro de Investigación y Asistencia en Tecnología y diseño del Estado de Jalisco. México) 16:05-16:25 MOLECULAR CHARACTERIZATION OF THE VITELLOGENIN 3 GENE FROM A MEXICAN RHIPICEPHALUS (BOOPHILUS) MICROPLUS TICK STRAIN (Moisés Martínez, Centro de Investigación y Asistencia en Tecnología y diseño del Estado de Jalisco. México) 16:25-16:45 IMPLEMENTATION OF THE CUBAN GUIDES FOR GOOD CLINICAL VETERINARY PRACTICE BY CENSA (Octavio Fernández Lima, CENSA. Cuba) 16:45-17:05 DESIGN AND OPTIMIZATION OF PURIFICATION PROCESS OF MY32LS PROTEIN SOLUBILIZING INCLUSION BODIES FOR A NEW VACCINE AGAINST SEA LICE (Carlos Perez, CIGB Camaguey. Cuba) 17:05-17:25 MOLECULAR CLONING AND EXPRESSION OF GENE FRAGMENTS FROM COMPUTATIONALLY PREDICTED MYCOPLASMA GALLISEPTICUM SURFACE ANTIGENIC PROTEINS (Jose Antonio Agüero CENSA. Cuba) 17:25-17:40 DISCUSSION 32 IMMUNOPHARMACOLOGY - VACCIPHARMA 2015 SYMPOSIUM BIOPROCESSES (Room 6) TUESDAY 16 (09.00-13.30) Topic: Upstream Bioprocesses Chairs: Miguel A. Jácome Vital, CINESTAV-IPN (México) / Odalys Ruíz, CIGB (Cuba) 09.00-09.05 OPENING SESSION (Odalys Ruíz, Cuba) 09.05-09.35 CHARACTERIZATION OF MICROBIAL CULTURES IN A HIGH-THROUGHPUT 24-WELL MICROBIOREACTOR SYSTEM BY RESPIROMETRY (Miguel A. Jácome Vital, CINESTAV-IPN. México) 09.40-10.10 CHARACTERIZATION OF A BIOREACTOR FOR CANCER VACCINE DEVELOPMENT, BASED ON HER-1 EXTRACELLULAR DOMAIN, WITH CFD AID (Osmán Fernández, CENTER OF MOLECULAR IMMUNOLOGY. Cuba). 10.15-10.45 STRATEGIES FOR REDUCTION OF BIOREACTOR CONTAMINATIONS AND ENHANCED PRODUCTIVITY IN INDUSTRIAL FERMENTATIONS. PRODUCTION OF HBSAG IN PICHIA PASTORIS FERMENTATION AS CASE OF STUDY (Juan Miguel Rivera, CIGB. Cuba) 10.50-11.20 ADENOVIRAL PARTICLES AS VECTORS FOR GENE THERAPY AND VACCINE TECHNOLOGY: AN INTEGRAL PERFORMANCE FOR PRODUCTION (Angélica Meneses, Morelos University. México) 11.25-11.35 DISCUSSION 11.35-12.05 STATISTICAL APPROACHES TO DEFINE MEDIUM COMPOSITION FOR BIOMASS PRODUCTION OF RECOMBINANT E.COLI CELLS TO OBTAIN A THERAPEUTIC VACCINE (Odalys Ruíz, CIGB. Cuba) 12.10-12.40 THE CHARACTERISTICS OF VIRUS REMOVAL FILTERS WITH DIFFERENT MEMBRANE MATERIALS AND STRUCTURES (Roya Dayani, Asahi Kasei Bioprocess Europe. Belgium) 12.45-13.00 PALL CAPABILITIES FOR THE BIOTECH INDUSTRY (Gina Meza, Sistemas Industriales de México, S.A. de C.V. México. México) TUESDAY 16 (15:00-18:00) Topic: Downstream Bioprocesses, high throughput technologies Chairs: Nika Lendero, BIASeparations (Slovenia) / Rodolfo Valdés, CIGB (Cuba) 15.00-15.30 USING MONOLITHIC CHROMATOGRAPHIC COLUMNS TO CONTROL DE BIOPHARMACEUTICAL MANUFACTURING PROCESS (Nika Lendero, BIASeparations. Slovenia) 15.35-16.05 EVALUATION OF A PROCESS REDESIGN FOR THE PURIFICATION OF A RECOMBINANT STREPTOKINASE USING CIM QA MONOLITHIC COLUMN (Gabriel Márquez, CIGB. Cuba) 16.10-16.40 IMMUNOAFFINITY CHROMATOGRAPHIC MONOLITHS FROM ANALYTICS TO DOWNSTREAM (Nika Lendero, BIASeparations. Slovenia) 33 IMMUNOPHARMACOLOGY - VACCIPHARMA 2015 16.45-17.15 MONOLITHIC STRUCTURE SUPPORT APPLICATION FOR IMMUNOPURIFYING HEPATITIS B SURFACE ANTIGEN PARTICLES FOR HUMAN VACCINATION (Rodolfo Valdés, CIGB. Cuba) 17.20-17.50 BATCH OR CONTINUOUS CHROMATOGRAPHY? WHICH CHROMATOGRAPHIC METHOD DO YOU CHOOSE? (Ulrike Maschke, KNAUER. Germany) 17.55-18.00 CONCLUSIONS SYMPOSIUM BIOPROCESSES (Room 6) WEDNESDAY 17 (09.00-13.30) Topic: Downstream Bioprocesses Chairs: Steve Cramer, RPI (USA) / Miladys Limonta, CIGB (Cuba) 09.00-09.05 OPENING SESSION (Miladys Limonta) 09.05-09.35 UNDERSTANDING AND ENHANCING SELECTIVITY IN MULTIMODAL CHROMATOGRAPHY FOR COMPLEX PROTEIN SEPARATIONS (Steve Cramer, RPI. USA) 09.40-10.10 PURIFICATION OF ACTIVE INGREDIENTS: A TRANSFER FROM BATCH TO CONTINUOUS COUNTERCURRENT MULTICOLUMN CHROMATOGRAPHY PROCESSES (Ulrike Maschke, KNAUER. Germany) 10.15-10.45 DESIGNING AND KNOWING THE SPACE FOR CIGB 550-E7, AN ACTIVE PHARMACEUTICAL INGREDIENT FOR HPV CANDIDATE VACCINE (Miladys Limonta, CIGB. Cuba) 10.50-11.20 VIRUS FILTRATION PROCESS DESIGN: MAXIMIZING VIRUS RETENTION BY SIMPLE PARAMETER ADJUSTMENTS (Sebastian Teitz, Asahi Kasei Bioprocess Europe. Germany) 11.25-11.35 DISCUSSION 11.35-12.05 VSSP PRODUCTIVE PROCESS FROM SYNTHETIC GANGLIOSIDE (Lourdes Hernández, CENTER OF MOLECULAR IMMUNOLOGY. Cuba) 12.10-12.40 PLASMA FRACTIONATION USING SIMULATED MOVING BED TECHNOLOGY (SMB) (Ulrike Maschke, KNAUER. Germany) 12.45-13.00 CONCLUSIONS WEDNESDAY 17 (15.00-18.00) Topic: Drug delivery Bioprocesses Chairs: Valerie Ferro, SIPBS (UK) / Lissette Agüero, BIOMAT (Cuba) 15.00-15.30 CHALLENGES IN DEVELOPING MUCOSAL VACCINES (Valerie Ferro, SIPBS. UK) 34 IMMUNOPHARMACOLOGY - VACCIPHARMA 2015 15.35-16.05 CATIONIC PH-RESPONSE MICROPARTICLES AS DEVICE FOR COLON SPECIFIC DELIVERY (Lissette Agüero, BIOMAT. Cuba) 16.10-16.40 TECHNOLOGICAL DEVELOPMENT OF PEGYLATED BIOPHARMACEUTICAL PRODUCTS. CASES OF STUDY IN THE CENTER FOR GENETIC ENGINEERING AND BIOTECHNOLOGY (CIGB) (Liurdis Caballero, CIGB. Cuba) 16.45-17.15 SYNTHESIS OF FLUORESCENT NANOPARTICLES OF PEG-PLA COPOLYMERS BY UGI FOUR COMPONENT CONDENSATION (Marcos López, Universidade Federal do Rio de Janeiro, Instituto de Macromoléculas. Brasil) 17.20-17.50 NANOSCOPIC STUDIES TO TRACK THE EFFECTS OF NEXT-GENERATION NANOMEDICINES ON PATIENTS (Dimitrios Lamprou, SIPBS. UK) 17.55-18.00 CONCLUSIONS 35 IMMUNOPHARMACOLOGY - VACCIPHARMA 2015 POSTERS SESSIONS Wednesday 17 (15:00-18:00) SYMPOSIUM MENINGOCOCCAL VACCINES Chairs: Caridad Zayas (Finlay Institute) and Fidel Ramírez (Finlay Institute) 01: STANDARDIZATION OF AN ELISA FOR DETERMINING CONTENT OF POLYSACCHARIDES A, C, Y, W IN MULTIVALENT VACCINES Fernández Y, Gutiérrez N, Lara M, Corcho L, Alfonso S, Chovel ML. FINLAY INSTITUTE, HAVANA, CUBA 02: NEISSERIA MENINGITIDIS SEROGROUP X: NEW VACCINE STRATEGIES Zayas C, Acevedo R, Gunnstein, García L, Valmaseda T, Cedré B, Cuello M, et al. FINLAY INSTITUTE, HAVANA, CUBA 03: NEW PURIFICATION TECHNOLOGY TO OBTAIN MENINGOCOCCAL POLYSACHARIDES FROM SEROGROUPS A, C, Y, W AND X González H, González D, Hernández M, Guerra M, Concepción F, Guzmán LA, Martínez JC et al. FINLAY INSTITUTE, HAVANA, CUBA 04: RETROSPECTIVE VALIDATION OF THE PROCESS FOR OBTAINING THE SEROGROUP B NEISSERIA MENINGITIDIS OUTER MEMBRANE VESICLES Lozada SL, Bayolo J, Rojo D, Soto C, Aguiar S, Troya Y and Merladet Y. FINLAY INSTITUTE, HAVANA, CUBA 05: SELECTION OF NEISSERIA MENINGITIDIS SEROGROUP Y STRAINS AS TARGET OF BACTERICIDAL ACTIVITY IN THE EVALUATION OF MENINGOCOCCAL VACCINES Callis AH. Cedré B, Acevedo R, García M, Cardoso F, Núñez D, García L. FINLAY INSTITUTE, HAVANA, CUBA 06: SURVEILLANCE OF AGENTS THAT CAUSE BACTERIAL MENINGITIS IN CUBA BY PCR Gutiérrez O, Feliciano O, Vásquez V, Rodríguez N, Llanes R. TROPICAL MEDICINE INSTITUTE «PEDRO KOURÍ» (IPK), HAVANA, CUBA 07: DEVELOPMENT A NEOGLYCOCONJUGATE VACCINE FROM NEISSERIA MENINGITIDIS SEROGROUP X Cardoso F, Glez M, Garrido R, Baró B, Aliaga I, Rey E. D, Acevedo R. FINLAY INSTITUTE, HAVANA, CUBA 36 IMMUNOPHARMACOLOGY - VACCIPHARMA 2015 08: DEVELOPMENT OF INDIRECT ELISAS FOR EVALUATING HUMAN IGG ANTIBODIES AGAINST OUTER MEMBRANE VESICLES OF NEISSERIA MENINGITIDIS SEROGROUPS A AND W Aranguen Y, Balboa JA, Álvarez M, García LG, Cedré B, Naess L, Mandiarote A et al. FINLAY INSTITUTE, HAVANA, CUBA 09: NEISSERIA MENINGITIDIS DERIVED PROTEOLIPOSOME AS AN ADJUVANT FOR ALLERGEN VACCINES Ramírez W, Labrada A, Facenda E, Bourg V, González B, Más A et al. NATIONAL CENTER OF BIOPRODUCTS (BIOCEN), ARTEMISA, CUBA 10: METHODOLOGY FOR THE MONITORING OF CHEMICAL STANDARDS FOR VACCINES BY COMBINING SHELF-LIFE STABILITY AND SYSTEMATIC IN-USE RESULTS Díaz D, Chovel ML, Lara D, Alfonso S. FINLAY INSTITUTE, HAVANA, CUBA 11: CHARACTERIZATION OF AN IN-HOUSE POLYSACCHARIDE A STANDARD FOR QUALITY CONTROL TESTING OF MENINGOCOCCAL VACCINES Gutiérrez N, Chovel ML, Díaz D, Lara D. FINLAY INSTITUTE, HAVANA, CUBA 12: NEUMOCOCCAL MENINGOENCEFALITIS, A REASON FOR A PREVENTIVE VACCINE Pantoja O, Álvarez I, Luis I, Rivero M, Luis MC. Hospital Pediátrico Universitario «William Soler» 13: CHARACTERIZATION OF CAPSULAR POLYSACCHARIDES STANDARDS FOR THE QUALITY CONTROL OF MENINGOCOCCAL VACCINES Alfonso S, Chovel ML, Díaz D, Gutiérrez N, Tamayo Y. FINLAY INSTITUTE, HAVANA, CUBA SYMPOSIUM ENTERIC VACCINE Chairs: Sonsire Fernández and Jose Luis Pérez 14: PRECLINICAL EVALUATION: TOXICITY OF SINGLE DOSE OF THE VACCINE TYPHOID OF POLYSACCHARIDE VI CONJUGATE IN SPRAGUE DAWLEY RATS Oliva R, Fariñas M, Infante JF, González MO, Hernández T, Núñez D, Pérez V, Valdés BY, Aranguren Y, Bacallao EG, Campos L, Fernández S. FINLAY INSTITUTE, HAVANA, CUBA 37 IMMUNOPHARMACOLOGY - VACCIPHARMA 2015 15: MONITORING OF THE CONTROLED WITH PLACEBO, RANDOMIZED AND DOUBLE BLIND PHASE I CLINICAL TRIAL TO ASSESS SAFETY, REACTOGENICITY AND IMMUNOGENICITY, OF THE CV 638 HEALTLY CHILDREN AND ADOLESCENTS IN CUBA García HM, Valera RF, Pérez JE, Fando R, Cardoso E, Armesto MI et al. FINLAY INSTITUTE, HAVANA, CUBA 16: CHARACTERIZATION OF MURINE MONOCLONAL ANTIBODY TO CAPSULAR POLYSACCHARIDE FROM SALMONELLA TYPHI AND ITS POTENCIAL USE IN QUANTIFICATION OF TYPHOID VACCINES Amin N, Reyes F, Camacho F, Cuello M, Otero O, Núñez D, Ochoa R, Fernández S, García L, Cardoso D. FINLAY INSTITUTE, HAVANA, CUBA 17: COMPARISON OF TWO VIBRIOCIDAL ASSAYS TO EVALUATE THE IMMUNOGENICITY OF CHOLERA VACCINES Cedré B, García M, Landys M, Tamayo Y, Lisbeth N, Mandariaga S, Acevedo R, García L. FINLAY INSTITUTE, HAVANA, CUBA 18: MONOCLONAL ANTIBODY AGAINST VIBRIO CHOLERAE O1 LIPOPOLYSACCHARIDE COUPLED TO LATEX PARTICLES. A TOOL FOR THE RAPID DIAGNOSIS OF CHOLERA DISEASE Otero O, Cuello M, Reyes F, Camacho F, Duranti G, Morales MM, Mora R. FINLAY INSTITUTE, HAVANA, CUBA 19: PHYSICOCHEMICAL AND IMMUNOLOGICAL CHARACTERIZATION OF VI POLYSACCHARIDE CONJUGATED TO TETANUS TOXOID Soubal JP, Santana D, Espinosa C, Garrido R, Pedroso J, Torres L. FINLAY INSTITUTE, HAVANA, CUBA 20: CHEMICAL ANALYSIS OF O-ANTIGEN DERIVED LPS FROM SALMONELLA PARATYPHI A Hernández M, Pérez JL, Blain K, Fernández S, Martínez M, Lescaille D and col. FINLAY INSTITUTE, HAVANA, CUBA 21: PURIFICATION AND PRELIMINARY CHARACTERIZATION OF OMV DERIVED FROM OUTER SURFACE OF SALMONELLA PARATYPHI A Pérez JL, Fernández S, Martínez M, Blain K, Lescaille D, Serrano D and col. FINLAY INSTITUTE, HAVANA, CUBA 22: PURIFICATION OF O-ANTIGEN DERIVED LPS FROM SALMONELLA PARATYPHI A Pérez JL, Blain K, Fernández S, Martínez M, Lescaille D, Serrano D and col. FINLAY INSTITUTE, HAVANA, CUBA 38 IMMUNOPHARMACOLOGY - VACCIPHARMA 2015 23: IMMUNOGENICITY OF VI POLYSACCHARIDE OF SALMONELLA TYPHI CONJUGATED TO DIPHTHERIA TOXOID Soroa Y, Fernández S, Rodríguez L, Rodríguez Y, Martin Y, Soubal JP. FINLAY INSTITUTE, HAVANA, CUBA 24: CHARACTERIZATION OF STANDARDS FOR THE QUANTIFICATION OF POLYSACCHARIDE IN A CONJUGATE SALMONELLA VACCINE Lara D, Chovel ML, Diaz D, Gutiérrez N. FINLAY INSTITUTE, HAVANA, CUBA SYMPOSIUM PNEUMOCOCCAL VACCINES Chairs: Indira Utria and Laura Rodríguez 25: THE CONJUGATE SYNTHESIS WITH A LONG SPACER ARM INCREASES THE IMMUNOGENICITY OF PNEUMOCOCCAL SEROTYPE 5 POLYSACCHARIDE CONJUGATE VACCINE Santana D, Felipe J, Valdés Y, Soroa Y, Soubal JP, Aleaga I. FINLAY INSTITUTE, HAVANA, CUBA 26: DEVELOPMENT AND VALIDATION OF ELISA FOR QUANTITATIVE SEROTYPE SPECIFIC POLYSACCHARIDE IGG OF STREPTOCOCCUS PNEUMONIAE IN RABBIT SERUM Rodríguez LM, Martín Y, Pérez A, Espinosa-Viñals C, García-Rivera D, Travieso M, Nicot M. FINLAY INSTITUTE, HAVANA, CUBA 27: DESIGN AND MANUFACTURE OF ANTIGEN-DISPLAYING POLYHYDROXYALKANOATE BEADS AS NOVEL PARTICULATE VACCINE TO PREVENT PNEUMOCOCCAL AND MENINGOCOCCAL DISEASES González M, Rodríguez L, Vérez V, Rehm H. FINLAY INSTITUTE, HAVANA, CUBA 28: PHASE I CLINICAL TRIAL OF A CUBAN 7-VALENT PNEUMOCOCCAL CONJUGATE VACCINE IN HEALTHY INFANTS González N, Paredes B, Dotres CP, Puga R, Ricardo Y, García Y, del Valle RA et al. FINLAY INSTITUTE, HAVANA, CUBA 29: RELEVANCE OF O-ACETYL AND PHOSPHOGLYCEROL GROUPS FOR THE ANTIGENICITY OF STREPTOCOCCUS PNEUMONIAE SEROTYPE 18C CAPSULAR POLYSACCHARIDE Chang J, Serrano Y, Garrido R, Rodríguez L. M, Pedroso J, Cardoso F et al. FINLAY INSTITUTE, HAVANA, CUBA 39 IMMUNOPHARMACOLOGY - VACCIPHARMA 2015 30: VALIDATION OF ANALYTICAL PROCEDURES FOR QUALITY CONTROL OF PNEUMOCOCCAL VACCINE QUIMI-VIO BY HPLC Pedroso J, Aliaga I, Rodríguez E, Villar A, Ramírez U, Santana D, García D, Valdés Y, Vérez V. FINLAY INSTITUTE, HAVANA, CUBA 31: DEVELOPMENT OF A DECAVALENT CONJUGATE VACCINE AGAINST STREPTOCOCCUS PNEUMONIAE Mariño D, Chang J, Santana D, Herrera L, Carrera M, Pérez A, Fonseca D et al. FINLAY INSTITUTE, HAVANA, CUBA 32: VALIDATION AND CONFIRMATION OF THE WHO RECOMMENDED ELISA FOR QUANTITATION OF IGG AGAINST POLYSACCHARIDES 1, 5, 6A, 6B, 14, 19A, 19F AND 23F OF STREPTOCOCCUS PNEUMONIAE IN HUMAN SERA, AT IMMUNOLOGY LABORATORY FROM CENTER FOR BIOMOLECULAR CHEMISTRY Pérez A, Rodríguez LM, Garcés A, Martínez D, Espinosa-Viñals C, Soroa Y. FINLAY INSTITUTE, HAVANA, CUBA 33: CHARACTERIZATION OF STRAINS OF STREPTOCOCCUS PNEUMONIAE SEROTYPE 7F, 9V AND 19 A AS FUTURE VACCINE CANDIDATES. Hernández M, González H, Guerra M, Guzmán L.A, Martínez J. C, Concepción F, Costa W et al. FINLAY INSTITUTE, HAVANA, CUBA 34: PHYSICOCHEMICAL CHARACTERIZATION OF «IN-HOUSE» ALUMINUM PHOSPHATE ADJYVANT USED IN THE FORMULATION OF CUBAN PNEUMOCOCCAL VACCINE: QUIMI-VIO Fonseca D, Reguera E, Nadal L, Felipe J, Arias D, Triana L. FINLAY INSTITUTE, HAVANA, CUBA 35: COMPLICATED COMMUNITARIAN PNEUMONIA. CLINICAL EVOLUTION MICROBIOLOGICAL ISOLATION AND ANTIBIOTIC COST. WILLIAM SOLER HOSPITAL. 2013-2014 Sánchez C, Ramos LT, Reyes C, Barreiro B, Cantillo H and Martínez I. Pediatric Hospital «William SoIer» 36: SENTINEL SURVEILLANCE OF PNEUMOCOCCAL DISEASE AND NASOPHARYNGEAL COLONIZATION: STRATEGY FOR MONITORING THE EFFECTIVENESS AND IMPACT OF THE HEPTAVALENT PNEUMOCOCCAL CUBAN VACCINE. Linares N, Toraño G, Fonseca M, Dotres CP, Reyes A, Montes de Oca M. FINLAY INSTITUTE, HAVANA, CUBA 40 IMMUNOPHARMACOLOGY - VACCIPHARMA 2015 SYMPOSIUM VIRAL VACCINES Chairs: Ana Beatriz Pérez (IPK) and Ernesto Marcos (CIGB) 37: INDUCTION OF NEUTRALIZING ANTIBODIES AND MULTI-SPECIFIC CELLULAR IMMUNE RESPONSE EMPLOYING A CHIMERIC PROTEIN ENCOMPASSING HEPATITIS C VIRUS EPITOPES Aguilar D, Dueñas S, Álvarez L, Santana FL, Dubuisson J, Wychowski C et al. CENTER FOR GENETIC ENGINEERING AND BIOTECHNOLOGY, HAVANA, CUBA 38: A TETRAVALENT DENGUE VACCINE CONTAINING A MIX OF DOMAIN III-P64K AND DOMAIN IIICAPSID PROTEINS INDUCES A PROTECTIVE RESPONSE IN MICE Izquierdo A, García A, Lazo L, Gil L, Álvarez M, Hermida L, Guillén G, Guzmán MG. TROPICAL MEDICINE INSTITUTE «PEDRO KOURÍ» (IPK), HAVANA, CUBA 39: POLYHISTIDINE TAG LOCATION TRIGGER DIFFERENTIATED EXPRESSION LEVELS OF DENGUE 2 VIRUS RECOMBINANT NS3 PROTEIN IN ESCHERICHIA COLI Falcón R, Ramírez R, Hernández MS, Fleitas O, Almaguer T, Ortega O, et al. TROPICAL MEDICINE INSTITUTE «PEDRO KOURÍ» (IPK), HAVANA, CUBA 40: ROLE OF CC CHEMOKINE RECEPTOR 1 AND TWO OF ITS LIGANDS IN HUMAN DENGUE INFECTION. THREE APPROACHES UNDER THE CUBAN SITUATION Sierra B, Pérez, AB, García G, Aguirre E, Álvarez M, González D, Guzmán MG. TROPICAL MEDICINE INSTITUTE «PEDRO KOURÍ» (IPK), HAVANA, CUBA 41: DEVELOPMENT OF TWO NOVEL TECHNOLOGIES TO FOLLOW UP THE HBV THERAPEUTIC VACCINATION: QUANTIFICATION AND GENOTYPING OF HBV-DNA FROM HUMAN SERUM Aguiar J, Aguilar JC, Rodríguez L, Freire F, Montalvo MC, León Y, Pujol F, Loureiro C, Muzio V, Pentón E, Guillén G. CENTER FOR GENETIC ENGINEERING AND BIOTECHNOLOGY, HAVANA, CUBA 42: OCCULT HEPATITIS B VIRUS INFECTION IN CHILDREN BORN TO HBSAG-POSITIVE MOTHERS WITH ACTIVE-PASSIVE IMMUNIZATION Bello M, Rodríguez L, Rodríguez D, Montalvo MC, Pedroso P, Sariego S, Sánchez M, Naranjo N, Moyano S. TROPICAL MEDICINE INSTITUTE «PEDRO KOURÍ» (IPK), HAVANA, CUBA 43: PREVALENCE OF ROTAVIRUS GENOTYPES IN CHILDREN YOUNGER THAN 5 YEARS OF AGE, BEFORE THE INTRODUCTION OF A UNIVERSAL ROTAVIRUS VACCINATION PROGRAM Tejero Y, Ribas MA, León MA, Cordero Y, Ramírez Y, Pérez D, Roque R. TROPICAL MEDICINE INSTITUTE «PEDRO KOURÍ» (IPK), HAVANA, CUBA 41 IMMUNOPHARMACOLOGY - VACCIPHARMA 2015 44: HBV AND HCV MUTANTS ASSOCIATE WITH VACCINE ESCAPE AND ANTIVIRAL RESISTANCE Rodríguez L, Montalvo MC, Bello M, Pérez A, Moyano S. TROPICAL MEDICINE INSTITUTE «PEDRO KOURÍ» (IPK), HAVANA, CUBA 45: EVALUATION OF HUMORAL RESPONSE TO HEBERBIOVAC HB IN HAEMODIALYSIS PATIENTS FROM HAVANA CITY Montalvo MC, Bello M, Delgado G, Díaz M, Rodríguez L. TROPICAL MEDICINE INSTITUTE «PEDRO KOURÍ» (IPK), HAVANA, CUBA 46: MOLECULAR EPIDEMIOLOGY OF HUMAN PAPILLOMAVIRUS INFECTIONS IN CUBAN POPULATION Soto Y, Limia CM, Kourí V, Goicolea A, Torres G, García Y, López MV, Blanco OA et al. TROPICAL MEDICINE INSTITUTE «PEDRO KOURÍ» (IPK), HAVANA, CUBA 47: BROAD AND FUNCTIONAL T CELL IMMUNE RESPONSE FOLLOWING IMMUNIZATION WITH HEPATITIS C VIRUS PROTEINS-BASED VACCINE FORMULATED WITH POLYESTER BEADS Piniella B, Amador-Cañizares Y, Álvarez-Lajonchere L, Pérez A, Aguilar D, Castañedo Y et al. CENTER FOR GENETIC ENGINEERING AND BIOTECHNOLOGY, HAVANA, CUBA 48: HEPATITIS C VIRUS PREVALENCE IN HEMODIALYSIS UNITS IN HAVANA AND ARTEMISA PROVINCES AND ANTI-HCV HUMORAL IMMUNE RESPONSE Álvarez-Lajonchere L, Olivera S, Figueredo J, González Y, Cinza Z, Castelo X. CENTER FOR GENETIC ENGINEERING AND BIOTECHNOLOGY, HAVANA, CUBA WTV: WORKSHOP THERAPEUTIC VACCINES (INFECTIOUS DESEASES) Chairs: 49: SAFETY AND EFFICACY OF TERAP C: A THERAPEUTIC DNA VACCINE PREPARATION AGAINST HEPATITIS C. PHASE II CLINICAL TRIAL Dorta Z, Castellanos M, Cinza Z, Dueñas S, Valenzuela C et al. CENTER FOR GENETIC ENGINEERING AND BIOTECHNOLOGY, HAVANA, CUBA 50: THE CIGB550 PEPTIDE AS COMPONENT OF HPV THERAPEUTIC VACCINE. Granadillo M, Alfonso AB, Vallespi MG, Batte A, Soria Y. CENTER FOR GENETIC ENGINEERING AND BIOTECHNOLOGY, HAVANA, CUBA 51: CONTINUITY OF A WORKING REFERENCE MATERIAL OF HEPATITIS B CORE ANTIGEN FOR DEVELOPING A NASAL VACCINE. Vega M, Rodríguez C, Plá I, García G, Dorta A, Palacio Y, Padrón S. CENTER FOR GENETIC ENGINEERING AND BIOTECHNOLOGY, HAVANA, CUBA 42 IMMUNOPHARMACOLOGY - VACCIPHARMA 2015 52: HEBERNASVAC, A NOVEL THERAPEUTIC VACCINE CANDIDATE FOR CHRONIC HEPATITIS B: TOXICOLOGICAL STUDIES. Aldana L, Cosme K, Bacardí D, Ancizar J, Suárez J, Blanco A, Urquiza D, Castro J, et al. CENTER FOR GENETIC ENGINEERING AND BIOTECHNOLOGY, HAVANA, CUBA 53: VALIDATION OF THE METHOD OF HBCAG IMMUNOGENICITY FOR THE THERAPEUTIC VACCINE HEBERNASVAC Martínez Y, Valle A, Nuñez Z, Soria Y, Blanco A, Brown E, Izquierdo M, García G, Rosales I et al. CENTER FOR GENETIC ENGINEERING AND BIOTECHNOLOGY, HAVANA, CUBA WRS: WORKSHOP REGULATORY SYSTEM Chairs: Judith Cartaya and Violeta Rodríguez (CECMED) 54: BIOSIMILARS NON-CLINICAL REGULATIONS: NEW KNOWLEDGE NEW APPRAISAL Martínez L, Valle E. NATIONAL CENTRE FOR STATE CONTROL OF DRUGS, EQUIPMENTS AND MEDICAL DEVICES (CECMED), HAVANA, CUBA. 55: POST APPROVAL CHEMISTRY, MANUFACTURATING AND CONTROL CHANGES IN CUBA WITH A FOCUS ON BIOPHARMACEUTICALS. Preval D, Hechavarría Y, Pérez V, Escoto J. NATIONAL CENTRE FOR STATE CONTROL OF DRUGS, EQUIPMENTS AND MEDICAL DEVICES (CECMED), HAVANA, CUBA. 56: THE NEW MARKETING AUTHORIZATION REQUIREMENTS FOR BIOLOGICALS PRODUCTS Pérez R, Pérez V, Hechavarría Y, Orta D and Martínez L. NATIONAL CENTRE FOR STATE CONTROL OF DRUGS, EQUIPMENTS AND MEDICAL DEVICES (CECMED), HAVANA, CUBA. 57: SAFETY AND BIOSIMILARITY OF IOR® EPOCIM COMPARED WITH EPREX® BASED ON TOXICOLOGIC, PHARMACODYNAMIC, AND PHARMACOKINETIC STUDIES IN THE SPRAGUEDAWLEY RAT Pucaj K, Riddle K, Taylor SR, Ledon N, Bolger GT. CENTER OF MOLECULAR IMMUNOLOGY, HAVANA, CUBA. 58: IMPLEMENTATION OF A REGULATORY SYSTEM FOR THE CONTROL AND AUTHORIZATION OF BLOOD BANKS IN CUBA Álvarez MP, Soza A, Claro Y, Scull I, Mesa A. NATIONAL CENTRE FOR STATE CONTROL OF DRUGS, EQUIPMENTS AND MEDICAL DEVICES (CECMED), HAVANA, CUBA. 43 IMMUNOPHARMACOLOGY - VACCIPHARMA 2015 59: ISOLATION OF MESENCHYMAL STEM CELLS DERIVED FROM ADIPOSE TISSUE. Galván JA, Miranda A, De León Y, Rondó T, Macías C, del Valle L, González A et al. HEMATOLOGY INSTITUTE, HAVANA, CUBA 60: STEM CELL THERAPY FOR DEGENERATIVE DISEASE OF THE KNEE JOINT Baganet A, Fernández N, Forrellat M, Hernández P, Macías C, Galván J, González A, Lam R, del Valle L. HEMATOLOGY INSTITUTE, HAVANA, CUBA 61: IMPROVEMENT OF THE VACCINE QUALITY ASSURANCE BY IMPLEMENTING RELEVANT EFFICIENCY INDICATORS Martínez R, Candia J, Agüero B, Sartorio J, Mandiarote A, Suárez M, et al. FINLAY INSTITUTE, HAVANA, CUBA 62: THE CONTAMINATION CONTROL IN THE PRODUCTION OF VACCINES, A GLOBAL APPROACH. Figueroa R. NATIONAL CENTRE FOR STATE CONTROL OF DRUGS, EQUIPMENTS AND MEDICAL DEVICES (CECMED), HAVANA, CUBA. 63: STUDY OF SODIUM AND POTASSIUM IN A TOXICITY TEST REPEATED DOSE OF BIOSIMILAR CD20 INTRAVENOUSLY IN MACACA FASCICULARIS González C, Mancebo A, Arteaga ME, González B, Bada AM, Merino N, León A et al. TROPICAL MEDICINE INSTITUTE «PEDRO KOURÍ» (IPK), HAVANA, CUBA 64: PERSPECTIVES AND PRINCIPLES FOR GENE THERAPY REGULATIONS Alfonso Y, Hechavarría Y. NATIONAL CENTRE FOR STATE CONTROL OF DRUGS, EQUIPMENTS AND MEDICAL DEVICES (CECMED), HAVANA, CUBA. 65: DEVELOPMENT OF REGULATORY SYSTEM OF ORGANS FOR TRANSPLANTATION IN CUBA. Claro Y, Álvarez MP, Hechavarría Y, Fernández L, Hermida D. NATIONAL CENTRE FOR STATE CONTROL OF DRUGS, EQUIPMENTS AND MEDICAL DEVICES (CECMED), HAVANA, CUBA. 66: POINTS TO CONSIDER ON ELECTRONIC DATA COLLECTION IN VACCINE CLINICAL TRIALS. FOCUS ON CASE REPORT FORMS Duque E, Orta D, Cartaya J, Fernández L. NATIONAL CENTRE FOR STATE CONTROL OF DRUGS, EQUIPMENTS AND MEDICAL DEVICES (CECMED), HAVANA, CUBA. 67: WORLD SCIENTIFIC – TECHNOLOGY TENDENCIES OF THE TREATMENT WITH STEM CELLS. Cossío G, Cartaya J. CONSULTANCY BIOMUNDI, HAVANA, CUBA 44 IMMUNOPHARMACOLOGY - VACCIPHARMA 2015 68: PERSPECTIVES AND PRINCIPLES FOR GENE THERAPY REGULATIONS Alfonso Y, Hechavarría Y. NATIONAL CENTRE FOR STATE CONTROL OF DRUGS, EQUIPMENTS AND MEDICAL DEVICES (CECMED), HAVANA, CUBA. 69: PENAL RESPONSABILITY IN THE PRODUCTION AND MARKETING OF VACCINES. López A, López L. NATIONAL CENTRE FOR STATE CONTROL OF DRUGS, EQUIPMENTS AND MEDICAL DEVICES (CECMED), HAVANA, CUBA. SYMPOSIUM COMBINED VACCINES Chairs: 70: STUDY OF USE OF VACCINE PENTAVALENTE OF TRINIDAD. Rodríguez A, Ruíz A, Rodríguez. R. Trinidad Hospital «Tomás Carreras Galiano», Villa Clara, Cuba 71: ASSESSMENT OF THE BORDETELLA PERTUSSIS BPCNIC0311 AS PRODUCING STRAIN FOR GENETICALLY DETOXIFIED TOXOID (PTG), FILAMENTOUS HEMAGGLUTININ (FHA) AND PERTACTIN TYPE 2 (PRN2). Álvarez A, Quintana D, Delgado M, Lemos G, Coizeau E, Ramos R, Tambara Y, González I, et al. CENTER FOR GENETIC ENGINEERING AND BIOTECHNOLOGY, HAVANA, CUBA 72: COMPARATIVE RESULTS OF QUANTIFICATION OF PRP IN HEBERPENTA-L VACCINE WITH TWO HYDROLYSIS METHODS BY USE OF HIGH-PERFORMANCE ANION-EXCHANGE CHROMATOGRAPHY WITH PULSE AMPEROMETRIC DETECTION (HPAEC-PAD). Marcelo JL, De Senna L, Costa L, Claudio L, Izquierdo M, Martínez E, Gomes E, Torres M , Denis M, Akemi D. CENTER FOR GENETIC ENGINEERING AND BIOTECHNOLOGY, HAVANA, CUBA 73: DEVELOPMENT OF SANDWICH ELISA-BASED METHODS FOR SCREENING BORDETELLA PERTUSSIS ANTIGENS EXPRESSED IN THE BACTERIAL CELL CULTURE Lemos G, Delgado M, Quintana D, Coizeau E, Caballero E and Álvarez A. CENTER FOR GENETIC ENGINEERING AND BIOTECHNOLOGY, HAVANA, CUBA 74: EVENTS SUPPOSEDLY ATTRIBUTABLE TO VACCINATION OR IMMUNIZATION, LA HABANA, CUBA, 2010-2014. Egües LI, Pérez S. Epidemiology Provincial Centre, La Habana, Cuba 45 IMMUNOPHARMACOLOGY - VACCIPHARMA 2015 75: CONCOMITANT ADMINISTRATION OF VACCINES QUIMI-VIO, VA-MENGOC-BC® AND HEBERPENTA® IN RABBITS AS EXPERIMENTAL MODEL Espinosa C, García D, Rodríguez L, Amador A, Nicot M, Valle L. FINLAY INSTITUTE, HAVANA, CUBA 76: BEHAVIOUR OF VACCINE ADVERSE REACTIONS IN MTZAS PROVINCE FROM 2009 TO 2012 Marin N, Santos L. Health Municipal of Matanzas, Matanzas, Cuba 77: VACCINE ADVERSE REACTIONS IN CHILDREN REPORTED BY THE CUBAN SYSTEM PHARMACOVIGILANCE, 2003-2013 Furones JA, Cruz MA, López AF. Escuela Nacional de Salud Pública 78: ESTABLISHMENT OF A DIPHTHERIA TOXIN IN-HOUSE STANDARD FOR A VERO TOXICITY TESTING FOR VACCINES Herrera L, Chovel ML, Bolaños G, Monteagudo R, Fidalgo O. FINLAY INSTITUTE, HAVANA, CUBA 79: SHELF-LIFE STABILITY AND SYSTEMATIC IN-USE RESULTS OF A REFERENCE TETANUS ANTITOXIN FOR THE IN VIVO SERONEUTRALIZATION TEST Mahy T, Cisneros D, Herrera L, Ontivero I, Chovel ML. FINLAY INSTITUTE, HAVANA, CUBA 80: PERTUSSIS POTENCY TEST PERFORMANCE ASSESSMENT FOR HEBERPENTA-L VACCINE AS TOOL FOR ASSAY QUALITY CONTROL Bourg V, Díaz M, Huergo L, Pérez C. NATIONAL CENTER OF BIOPRODUCTS (BIOCEN), ARTEMISA, CUBA 81: DESIGN OF HPLC METHOD FOR DETERMINATION OF TOTAL CARBOHYDRATES IN QUIMIHIB APPLYING QUALITY BY DESIGN Borrego K, Meneau R, Baeza A, Álvarez A. NATIONAL CENTRE FOR STATE CONTROL OF DRUGS, EQUIPMENTS AND MEDICAL DEVICES (CECMED), HAVANA, CUBA. 82: PERTUSSIS SEROLOGICAL POTENCY TEST: LINKS TO THE PROTECTION AND SIGNIFICANCE FOR VACCINE LOT RELEASE Chovel ML, Gutiérrez N, Mahy T, Herrera L, Mandiarote A. FINLAY INSTITUTE, HAVANA, CUBA 46 IMMUNOPHARMACOLOGY - VACCIPHARMA 2015 83: PREPARATION OF MASTER AND WORKING CELL BANKS FROM BORDETELLA PERTUSSIS BPCNIC0311 STRAIN. Coizeau E, Delgado M, Quintana D, Lemos G, Maida C, Soraya P, Yenay D, Dailis V, and Álvarez A. FINLAY INSTITUTE, HAVANA, CUBA 84: ADVANCES IN THE CHARACTERIZATION OF A BORDETELLA PERTUSSIS DERIVED PROTEOLIPOSOME AS VACCINE CANDIDATE AGAINST WHOOPING COUGH. Rodríguez Y, Fernández S, Infante J, Herrera Y, Fernández Y, Fajardo EM, Mandiarote A, Landys M. FINLAY INSTITUTE, HAVANA, CUBA WORKSHOP THERAPEUTIC VACCINES Chairs: 85: EFFICACY AND SAFETY OF NGCGM3/VSSP VACCINE IN ADVANCED BREAST CANCER PATIENTS. de la Torre A, Pérez K, Vega AM, Durán Y, Álvarez M, Viada C, Sánchez L et al. CENTER OF MOLECULAR IMMUNOLOGY, HAVANA, CUBA. 86: IMMUNOLOGICAL RESPONSE IN UNRESECTABLE III AN SCLC PATIENTS TREATED WITH A CONCURRENT COMBINATION OF CIMAVAX-EGF AND CHEMOTHERAPY Alfonso AL, Neninger E, González A, Hernández M, Fernández A, Mazorra Z, Sánchez L et al. CENTER OF MOLECULAR IMMUNOLOGY, HAVANA, CUBA. 87: SURROGATE BIOMARKERS OF CLINICAL RESPONSE IN STAGE IIIB/IV NON-SMALL-CELL LUNG CANCER PATIENTS TREATED WITH AN EGF-BASED THERAPEUTIC VACCINE AS A SECOND LINE OF THERAPY. Popa X, Fuentes K, Viada C, Neninger E, Rodríguez C, González Z, González A et al. CENTER OF MOLECULAR IMMUNOLOGY, HAVANA, CUBA. 88: EXPERIMENTAL STUDIES OF A VACCINE THAT COMBINES RECOMBINANT HUMAN VEGF AS ANTIGEN AND ALUMINIUM PHOSPHATE. Pérez L, Morera Y, Bequet-Romero M, Ramses Hernández G, Rodríguez Y, Castro J, Puente P, Ayala M and Gavilondo J V. CENTER FOR GENETIC ENGINEERING AND BIOTECHNOLOGY, HAVANA, CUBA 89: ENDOGENOUS POLYCLONAL ANTIBODIES GENERATED BY IMMUNIZA-TION WITH EXTRACELLULAR DOMAINS OF HER1 AND HER2 DECREASE ACTI-VATION AND EXPRESSION OF HER1 AND HER2 IN TUMOR CELLS INDUCING PRO-APOPTOTIC EFFECTS ONGENE ADDICTION: A GOOD REASON FOR DESIGNING THERAPIES BASED ON HER1 AND HER2 González N, Bergado G, Hernández DR, Chao L, and Sánchez B. CENTER OF MOLECULAR IMMUNOLOGY, HAVANA, CUBA. 47 IMMUNOPHARMACOLOGY - VACCIPHARMA 2015 90: SAFETY, PHARMACOKINETIC EVALUATION AND EFFICACY SIGNS OF INTRAVENOUS CIGB-300 IN PATIENTS WITH SOLID TUMORS, REFRACTORY TO ONCOSPECIFIC TREATMENTS González Lidia, Noyde B, Soriano J, García R, Ugando E. Hospital Hermanos Ameijeiras 91: IMMUNOGENICITY OF PARTICLES ADJUVANTS AIF/PI IN THE CANCER VACCINE CANDIDATE ECD-MEGFR/AIF-PI Fuentes F, Junco J, Calzada L, Baladrón I, Pimentel E, Basulto R, Reyes O et al. CENTER FOR GENETIC ENGINEERING AND BIOTECHNOLOGY, HAVANA, CUBA 92: ANTI-TUMOR EFFECTS OF RACOTUMOMAB VACCINE COMBINED WITH LOW DOSE CYCLOPHOSPHAMIDE OVERCOME THE DELETERIOUS CONSEQUENCES OF AGING IN A BREAST CANCER MODEL. Fuentes D, Cabezas A, Beausoleil I, Avellanet J, García A, Fernández A. TROPICAL MEDICINE INSTITUTE «PEDRO KOURÍ» (IPK), HAVANA, CUBA 93: IMMUNE RESPONSE IN LONG-TERM NSCLC SURVIVORS TREATED WITH AN EGF-BASED VACCINE. Saavedra D, Aguilar Y, Alfonso AL, González A, Mazorra Z, Lorenzo P, Sánchez L, Viada C et al. CENTER OF MOLECULAR IMMUNOLOGY, HAVANA, CUBA. 94: DEVELOPMENT OF AN ANTI-IL-15 VACCINE Rodríguez Y, Silva R, Gerónimo H, Arrieta C, Hardy E, Castro J, Morera Y, Rodríguez A, Martínez Moro AR, Perea S, Guillen G, Santos A. CENTER FOR GENETIC ENGINEERING AND BIOTECHNOLOGY, HAVANA, CUBA 95: MONOCLONAL ANTIBODIES: ANANALYTICALTOOL IN VACCINE DEVELOPMENT González E, Otero O, Ramírez F, Reyes F, Camacho F, Fajardo A, Amín N et al. CENTER OF MOLECULAR IMMUNOLOGY, HAVANA, CUBA. 96: IMPACT OF N-GLYCOSYLATION OF THE ANTI-IDIOTYPIC MONOCLONAL ANTIBODYRACOTUMOMAB IN BIOLOGICALACTIVITY OF VAXIRA VACCINE Aguilar Y, Rabasa Y, Fuentes D, De la Luz KR. CENTER OF MOLECULAR IMMUNOLOGY, HAVANA, CUBA. 97: SATISFACTION WITH HEALTH CARE OF CAREGIVERS AND PATIENTS ENROLLED IN CLINICAL TRIALS WITH THERAPEUTIC VACCINES AND MONOCLONAL ANTIBODIES FOR THE TREATMENT OF ADVANCED LUNG CANCER IN 2014. VILLA CLARA Lorenzo G, Gil P, Castellanos H, Hernández MA, Martín MI, Cabrera AM, Ortiz RA, Bermúdez A. CENTER OF MOLECULAR IMMUNOLOGY, HAVANA, CUBA. 48 IMMUNOPHARMACOLOGY - VACCIPHARMA 2015 98: GANGLIOSIDES-BASEDCANCERVACCINES: TOXICOLOGICALASSAYS Bada AM, Casacó A, Mancebo A, González B, Fuentes D, Hernández O, Arteaga ME, et al. TROPICAL MEDICINE INSTITUTE «PEDRO KOURÍ» (IPK), HAVANA, CUBA 99: RESULTS OF THE SAFETY EVALUATION OF CANCER VACCINES DEALING WITH NOVEL TARGETS FOR CANCER IMMUNOTHERAPY Mancebo A, Bada AM, Casacó A, González B, León A, Arteaga ME, González C, et al. TROPICAL MEDICINE INSTITUTE «PEDRO KOURÍ» (IPK), HAVANA, CUBA 100: DEVELOPMENT AND PERFORMANCE EVALUATION OF AN ELISA METHOD FOR POTENCY ESTIMATION OF CIMAVAX-EGF VACCINE. Solozábal J, Viña L, Gómez T, Baldriche J, González G, Ruiz E, Sánchez F, Ferrer G. CENTER OF MOLECULAR IMMUNOLOGY, HAVANA, CUBA. 101: DETERMINATION OF RESULTS CORRESPONDENCE BETWEEN FINAL AND INTERIM REPORTS OF CIMAVAXEGF® CLINICAL TRIAL. Wong L, Rodríguez C, Fernández E. INSTITUTE OF PHARMACY & FOODS, HAVANA, CUBA 102: ADHERENCE TO THERAPEUTIC CANCER VACCINES IN CLINICAL TRIALS PATIENTS. Arencibia M, M Cepeda, Saumell A, Cabrera L, Torres O, Carr A et al. CENTER OF MOLECULAR IMMUNOLOGY, HAVANA, CUBA. 103: SAFETY OF NIMOTUZUMAB IN THE TREATMENT OF HEAD AND NECK TUMORS IN ADVANCED STAGES IN CAMAGUEY Ramírez M, Margenat A, Infante E, de Quesada L, Alvarez A, Vila L. Medical University. Camagüey, Cuba 104: IMMUNOGENICITY OF PARTICLES ADJUVANTS AIF/PI IN THE CANCER VACCINE CANDIDATE ECD-MEGFR/AIF-PI Tamargo B, Rubio A, Sánchez B, Gutierrez A, Bergado G, Sierra G. INSTITUTE OF PHARMACY & FOODS, HAVANA, CUBA 105: SELECTION OF ALUMINUM SALT ADJUVANT TO BE USED IN PREPARA-TION OF THERAPEUTIC PROTEIN CIGB 247-A. ANTIGEN STABILITY EVALUATION Hernández GR, Aldana R, Padrón S, Expósito N, Izquierdo M, Pérez M, Terrero Y. CENTER FOR GENETIC ENGINEERING AND BIOTECHNOLOGY, HAVANA, CUBA 106: IMPACT OF CIMAVAX-EGF VACCINE IN PATIENTS WITH NON–SMALL CELL LUNG CANCER TREATED IN TWO POLICLINICS OF CAMAGUEY Valls AR, López N, Rivera T, Rodríguez Z, del Sol T, Sotomayor M, Nodarse G, Reid J. CENTER OF MOLECULAR IMMUNOLOGY, HAVANA, CUBA. 49 IMMUNOPHARMACOLOGY - VACCIPHARMA 2015 107: MAKING SENSE OF CLINICAL TRIAL DATA: CORRECTING FOR SWITCHING TO SECOND LINE TREATMENT IN THE SURVIVAL ANALYSIS. Sánchez L, Lorenzo-Luaces P, Crombet T. CENTER OF MOLECULAR IMMUNOLOGY, HAVANA, CUBA. 108: VEGF SPECIFIC CELLULAR RESPONSE TO CIGB-247 CANCER THERAPEUTIC VACCINE: FROM BENCH TO BEDSIDE. Bequet M, Ayala M, Morera Y, Sánchez J, Echegoyen AY, Pérez L, Gavilondo JV. CENTER FOR GENETIC ENGINEERING AND BIOTECHNOLOGY, HAVANA, CUBA. 109: EFFICACY TRIAL OF THE EPIDERMAL GROWTH FACTOR VACCINE CIMAVAX-EGF IN ADVANCED NON-SMALL-CELL LUNG CANCER. Rodriguez PC, Xitllaly Popa, Martínez O, Mendoza S, Santiesteban E. CENTER OF MOLECULAR IMMUNOLOGY, HAVANA, CUBA. 110: VACCINATION WITH A MUTATED VARIANT OF HUMAN VASCULAR ENDOTHELIAL GROWTH FACTOR BLOCKS VEGF-INDUCED RETINAL NEOVASCULARIZATION IN A EXPERIMENTAL MODEL Morera Y, González R, Lamdan H, Pérez L, González Y, Agüero J, Castro J, Romero JC et al. CENTER FOR GENETIC ENGINEERING AND BIOTECHNOLOGY, HAVANA, CUBA. 111: IMMUNOLOGICAL AND CLINICAL RESULTS OBTAINED IN CASTRATION-RESISTANT PROSTATE CANCER PATIENTS TREATED WITH AN EGFR-BASED VACCINE Lavastida A, Aira LE, Popa X, González Z, Mesa M, González Narjara, Bergado G et al. CENTER OF MOLECULAR IMMUNOLOGY, HAVANA, CUBA. 112: IDENTIFICATION AND CHARACTERIZATION OF LONG TERM SURVIVAL POPULATION IN NONSMALL CELL LUNG CANCER PATIENTS TREATED WITH IMMUNOTHERAPIES. Lorenzo P, Sánchez L, Viada C, Rodríguez C, Álvarez M, Fonte C, Muchene L, Shkedy Z, Lage A. CENTER OF MOLECULAR IMMUNOLOGY, HAVANA, CUBA. STBV: SYMPOSIUM TUBERCULOSIS VACCINES Chairs: Nadine Álvarez and Yanelis Tirado 113: FORMULATION OF LIPID-BASED PREPARATION FOR IMMUNOTHERAPY Morales Y, García M, Casanova M, Hdez M, Medina R, Sifontes S, Nieto L et al. CHEMICAL BIOACTIVES CENTER, VILLA CLARA, CUBA. 114: PNEUMONIA AS TB LUNG SHAPE (PRESENTATION OF TWO CASES) Barreiro B, Ramos LT. Pediatric Hospital Willian Soler 50 IMMUNOPHARMACOLOGY - VACCIPHARMA 2015 115: EVALUATION OF THE PROTECTIVE CAPABILITY OF A LIPID EXTRACT DERIVED FROM M. SMEGMATIS IN A MURINE MODEL OF PROGRESSIVE PULMONARY TUBERCULOSIS. MA. García, R. Borrero, ME. Lanio, Y. Tirado, N. Álvarez, A. Puig, A. Aguilar et al. FINLAY INSTITUTE, HAVANA, CUBA 116: DIFFERENTIAL INDUCTION OF SEVERAL CYTOKINES OF RELEVANCE IN TUBERCULOSIS BY CELLS AND CORD FACTOR OF MYCOBACTERIUM SIMIAE, INCLUDING THE IMMUNOGENIC STRAIN ‘HABANA’ TMC 5135 Mederos LM, Linares C , Bernabéu A , Valero-Guillén PL. TROPICAL MEDICINE INSTITUTE «PEDRO KOURÍ» (IPK), HAVANA, CUBA 117: ANAL TUBERCULOSIS IN AIDS PATIENT: FIRST CUBAN REPORT. Mederos LM, Fleites G, Sardiñas, García G, Martínez MR, Díaz R. TROPICAL MEDICINE INSTITUTE «PEDRO KOURÍ» (IPK), HAVANA, CUBA 118: SURVEILLANCE OF ANTITUBERCULOSISDRUGRESISTANCE IN CUBA, 2010-2014 Lemus D, Echemendía M, Díaz R, Llanes MJ, Suárez L, Marrero A. TROPICAL MEDICINE INSTITUTE «PEDRO KOURÍ» (IPK), HAVANA, CUBA SBP: SYMPOSIUM BIOPROCESSES Chairs: Katia R. de la Luz (CIM) y Ivonne Rodríguez (CIGB) 119: CURRENT TRENDS IN THE VACCINES FIELD. MAIN APPROACHES AT THE FINLAY INSTITUTE. Hernández J, Utria I, Guzmán M, Crespo Y, Ochoa R, Fernández S, Pérez R et al. FINLAY INSTITUTE, HAVANA, CUBA 120: THE ANNUAL PRODUCT REVIEW AS A TOOL FOR REAL-TIME VALIDATION IN THE PRODUCTION OF HEPATITIS B SURFACE ANTIGEN. Rodríguez I, Rivera J, Madruga Y, Fernández R, De la Torre Y, Suárez G, Martínez C, Hernández. CENTER FOR GENETIC ENGINEERING AND BIOTECHNOLOGY, HAVANA, CUBA 121: IMPROVING THE QUALITY AND CONTROL OF THE KINETIC ENDOTOXIN ASSAY (LAL) Viña L, Rodríguez AG, Vigil L, Girón M, Madera L, Gómez T, Martin L. CENTER OF MOLECULAR IMMUNOLOGY, HAVANA, CUBA. 122: DOCUMENT MANAGEMENT SYSTEM IN THE DEVELOPMENT PHASE, Apezteguía I, Diago D, González T, González N, Rodríguez E, Santana H, García C, Páez R. CENTER FOR GENETIC ENGINEERING AND BIOTECHNOLOGY, HAVANA, CUBA 51 IMMUNOPHARMACOLOGY - VACCIPHARMA 2015 123: VALIDATION OF A SANDWICH ELISA FOR THE IDENTITY OF CARBOHYDRATE AND CARRIER PROTEIN IN MONOVALENT CONJUGATES AND FINAL PRODUCT OF QUIMIVIO VACCINE. Martínez D, Rodríguez L, Serrano Y, Sánchez H, García N, García-Rivera D. FINLAY INSTITUTE, HAVANA, CUBA 124: INCREASE THE CELLULAR CONCENTRATION OF MAMMALIAN CELL CULTURE IN BIOREACTORS STIRRED TANK IN MODE PERFUSION, TO INDUSTRIAL SCALE. Borrego Y, Ojito E, Chico E, Rodríguez R, Núñez J. CENTER OF MOLECULAR IMMUNOLOGY, HAVANA, CUBA. 125: RESEARH OF DEVIATIONS IN THE RHEGF-RP64K CHEMICAL CONJUGATION PROCESS González G, Viña L, Peña V, Quintana Y, Castro D, Amaro D. CENTER OF MOLECULAR IMMUNOLOGY, HAVANA, CUBA. 126: RHEUMATOID ARTHRITIS DIAGNOSIS: DEVELOPMENT OF A POLYSTYRENE LATEX-BASED REAGENT FOR RHEUMATOID FACTOR DETECTION Marrero G, Delgado LP, Carol H, Ortiz N, Musacchio A and Menéndez T. BIOMATERIALS CENTER (BIOMAT), HAVANA, CUBA. 127: NMR, OPPORTUNITIES FOR QUALITY CONTROL OF INTERMEDIATES ON CARBOHYDRATE-BASED VACCINES Garrido R, Vélez H, Vérez V. FINLAY INSTITUTE, HAVANA, CUBA 128: CHARACTERIZATION OF VI POLYSACCHARIDE-TETANUS TOXOID CONJUGATE BATCHES OBTAINED AT PILOT SCALE Ramírez U, Arias D, Garrido R, Baró B, Pedroso J, Aliaga I, Espinosa C, Villar A. FINLAY INSTITUTE, HAVANA, CUBA 129: DEVELOPMENT OF AN ANTI-IDIOTYPIC MAB AS CANCER VACCINE: FROM DISCOVERY TO APPROVAL de la Luz K, Santo-Tomás J, Aguilar Y, Morales O, Fuentes D, Vidal D, Rabasa Y et al. CENTER OF MOLECULAR IMMUNOLOGY, HAVANA, CUBA. 130: ASSESSMENT THE IMPACT OF MANUFACTURING CHANGES ON HER1-ECD CHARACTERISTICS (PHYSIC-CHEMICAL AND BIOLOGICAL) DURING THE VACCINE DEVELOPMENT García K, Prieto Y, Raymond J, Rabasa Y, Sánchez B, Castillo A, and de la Luz K. CENTER OF MOLECULAR IMMUNOLOGY, HAVANA, CUBA. 52 IMMUNOPHARMACOLOGY - VACCIPHARMA 2015 131: ISOLATION OF 1E4 IGM ANTI-FASCIOLA HEPATICA Alba A, Marcet R, Otero O, Hernández HM, Figueredo M, Sarracent J. TROPICAL MEDICINE INSTITUTE «PEDRO KOURÍ» (IPK), HAVANA, CUBA 132: RESULTS OF THE APPLICATION OF WORK ALGORITHMS FOR THE HEMODERIVADOS CERTIFICATION AND OTHERS PRODUCTS WITH RISK OF VIRAL CONTAMINATION IN THE YEAR 2014 Romero K, Pérez MT, Blanco M Aguiar Y, Sánchez L, Sánchez E and col. AIDS RESEARCH LABORATORY, MAYABEQUE, CUBA 133: SYNTHESIS OF POLYSTYRENE LATEX PARTICLES FOR PHARMACEUTICAL APPLICATIONS Marrero G, Delgado LP, Musacchio A, Menéndez T. BIOMATERIALS CENTER, HAVANA, CUBA 134: STANDARDIZATION OF AN ELISA FOR DETERMINING HUMAN ANTIBODIES ANTIPOLYSACCHARIDE VI Álvarez M, Aranguren Y, Fernández S, Rodríguez L. FINLAY INSTITUTE, HAVANA, CUBA 135: PURIFICATION AND PRELIMINARY CHARACTERIZATION OF OMV DERIVED FROM OUTER SURFACE OF SALMONELLA PARATYPHY A Pérez JL, Fernández S, Martínez M, Lescaille D, Serrano D, Blain K, Burguet A. FINLAY INSTITUTE, HAVANA, CUBA 136: SUSTAINED RELEASE OF BIOLOGICALLY ACTIVE EPIDERMAL GROWTH FACTOR (EGF) FROM INJECTABLE POLYMERIC MICROSPHERES PROMOTES WOUND HEALING Cruz E, Caballero L, Aldana R, Berlanga J, Sáez V, Páez R, Castro F. CENTER FOR GENETIC ENGINEERING AND BIOTECHNOLOGY, HAVANA, CUBA 137: IN SITU FORMING DRUG DELIVERY SYSTEM FOR THE PARENTERAL CONTROLLED RELEASE OF RISPERIDONE Peniche C J, Sáez V, Acosta N, Peniche C A. BIOMATERIALES CENTER, HAVANA, CUBA 138: BLO T2 ALLERGEN PURIFICATION AND ALLERGENICITY IN ASTHMATIC PATIENTS SENSITIVE TO BLOMIA TROPICALIS HOUSE DUST MITE Mateo M, Capote M, Pérez-Llano Y, García A, Cruz R, Luzardo MC, Labrada A. NATIONAL CENTER OF BIOPRODUCTS (BIOCEN), ARTEMISA, CUBA. 139: EVALUATION OF THE EFFECT OF SILENCING CMAH AND ADAPTATION TO PROTEIN-FREE DIUM ON THE PROPERTIES OF 14F7 RECOMBINANT MONOCLONAL ANTIBODY. Morales O, Rabasa Y, Dorvignit D, and de la Luz K. CENTER OF MOLECULAR IMMUNOLOGY, HAVANA, CUBA. 53 IMMUNOPHARMACOLOGY - VACCIPHARMA 2015 WORKSHOP HIV-AIDS Chairs: Carlos Duarte and Celia Fernández 140: ACUTE TOXICOLOGY OF THE VACCINE CANDIDATE TERAVAC AGAINST THE HIV-1 Bacardí D, Cosme K, Suárez J, Ancizar J, Renault JI, Madrigal R, Romero JC, et al. CENTER FOR GENETIC ENGINEERING AND BIOTECHNOLOGY, HAVANA, CUBA 141: HIGHLY CONSERVED HIV-1 SUBTYPE B STRAINS REVEALS ANALYSIS OF NEAR FULL-LENGTH GENOME SEQUENCES OF HIV TYPE 1 IN CUBA. Blanco M, Machado LY, Martínez O, Noa E, Díaz HM, Romay D, Ruiz N. AIDS RESEARCH LABORATORY, MAYABEQUE, CUBA 142: CD4+ T-LYMPHOCYTES AND VIRAL LOAD IN PATIENTS WITH AIDS DEBUT WHO RECEIVE ANTIRETROVIRAL TREATMENT. Hernández D, Pérez J, Carr A. TROPICAL MEDICINE INSTITUTE «PEDRO KOURÍ» (IPK), HAVANA, CUBA 143: PHYLODINAMIC OF HIV-1 SUBTYPE B IN CUBA Machado LY, Martínez O, Díaz HM, Blanco M, Romay D, Dubed M, Silva E. AIDS RESEARCH LABORATORY, MAYABEQUE, CUBA 144: EVALUATION OF REDOX STATUS IN PATIENTS WITH KAPOSI’S SARCOMA-AIDS. Duque M, Calás V, Cárdenas A, Leal M, Ugarte Y, Gravier R, Gil L, Jiménez N. TROPICAL MEDICINE INSTITUTE «PEDRO KOURÍ» (IPK), HAVANA, CUBA 145: THE DIAGNOSIS OF HIV IN CUBA, ROLE OF NATIONAL LABORATORY REFERENCE IN THE NATIONAL PROGRAM FOR PREVENTION AND CONTROL OF STI / HIV / AIDS. Silva E, Pérez MT, Díaz H, Romero K, Nibot C, Valdés N, Hernández M. AIDS RESEARCH LABORATORY, MAYABEQUE, CUBA. 146: COLLOIDAL GOLD NANOPARTICLES CONJUGATION TO BIOMOLECULES OF INTEREST TO DIAGNOSE INFECTIOUS DISEASES. Cruz Y, Díaz D. F, Cruz O, Fragas A, Montano L. AIDS RESEARCH LABORATORY, MAYABEQUE, CUBA 147: SURVEILLANCE OF HUMAN IMMUNODEFICIENCY VIRUS TYPE 1 TRANSMITTED DRUG RESISTANCE IN CUBA: IMPORTANT TOOL FOR DESIGN OF NEW THERAPEUTIC STRATEGIES. Machado LY, Díaz HM , Dubed M , Blanco M , Ruiz N , Romay D , Valdés N et al. AIDS RESEARCH LABORATORY, MAYABEQUE, CUBA 54 IMMUNOPHARMACOLOGY - VACCIPHARMA 2015 Symposium Veterinary Vaccines Chairs: Deybis Orta 148: METASERVER FOR IN SILICO IDENTIFICATION OF BACTERIAL TARGETS WITH DIAGNOSTIC AND/ OR VACCINE VALUE Abreu Y, Estévez Y, Bultet L, Rodríguez Y, Agüero JA NATIONAL CENTRE FOR ANIMAL AND PLANT HEALTH (CENSA). MAYABEQUE, CUBA 149: HOMOLOGATION STUDY OF NEW ADJUVANT MONTANIDE ISA 50 V2 AND THE OILY PHASE OF GAVAC® IMMUNOGEN Pérez C, González N, Moreira A, Zamora J. Centre for Genetic Engineering and Biotechnology, Camagüey, Cuba. 150: PHYSICAL-CHEMICAL CHARACTERIZATION AND COMPARISON THE OILY PHASE OF THE GAVAC® IMMUNOGEN AND MONTANIDE ISA 50 V2 ADJUVANT. QUALITY EVALUATION AND STABILITY OF THE FORMED EMULSIONS. Pérez C, Bricaud M, González N, Gaucheron J. Centre for Genetic Engineering and Biotechnology, Camagüey, Cuba. 151: ASSESSMENT OF PRECLINIC TOXICITY OF BIVALENT NON-CELLULAR VACCINE AGAINST LEPTOSPIRA SPP SEROVARS OF VETERINARY EPIDEMIOLOGY INTEREST FOR CUBA Arencibia DF, Rosario LA, Tamargo B, Infante JF, Batista N. FINLAY INSTITUTE, HAVANA, CUBA POSTERS SESSIONS Thursday 18 (15:00-18:00) Workshop Immunopharmacology Chairs: Brizaida Oliva/Darel Martinez (Cuba) IP-01: PROINFLAMATORY SOLUBLE INTERLEUKIN-15 RECEPTOR ALPHA IS INCREASED IN RHEUMATOID ARTHRITIS AND IT´S INHIBITED FOR IL-15 ANTAGONIST PEPTIDE. Santos A, Chico A, Machado A.C., Rodríguez Y, Reyes O, Cabrales A, Gerónimo H, Garay H, Estévez M, Guillen G. Center for Genetic Engineering and Biotechnology (CIGB), Havana, Cuba 55 IMMUNOPHARMACOLOGY - VACCIPHARMA 2015 IP-02: CYTOPLASMIC P27KIP1 PREDICTS EARLY RELAPSE IN PATIENTS WITH INVASIVE DUCTAL BREAST CANCER. Blanco D, Gutiérrez Z, Jiménez J, Rubio MC, Rodríguez R, Pérez I, Sánchez I, Valdés Z, Martín LF, Camacho R, Sánchez L, Casanella O, Terry A, Frontela M, Moro A Instituto de Oncología y Radiobiología (INOR), Havana, Cuba IP-03: ENHANCED PHARMACODYNAMIC PROPERTIES OF A NOVEL FORMULATION CONTAINING A SYNERGISTIC MIXTURE OF INTERFERONS ALPHA-2B AND GAMMA IN NON-CLINICAL AND CLINICAL CONTEXT García-García I, Díaz-Machado A, González-Delgado C, Tuero-Iglesias A, Pérez-Rodríguez S, GarcíaVega Y, Campos-Mojena R, Cruz-Ramírez A, Castro-Velazco J, Martín-Trujillo A, Santana-Milián H, López-Saura P, Bello-Rivero I. Center for Genetic Engineering and Biotechnology CIGB), Havana, Cuba IP-04: ANTITUMOR EFFICACY, PHARMACOKINETIC AND BIODISTRIBUTION STUDIES OF THE ANTICANCER PEPTIDE CIGB-552 IN MOUSE MODELS Vallespí, MG, Pimentel G, Cabrales-Rico A, Garza J, Oliva B, Mendoza O, Gómez Y, Basaco T, Sánchez I, Calderón C, Rodríguez JC, Markelova M, Fichtner I, Astrada S, Bollati-Fogolín M, Garay E and Reyes O. Center of Genetics Engineering and Biochtecnology (CIGB), Havana, Cuba. IP-05: PHARMACOLOGIC INHIBITION OF CASEIN KINASE 2 (CK2)-MEDIATED PHOSPHORYLATION TO INDUCE CELL DEATH IN ACUTE MYELOID LEUKEMIA CELLS Cruz Y, Perera Y, Ramos Y, Nuñez T, Cruz LD, González LJ, Perea SE National Institute of Oncology and Radiobiology (INOR), Havana, Cuba. IP-06: DIABETES AND ULCERATIVE COLITIS, EVALUATION OF EPIDERMAL GROWTH FACTOR PELLETS IN ULCERATIVE COLITIS BIOMODEL IN RATS Aguilera A, Bermúdez Y, Martínez E, Cosme C, Ancizar JA, Bacardí D, Suárez J, Romero JC, Brown E, Blanco A, Madrigal R, Gorovaya L, Valdes AM, Ferrera A, Martínez L, Urquiza D, Rodríguez Y, Soria Y, Berlanga J, Páez R. Center for Genetic Engineering and Biotechnology (CIGB), Havana, Cuba. IP-07: THE POPULATION APPROACH TO EVALUATE THE PHARMACOKINETIC AND PHARMACODINAMIC FOR THREE DOSES OF HEBERPROT-P (25 µG, 75 µG AND 225 µG) COMBINING THE RESULTS OF TWO CLINICAL TRIALS. SIMULATION OF NON EVALUATED SCENARIOS Valenzuela C, Hernández I, López P, Pentón G, Cruz A, Campos R, Cervantes M, del Río M, Bataille A, Herrera A, Rojas D, Brea Y, Hernández R, Baldomero J, Muzio V, Díaz A, Pérez S, Martín A, David M, Rivero I, Tamayo M, Alvarez M, Barrero L, Reynaldo D, Savigne W, Castillo S y González C. Center for Genetic Engineering and Biotechnology (CIGB), Havana, Cuba. 56 IMMUNOPHARMACOLOGY - VACCIPHARMA 2015 IP-08: EFFECT AND SAFETELY OF THE ADMINISTRATION CONCOMITANT OF THE PEPTIDE CIGB-300 WITH STANDRAD CHEMPRADIOTHERAPY REGIMEN IN PATIENTS WITH CERVICAL STAGE IB2/II. I BALADRÓN (1), L. GONZALEZ (1), L ESTEVEZ (2), G.CRESPO (3),K GONZÁLEZ (4),J SERRET(5) JA ALVAREZ (6) A. TUERO (1), C. VALENZUELA (1), S. PEREA (7), B. ACEVEDO (8), Y. ROSALES (1), MD CASTRO (1), K CATASUS (1), P. LOPEZ (1), FOR THE CERVICONC-300 GROUP*. Genetic Engineering and Biotechnology (CIGB), Havana, Cuba. IP-09: CHARACTERIZING FINE EPITOPE SPECIFCITY OF THE THERAPEUTIC ANTIBODY NIMOTUZUMAB: BIOLOGICAL IMPLICATIONS Tundidor Y, García C, Pupo A, Cabrera Y and Rojas G. Center of Molecular Immunology (CIM), Havana, Cuba. IP-10: SAFETY, PHARMACOKINETIC EVALUATION AND EFFICACY SIGNS OF INTRAVENOUS CIGB-300 IN PATIENTS WITH SOLID TUMORS, REFRACTORY TO ONCOSPECIFIC TREATMENTS González L, Noyde B., Soriano J., García R., Ugando E., Reyes V., Méndez L., Raíces I , Valenzuela C. Álvarez L., Fernández E, Perera Y.1, Martin Y., de la Torre A., de la Torre J., Catalá M., Izquierdo M. García I., Rosales Y., López P., Alonso D., Gómez R., Acevedo B., Perea SE., Muzio VL., TS-300 group. Genetic Engineering and Biotechnology (CIGB), Havana, Cuba. IP-11: CELL DEATH AND IMMUNOGENICITY INDUCED BY NIMOTUZUMAB Lisset Chao, Ailem Rabasa, Greta Garrido, Gretchen Bergado, Cristina Garrido, Federico Garrido, Angel Miguel García-Lora, Douglas Green, Belinda Sánchez Center of Molecular Immunology (CIM), Havana, Cuba. IP-12: PEG-Heberon®, IN COMBINATION WITH RIBAVIRIN IN THE TREATMENT OF CHRONIC HEPATITIS C IN CUBA. RESULTS FROM INTRODUCTION INTO NATIONAL HEALTH SYSTEM. Nodarse H, Raices I, Castellanos M, Dorta Z, Arus E, Samada M, Barroso L, Mas M, Velbes P, Nancy R, Blanco M, Valenzuela C, Lopez P, Campos R, Paez R, Castro F, Muzio V. Genetic Engineering and Biotechnology (CIGB), Havana, Cuba. IP-13: META-ANALYSIS OF SAFETY AND EFFICACY IN PATIENTS WITH DIABETIC FOOT ULCERS. INTERNATIONAL PROYECTION OF HEBERPROT-P®. Tuero A, González O, Valenzuela C, Alonso M, Baldomero J, Sauri J, del Río A, López P, Yera I, García E, Muzio V, Rodríguez A, Silva R, Raices M, Hernández A. Genetic Engineering and Biotechnology (CIGB), Havana, Cuba. IP-14: EFFECT ON B CELLS AND PHARMACOKINETICS OF AN ANTI-CD20 MONOCLONAL ANTIBODY IN PATIENTS WITH NON-HODGKIN’S LYMPHOMA: PRELIMINARY RESULTS. Aguilar Y, Alfonso AL, Aira LE, Lavastida A, Hernández P, Solazabal J, Cepero K, Hernández C, Hernández C, Cristo V and Mazorra Z. Center of Molecular Immunology (CIM), Havana, Cuba. 57 IMMUNOPHARMACOLOGY - VACCIPHARMA 2015 IP-15: CHARACTERIZATION OF THE SECURITY PROFILE IN 7 CLINICAL TRIALS USING CIGB-300 DURING 2006-2014. Raíces I., González L., Tuero A., Yera I., Baladrón I., Valenzuela C., García I., Rosales Y., Martin Y., Solares M., Fang R., Batista N , Soriano J., de la Torre A., Sarduy M., de la Torre J., Acevedo B., Perera Y., Reyes V., Perea S., Muzio V., CIGB-300 Group. Genetic Engineering and Biotechnology (CIGB), Havana, Cuba. IP-16: QUANTITATION OF THERAPEUTIC PEPTIDE IN HUMAN PLASMA BY USING MASS SPECTROMETRY: APPLICATION TO PHARMACOKINETIC STUDIES IN CLINICAL TRIALS. Cabrales-Rico A1, Gil J1, Garay HE, Besada V, Hernández-Bernal F, Berlanga J, Gómez JA, Audain E, Reyes V, Perera-Negrín Y, Perea SE, Reyes O and González LJ. Center for Genetic Engineering and Biotechnology, Havana, Cuba. IP-17: ISOLATION OF A HUMAN NEUTRALIZING ANTIBODY FRAGMENT AGAINST A NOVEL EPITOPE ON VASCULAR ENDOTHELIAL GROWTH FACTOR. Lamdan H, Gavilondo J.V, Muñoz Y, Pupo A, Huerta V, Musacchio A, Pérez L, Morera Y, Ayala M, Rojas G, Balint R.F, Larrick J.W Center for Genetic Engineering and Biotechnology, Havana, Cuba. IP-18: DEMONSTRATION OF THE ROLE OF GM3 (NEU5GC) ON THE TUMORIGENICITY OF A MOUSE LYMPHOCYTIC LEUKEMIA B CELL LINE: VALIDATION OF A TARGET FOR CANCER IMMUNOTHERAPY. Casadesús A, Fernández-Marrero Y, Clavell M, Gómez J, Hernández T, Moreno E, López-Requena A. Center of Molecular Immunology (CIM), Havana, Cuba. IP-19: HEBERPROT-P, HOPE AND A BETTER QUALITY OF LIFE. FULL PRECLINICAL PROGRAM. Bacardí D, Cosme K, Suárez J, Ancizar J, Renault JI, Madrigal R, Romero JC, Urquiza D, Aldana L, Martínez H, Berlanga J, López E, Acevedo B, Casado JL, Herrera L. Center for Genetic Engineering and Biotechnology, Havana, Cuba. IP-20: STICHOLYSINS, PORE FORMING TOXINS AS IMMUNOMODULATOR FOR ENHANCING CTL MEDIATED IMMUNE RESPONS Laborde R, Fernández A, Cruz-Leal Y, Oliver L, Luzardo MC, Mesa C, del Valle A, Álvarez C, Alonso ME, Abreu-Butin L, Longo-Maugéri I, Fernández LE and Lanio ME. Center for Protein Studies and Department of Biochemistry, Havana University, Cuba. IP-21: HIGH THROUGHPUT FUNCTIONAL EPITOPE MAPPING: REVISITING PHAGE DISPLAY PLATFORM TO SCAN TARGET ANTIGEN SURFACE Infante YC, Tundidor Y, Rojas G. Center of Molecular Immunology, Havana, Cuba. 58 IMMUNOPHARMACOLOGY - VACCIPHARMA 2015 IP-22: STICHOLYSINS, PORE-FORMING TOXINS ENHANCE THE ANTIGEN CROSS- PRESENTATION: A COMPARISON WITH LISTERIOLYSIN O Cruz-Leal Y, Laborde R, Viana CS, Grubaugha D, Fernández A, Oliver L, Mesa C, Escalona F, Álvarez C, Higgins D, Fernández LE and Lanio ME. Center for Protein Studies and Department of Biochemistry, Havana University, Cuba. IP-23: EVALUATION OF SAFETY AND THERAPEUTIC EFFECT OF ITOLIZUMAB IN PATIENTS WITH SEVERE PSORIASIS. Marrero Y, López I , Mantecón B, Gómez Y, Cardoso Ll. Manuel Ascunce Domenech» General Teaching Hospital. Camagüey. Cuba. IP-24: ISOLATION AND PRELIMINAR CARACTERIZATION OF NATURAL-LIKE MONOCLONAL ANTIBODIES REACTIVE TO A TUMOR-ASSOCIATED GANGLIOSIDE Nely Rodríguez, Rabade-Chediak M. , Martínez D., Griñán T, Rondón T, Hernández AM. Center of Molecular Immunology, Havana, Cuba. IP-25: ANTITUMORAL EFFECT OF STICHOLYSIN II, A PORE FORMING PROTEIN, ON TUMORAL CELLS IN VITRO AND IN VIVO Soto C, Del Valle A, Blanco R, Bencomo A, Griñan A, González A, Rodríguez J.C, Viera J, Lanio M1, Álvarez C, Hernandez A.M. Center of Molecular Immunology, Havana, Cuba. IP-26: ANTITUMOR EFFECT OF GM3-CONTAINING NANOPARTICLES-BASED VACCINES ON MICE UNDER BOTH, LEUKOPENIC CONDITIONS AND IMMUNOSUPPRESSED BY THE PRESENCE OF A TUMOR. Oliver L1, Fernández A, Raymond J, Fernández LE, Mesa C. Center of Molecular Immunology, Havana, Cuba. IP-27: PROGNOSTIC ROLE OF LOCAL IMMUNE INFILTRATE IN PATIENTS WITH COLON CANCER Calvo A, Lahera T, Torres G, Rengifo CE, de Armas MC, Quintero S, Danta D, Vázquez JM and Escobar X. Department of Cell Biology and Tissues Banking, National Institute of Oncology, Havana, Cuba. IP-28: HUMAN MONOCLONAL ANTIBODIES ISOLATED FROM CANCER PATIENTS RECOGNIZE TUMOR CELLS Tania Griñán, Hernández AM. Center of Molecular Immunology (CIM), Havana, Cuba. IP-29: N-GLYCANS BEARING SLEX EPITOPE AS GLYCOMARKER OF PROSTATE CANCER PROGRESION IN PATIENTS TREATED WITH HEBERPROVAC Cabrera G, González-Hernández A, Enríquez Y, Montesino R, Triguero A, Fuentes F, Calzada L, Junco J. Center for Genetic Engineering and Biotechnology, Havana, Cuba. 59 IMMUNOPHARMACOLOGY - VACCIPHARMA 2015 IP-30: POTENTIAL BIOMARKERS IN PATIENTS WITH CERVICAL CANCER STAGE IB2/II TREATED WITH CIGB-300. Reyes V, Perera Y, Ancizar J, Suarez J, García I, Valenzuela C, Baladrón I, Solares AM, Sarduy MR, Alonso D, Gómez D, López-Saura P, Perea S. Center for Genetic Engineering and Biotechnology, Havana, Cuba. IP-31: EVALUATION OF INTRAVENOUS CIGB-300 IN PATIENTS REFRACTORY TO ONCOSPECIFIC TREATMENTS WITH SOLID TUMORS. PHASE I CLINICAL TRIALS Noyde B., Soriano J., Lima M, Neninger E, Caballero I, García R., Ugando E., Cáceres H., González L. Reyes V., Méndez L., Raices I., Valenzuela C. Álvarez L., Fernández E., Perera Y., Martin Y., de la Torre A., de la Torre J., Catalá M., Izquierdo M. García I. Rosales Y., López P., Alonso D., Gómez R., Acevedo B., Perea SE., Muzio VL., TS-300 group. Oncology Department, Hermanos Ameijeiras Hospital, Havana, Cuba. IP-32: PHARMACOMETRIC APPROACH TO SUPPORT DOSING STRATEGY OF NIMOTUZUMAB IN PATIENTS WITH ADVANCED BREAST CANCER. Rodríguez L., Ramos M., Fernández E., Soriano J., Peraire C., Castañeda G., Jacobo C., de Castro N. and Colom H. Laboratory of Pharmacokinetic, Department of Pharmacology & Clinical Pharmacy, Institute of Pharmacy & Foods, Havana, Cuba. IP-33: CYTOKINE PATTERN INDUCED BY CRYPTOCOCCUS NEOFORMANS AND CRYPTOCOCCUS GATTII SPECIES COMPLEX Illnait-Zaragozí MT, Schoffelen T, Meis JF, Martínez G, Fernández C, Perurena M, Sprong T, Netea MG. Instituto de Medicina Tropical Pedro Kourí; Havana, Cuba. IP-34: DIAGNOSIS OF RHEUMATIC DISEASES AUTOINMUMNES THROUGH RHEUMATOID FACTOR IN THE GENERAL HOSPITAL OF BENGUELA, ANGOLA. Cardosa E, Aguilar I. Universidad de Ciencias Médicas Guantánamo, Cuba. IP-35: INFLAMATORY TUMORS IN THE CENTRAL NERVOUS SYSTEM. CASE REPORT Vaquer JE, Morales Y. Arnaldo Milián Castro Hospital, Villa Clara, Cuba. IP-36: SAFETY NIMOTUZUMAB IN THE TREATMENT OF HEAD AND NECK TUMORS IN ADVANCED STAGES IN CAMAGUEY Ramírez M, Margenat A, Infante E, de Quesada L, Álvarez A, Vila L. CPEC. Medical University. Camagüey. 60 IMMUNOPHARMACOLOGY - VACCIPHARMA 2015 IP-37: EFFECTIVENESS AND SAFETY ASSESSMENT OF HEBERPAG USE IN BASOCELLULAR CARCINOMA PATIENTS Batista K, Pérez E, Guerra O, Bello I, Patino Y Mario Gutiérrez Ardaya Clinical. Holguín. Cuba. IP-38: ANAPHYLAXIS TO ANTIMICROBIAL DRUG. CUBA, 2003-2014 Alfonso I, Jiménez G. National Centre for State Quality Control of Drugs, (CECMED, Havana, Cuba. IP-39: PHARMACOKINETICS AND PHARMACODYNAMICS OF PEGYLATED RECOMBINANT HUMAN ERYTHROPOIETIN (EPOFX1) IN RABBITS. Reynaldo G, Solozábal J, Becquer M, Colom Y, Gill A, Amaro D and Fernández E Department of Pharmacology & Clinical Pharmacy, Institute of Pharmacy & Foods. University of Havana, Havana, Cuba. IP-40: OPEN STUDY, PERILESIONAL AND INTRALESIONAL APPLICATION OF CIGB-128 (HEBERPAG) IN CUTANEOUS SQUAMOUS CELL CARCINOMA, STAGE I AND II». PRELIMINARY FINDINGS. Duncan Roberts Y, Álvarez Escobar PA, Salazar Sedano M, Castro Basart N, Arteaga Hernández E, Campollo Rodríguez I, Rodríguez Rojas JL, Tuero Iglesias A, García Vega Y, Bello Rivero I. Center for Genetic Engineering and Biotechnology, Havana, Cuba. IP-41: PETIVERIA ALLIACEA L HYDRO-ALCOHOLIC CRUDE EXTRACT IN VITRO ACTIVITY IN CANDIDA CLINIC ISOLATES. Velar RE, Illnait-Zaragozí MT, Illnait J, Fernández CF, Martínez GF, Perurena MR, Monroy EX, MeisJFG. Mycology Laboratory; Tropical Medicine Institute «Pedro Kourí» (IPK), Havana, Cuba. IP-42: BLOCKING IL-2 SIGNAL IN VIVO WITH AN IL-2 ANTAGONIST REDUCES TUMOUR GROWTH THROUGH THE CONTROL OF REGULATORY T CELL EXPANSION. Carmenate T, Ortiz Y, Enamorado M, Graca L, García-Martínez K, León L. Center of Molecular Immunology, Havana, Cuba. IP-43: FEASIBILITY EVALUATION AND NEW DESIGN TO DETERMINE SAFETY AND EFFECTIVENESS OF NIMOTUZUMAB IN ADVANCED ESOPHAGEAL TUMORS OF EPITHELIAL ORIGIN Saumell Y, Viada CE, Santiesteban Y, Arencibia M, Torres O. Center of Molecular Immunology, Havana, Cuba. 61 IMMUNOPHARMACOLOGY - VACCIPHARMA 2015 IP-44: PHARMACOKINETICS EVALUATION OF HUMANIZED MONOCLONAL ANTIBODY ANTI EPIDERMAL GROWTH FACTOR RECEPTOR NIMOTUZUMAB IN PATIENTS WITH AUTOSOMAL DOMINANT POLYCYSTIC KIDNEY DISEASE de Castro N., Rodríguez L., Villegas C., Dávalos J., Bacallao R. and Ramos M Laboratory of Biopharmaceutics, Department of Pharmacology & Toxicology, Institute of Pharmacy & Foods, University of Havana, Havana, Cuba. IP-45: IMMEDIATE RESPONSE OF HORMONAL FUNCTION DURING CIGB-128 PHARMACO-KINETICS. Valdés, M; Alonso, C.; García, Y. Hermanos Ameijeiras Hospital, Havana,Cuba. IP-46: EVALUATION OF AN ANIMAL MODEL FOR THE DETERMINATION OF THE BIOLOGICAL ACTIVITY OF THE RACOTUMOMAB ANTI-IDIOTIPIC VACCINE Jay D, Fuentes D, Santo Tomás JF, Acosta E, Soto D, Somoza N, Contreras B, Contreras F, Portillo A, Vázquez AM. National Center for Laboratory Animals Breeding (CENPALAB), Cuba. IP-47: LEVELS OF CYTOKINES INDUCED BY CUBAN SCORPION VENOM ROPHALURUS JUNCEUS. Yglesias A, Díaz-García A, Rodríguez H, Rodríguez L LABIOFAM, Havana, Cuba. IP-48: LIPOSOMAL ENCAPSULATION OF HOUSE DUST MITE ALLERGENS AND DEXAMETHASONE MODULATES ALLERGIC RESPONSE IN A MURINE MODEL OF ASTHMA. Pérez-Llano Y, Ramírez W, Calcines C, Hechavarría M, Cazanave D, Laborde R, Cruz-Leal Y, Morejón A, Bourg V, Gómez E, Russo M, Labrada A, Luzardo MC Center for Protein Studies (CEP), Faculty of Biology, University of Havana. Havana, Cuba. IP-49: CHARACTERIZATION OF HYPERSENSITIVITY ADVERSE REACTIONS. CUBA 2003-2013. Jiménez López G, Alfonso Orta I. National Centre for State Control of Drugs, Equipments and Medical Devices (CECMED), Havana, Cuba. IP-50: CIGB-300: PRECLINICAL STUDIES IN LUNG CANCER MODELS. Fernando R. Benavent Acero, Yasser Perera, Silvio E. Perea, Stéfano M. Cirigliano, Alejandro Urtreger, Daniel F. Alonso, Daniel E. Gomez, Hernán G. Farina. Laboratory of Molecular Oncology, National University of Quilmes, Buenos Aires. Argentina. IP-51: EXPRESSION OF MYCOBACTERIUM LEPRAE HSP65 IN TOBACCO AND ITS EFFECTIVENESS AS AN ORAL TREATMENT IN ADJUVANT-INDUCED ARTHRITIS. César Rodríguez-Narciso, Mayra Pérez-Tapia, Rosa María Rangel-Cano, Celio L. Silva, Mariana MeckesFisher, Rafael Salgado-Garciglia, Sergio Estrada-Parra, Rodolfo López-Gómez, Iris Estrada-García. Instituto de Investigaciones Químico-Biológicas, Universidad Michoacana de San Nicolás de Hidalgo, Michoacán. 62 IMMUNOPHARMACOLOGY - VACCIPHARMA 2015 IP-52: PHARMACOKINETICS AND RESIDUES OF AMOXICILLIN AND AMPICILLIN IN MILK OF LACTATING COWS AND THEIR POSSIBLE INTERACTIONS WITH IMMUNE SYSTEM AFTER INTRAMAMMARY ADMINISTRATION. Kowalski C, Burmañczuk A, Zañ R, Pormorska-Mól M, Giorgi M Sub-Department of Pharmacology, Department of Preclinical Veterinary Sciences Faculty of Veterinary Medicine, University of Life Sciences, Poland. IP-53: IMMUNOMODULATORY PROPERTIES OF ALLICIN IN MURINE LYMPHOMA. Padilla I, Martínez M, Lazcano E, Gutiérrez Y. Centro de investigación y Asistencia en Tecnología y Diseño del Estado de Jalisco, México. IP-54: ORAL ADMINISTRATION OF CRY1AC TOXIN INDUCE EFFECTS RELATED TO THE INTESTINAL ALLERGY AND LYMPHOID INTESTINAL HYPERPLASIA. Santos K.I, Ilhucatzi D, Moreno L., Universidad Nacional Autónoma de México, Facultad de Estudios superiores Iztacala, Doctorado en Ciencias Biomédicas, Tlalnepantla, México. IP-55: EFFECTIVENESS AND SAFETY ASSESSMENT OF HEBERON USE IN BASOCELLULAR CARCINOMA PATIENTS Pérez E, Batista K, Guerra O, Bello I, Plutin Y Mariana Grajales Coello Medical School. Holguín, Cuba. IP-56: ANTITUMOR ADJUVANT EFFECT OF THE PROTOXIN Cry1Ac IN A MOUSE MODEL OF BREAST CANCER. Servin G. R. R., Ilhuicatzi A. D., Moreno F. L. Laboratorio 9 Inmunidad en mucosas, UBIMED, Facultad de Estudios Superiores Iztacala, Av. De Los Barrios 1, 54090 Tlalnepantla, México. Universidad Nacional Autónoma de México. IP-57: MAKING SENSE OF CLINICAL TRIAL DATA: CORRECTING FOR SWITCHING TO SECOND LINE TREATMENT IN THE SURVIVAL ANALYSIS. Sánchez L, Lorenzo-Luaces P, Crombet T Center of Molecular Immunology, Havana, Cuba. Workshop of Neuroimmunology Chairs: IP-58: EFFECT OF DANCE AS THERAPEUTIC INTERVENTION FOR PATIENTS WITH SPINAL CORD INJURY. Caren Luciane Bernardi, Maria de Los Angeles Robinson, Regina Biasibetti, Carlos Alberto Gonçalves. UFRGS. Brazil. 63 IMMUNOPHARMACOLOGY - VACCIPHARMA 2015 IP-59: BRAIN HYPOXIA-ISCHEMIA OUTCOMES in rats ARE PREVENTED BY SWIMMING PROTOCOL DURING PREGNANCY Sanches, E.F.; Carabali, L.E, Tosta A., Rodrigues A., Schmidt, F, Siebert, C., Netto C.A, Wyse A.T. Department of Biochemistry, Instituto de Ciências Básicas da Saúde, Universidade Federal do Rio Grande do Sul, Porto Alegre, RS, Brazil. IP-60: A PANEL OF BRAIN DERIVED PROTEINS, INFLAMMATORY AND CELL DAMAGE MARKERS TO PREDICT SEVERITY OF STROKE AND PROGNOSIS. González García S, González-Quevedo A, Peña Sánchez M, Fernández Almirall I, Cordero Eiriz A, Menéndez Saínz MC, Fernández Carriera R. Institute of Neurology and Neurosurgery. Havana, Cuba. IP-61: SERUM INTERLEUKIN: 10, 17 AND TNF AND PARKINSON’S DISEASE. Pavón N, Lorigado L, León R, Álvarez M, Blanco L, Macías L, Pentón G. Centro Internacional de Restauración (CIREN). Neurológica, Cuba. IP-62: BEHAVIOURAL CHANGES AND OXIDATIVE STRESS IN ANIMAL MODEL OF AUTISM INDUCED BY PRENATAL EXPOSURE TO VALPROATE González Fraguela ME, Nardin P, Bernardi C, Galland F, Vega Hurtado Y, Gonçalves CA and RobinsonAgramonte MA. International Center for Neurological Restoration (CIREN). Havana. Cuba. IP-63: MORPHOLOGICAL AND FUNCTIONAL EVALUATION OF A MODEL OF FOCAL CEREBRAL ISCHEMIA INDUCED BY ENDOTHELIN-1. León R. Pavón N, Almaguer W, Lorigados L, Estupiñán B, Blanco L, Merceron D, Macías L, Ramírez M, García A International Center for Neurological Restoration (CIREN). Havana. Cuba. IP-64: THE IMMUNOHISTOCHEMISTRY UTILITY IN DIAGNOSIS OF PHARMACORESISTANT FOCAL EPILEPSY. Bárbara Estupiñán Díaz, Lourdes Lorigados Pedre, Lilia Morales Chacón, Iván García Maeso, Margarita Báez Martín, María Eugenia García Navarro, Nelson Quintanal Cordero, Juan E, Bender del Busto, Isabel Fernández Jiménez. International Center for Neurological Restoration (CIREN). Havana. Cuba. IP-65: SOMATOSENSORY EVOKED POTENTIALS IN CHILDREN WITH AUTISTIC SPECTRUM DISORDERS Ivette Cabrera, Margarita Báez, Lilia Morales, Reynaldo Galvizu, Carlos Maragoto, Héctor Vera, Ma. de los Ángeles Ortega. Clinical Neurophysiology Service. International Center for Neurological Restoration (CIREN). Havana, Cuba. 64 IMMUNOPHARMACOLOGY - VACCIPHARMA 2015 IP-66: PRACTICE GUIA FOR THE EVALUATION OF IMMUNE SYSTEM IN FARMACORESISTENT EPILEPSY. Lorigados L, Pavón N, Serrano T, Robinson MA, Morales L, Rocha L, Orozco S, Asiel López International Center for Neurological Restoration (CIREN). Havana. Cuba. IP-67: CEREBROSPINAL FLUID (CSF) PROTEIN ELECTROPHORESIS IN THE INSTITUTE OF NEUROLOGY AND NEUROSURGERY. MAIN FINDINGS IN 10 000 CSF SAMPLES. Fernández Carriera R, González-Quevedo A, González García S, Peña Sánchez M, Fernández Almirall I, Cordero Eiriz A, Menéndez Saínz MC. Institute of Neurology and Neurosurgery. Havana, Cuba. IP-68: SENSORY-MOTOR PERFORMANCE AFTER ACUTE GLUTATHIONE DEPLETION BY L-BUTHIONINE SULFOXIMINE INJECTION INTO SUBSTANTIA NIGRA PARS COMPACTA Martínez López JG, Díaz-Hung ML, Blanco L, González M, Orta E. International Center for Neurological Restoration (CIREN), Havana, Cuba. IP-69: ELECTROENCEPHALOGRAPHS DISCOVERIES AND CHARACTERISTICS OF SLEEPING IN THE CHILD AUTISM WITHOUT EPILEPSY Ramos L and Whilby M Hospital Pediátrico del Cerro, Havana, Cuba. IP-70: PHARMACOLOGIACAL INTERVENTION WITH RISPERIDONE IN AUTISTIC PATIENTS Whilby M, Annia Duany Navarro and Leyani Ramos Hernández Hospital Docente Pediátrico del Cerro, Havana, Cuba. IP-71: NUTRITION AND IMMUNOLOGICAL PARAMETERS IN THE REHABILITATION OF SPINAL CORD TRAUMA Zamora F, González C, Hernández E, Díaz A, Álvarez C. International Center for Neurological Restoration (CIREN), Havana, Cuba. IP-72: INFLUENCE OF PHYSICAL REHABILITATION IN THE IMMUNE RESPONSE OF PATIENTS WITH SPINAL CORD TRAUMA IN PEDIATRIC AGE. González C, Zamora F. International Center for Neurological Restoration (CIREN). Havana. Cuba. IP-73: NEUROPROTECTION IN A MODEL OF AUTISM TRANSPLANTED WITH BONE MARROW CELLS Yamile Vega Hurtado, Dunia Lee Mustelier, Esteban Alberti-Amador E, María Elena González Fraguela, Robinson-Agramonte M A. International Center for Neurological Restoration (CIREN). Havana. Cuba. IP-74: SELF-ESTEEM LEVELS IN CUBAN PATIENTS WITH SYSTEMIC ERYTHEMATOSUS LUPUS DIAGNOSIS María Eugenia Lánigan Gutiérrez. Hospital Clínico Quirúrgico Joaquín Albarrán. Cuba. 65 IMMUNOPHARMACOLOGY - VACCIPHARMA 2015 IP-75: RAPID NON-ENZYMATIC METHOD FOR MOLECULAR TYPING OF SACCHAROMYCES CEREVISIAE BY PULSED FIELD MINIGEL ELECTOPHORESIS UNI AND BY TWO-DIMENSIONAL. Santamaría Y, León K, Manrique V, Arencibia O, López-Cánovas L. Centro de Neurociencias de Cuba. IP-76: TRAINING PATIENTS WITH MULTIPLE SCLEROSIS FOR USE INTERFERON. D.Grass Fernández,.J A. Cabrera., A . González Quevedo International Center for Neurological Restoration (CIREN). Havana. Cuba. IP-77: NEUROPATHOLOGY, BIOCHEMICAL MARKERS AND DISEASES LYSOSOMAL. Larrinaga Vicente, Lázara Emma, Acosta Sánchez, Tatiana Menéndez Saínz Mary Caridad, Dialys Rodríguez Torres, Miranda Romero, Misleidys. National Genetics Centro Medical / Laboratory of Biochemical Genetics, Havana, Cuba. IP-78: THE NEUROPROTECTIVE EFFECT OF ERYTHROPOIETIN IN AUTISM MODEL IN RATS. Becquer María de los Angeles, Adonis Armenteros López, Hurtado Vega Yamile, González Fraguela María Elena, and María Robinson-Agramonte. INSTITUTE OF PHARMACY & FOODS, HAVANA, CUBA. Havana University. IP-79: EFFECT OF NEUROTOXIC LESION OF PEDUNCULOPONTINE NUCLEUS IN NIGRAL AND STRIATAL REDOX BALANCE AND MOTOR PERFORMANCE IN RATS. Lisette Blanco, Javier Jiménez, Ma. Elena González, Mei-Li Díaz , Teresa Serrano, Yoel Lacerda, Liliana Francis. International Center for Neurological Restoration (CIREN). Havana. Cuba. IP-80: IN SILICO STUDY OF THE INTERACTION BETWEEN b-AMYLOID PEPTIDE AND NAPHTHALENEDERIVATIVE COMPOUNDS: A FIRST STEP ON THE DISRUPTION OF AMYLOID AGGREGATION. Bencomo A, Rodríguez-Tanty C, Álvarez-Ginarte Y, Sablón-Carrazana M, Pupo A. Cuban Neuroscience Center, Havana, Cuba. IP-81: IFN-γγ AND C-PHYCOCYANIN COMBINATION IN VITRO IMMUNOMODULATORY RESPONSES. Cervantes-Llanos M, Alonso-Ramírez R, De Feo D, Cabrera Gómez JA, Valenzuela-Silva C, Llópiz Arzuaga A, Milian Jordan A, Ruffini F, Brambilla E, Martino G,Pentón-Rol G. Center for Genetic Engineering and Biotechnology (CIGB), Havana, Cuba. IP-82: VALPROIC ACID AND LAMOTRIGINE EFFECTS IN ELECTRIC CEREBRAL ACTIVITY OF JUVENILE MYOCLONIC EPILEPSY PATIENTS. Ivonne Jiménez, Maydelin Alfonso, Raúl Valdez. International Center for Neurological Restoration (CIREN). Havana. Cuba. 66 IMMUNOPHARMACOLOGY - VACCIPHARMA 2015 IP-83: IMPACT OF PLANT DERIVED FLAVONOIDS ON GLIA MODULATION AND NEURODEGENERATIVE DISEASES. Souza C.S., Santos, C.C., Borba F., Grangeiro M.S., Silva V.D.A., Costa S.L. Laboratory of Neurochemistry, Health Sciences Institute, Federal University of Bahia, Brazil. IP-84: IN VITRO INFECTION OF GLIA/NEURON CO-CULTURES BY NEOSPORA CANINUM: POSSIBLE ROLES OF INOS, IDO AND COX-2 IN IMMUNO MODULATION. Santos, A.B.; Arruda, M.R.; Jesus, L.B.; Freitas, S. C. M.; Jesús, E.E.V.; Cunha, E.F.S. and Costa, M.F.D. Laboratório de Neuroquímica e Biologia Celular-Federal University of BahiaINCT- Instituto Nacional de Neurociências Translacional/CNPq Brazil. IP-85: MATERNAL SWIMMING AS A NEUROPROTECTIVE STRATEGY IN A ADHD MODEL USING SPONTANEOUS HYPERTENSIVE RATS. Tosta A, Bernardi C, Sanches E, Gonçalves C.A. Universidad e Federal do Rio Grande do Sul –Porto Alegre/ RS, Brasil. IP-86: A NOVEL POTENT ANTIOXIDANT, DERIVATIVE ARILIDENMALONATE: CHARACTERIZATION OF THE NEUROPROTECTIVE PROPERTIES IN VIVO MODELS OF PARKINSON’S DISEASE. Fonseca Fonseca LA, Núñez Figueredo Y, Ramírez Sánchez J, García Pupo L, Wong Guerra M, Ochoa Rodríguez E, Verdecia Reyes Y, Amaral da Silva VD, Delgado Hernández R, Lima Costa S. Centro de Investigación y Desarrollo de Medicamentos, Havana, Cuba. IP-87: NEUROPROTECTIVE EFFECT OF JM-20, A NOVEL MULTI-TARGET LIGAND, IN DIFFERENT EXPERIMENTAL MODELS RELATED TO CEREBRAL ISCHEMIA. Nuñez Y, Ramírez J, Onofre D, Loureiro S, Salbego C, Hansel G, Delgado R, Ochoa E, Verdecia Y, Costa L, Merino N, Pardo G Centro de Investigación y Desarrollo de Medicamentos, Havana, Cuba. IP-88: EFFECT OF JM-20 AGAINST COGNITIVE DEFICITS INDUCED BY SCOPOLAMINE IN RATS. Wong G, Jiménez J, de Assis A, Onofre D, Delgado R, Ochoa E, Verdecia Y, Fonseca L, Ramírez J, García L, Pardo G, Núñez Y. Centro de Investigación y Desarrollo de Medicamentos, Havana, Cuba. IP-89: DISCERNING THE ANTIOXIDANT MECHANISM OF RAPANONE RELATED TO ITS IRON BINDING AND ROS SCAVENGING ACTIVITY: A PROMISING THERAPEUTIC APPROACH IN NEURODEGENERATIVE DISEASES de la Vega-Hernández K1, FonsecaL2, Núñez-FigueredoY2, Delgado-Hernández R2, AntuchM3, CuestaRubio O4, Pardo-Andreu GL5. INSTITUTE OF PHARMACY & FOODS, HAVANA, CUBA. Havana University. Havana, Cuba. 67 IMMUNOPHARMACOLOGY - VACCIPHARMA 2015 IP-90: NEUROPROTECTOR EFFECTS OF NEURO-EPO IN AMYLOID TOXICITY IN THE Aß 25-35 NONTRANSGENIC MOUSE MODEL OF ALZHEIMER’S DISEASE. Yamila Rodríguez Cruz, Julio César García Rodríguez; and Nibaldo Hernández Mesa. Histology Department from Havana Medical School University. Havana, Cuba. IP-91: IMMUNEREGULATORY PHENOTYPE SHIFT BY BEE APIS ACCUPUNCTURE IN PRIMARY PROGRESIVE MULTIPLE SCLEROSIS (PPMS). Abuín A., Fernández F., Milián L., Rodríguez Y. Matanzas Medical Science Universisty, Cuba. IP-92: EVALUATION OF THERAPEUTIC EFFECT OF HUMAN MESENCHYMAL STEM CELLS DERIVED FROM BONE MARROW IN CULTURE IN A MODELS OF FOCAL ISCHEMIC INJURY INDUCED BY THERMOCOAGULATION. Lee, Dunia; Almaguer, William; Vega, Yamile; de la Cuétara, Karelys; López, Asiel; Estupiñan, Bárbara; Fernández, Isabel. International Center for Neurological Restoration (CIREN), Havana, Cuba. IP-93: AUTOIMMUNE NEUROPATHIES. PHYSIOPATHOLOGYCAL REVIEW AND ELECTROPHYSIOLOGYCAL EXPRESSION Hernández A Clinical Neurophysiology Department. CCOI «Frank País», Cuba. IP-94: AUTO ANTIBODIES AGAINS BRAIN ANTIGENS AS ALZHEIMER’S DISEASE BIOMARKERS, EFECT OF APOE4 ALLELE Manrique Suárez V, Sosa S, Fernández Y, Urrutia N, Álvarez Y, Cristiá L, Doreste M, Ruiz E, Bobes MA, Posada A, Rodríguez-Tanty C. Cuban Neurosciences Center. Symposium of Atherosclerosis Chairs: IP-95: THE INVOLVEMENT OF RGS5 IN THE ANTI-ATHEROSCLEROTIC ACTIVITIES OF RED GINSENG WATER EXTRACT Rhee MH, Kim TH College of Veterinary Medicine, Kyungpook National University, Korea. IP-96: THERAPEUTIC EFFECT OF chP3R99 MONOCLONAL ANTIBODY AGAINST LIPOFUNDIN-INDUCED ATHEROSCLEROTIC LESIONS IN RABBITS Acosta E, Delgado L, Álvarez D, Medina JA, Vera M, Noa M, Bécquer MA, Fernández E, Vázquez AM. Center for Advanced Study in Cuba (CEAC), Havana, Cuba. 68 IMMUNOPHARMACOLOGY - VACCIPHARMA 2015 IP-97: KINETIC OF ANTI-ANTI-IDIOTYPE RESPONSE TO CHONDROITIN SULPHATE IN APOE DEFICIENT MICE IMMUNIZED WITH CHP3R99 MAB AT DIFFERENT STAGE OF ATHEROSCLEROSIS PROGRESSION Sarduy R*, Brito V, Soto Y, Griñán T, Viera J, Vázquez AM Center of Molecular Immunology, Havana, Cuba. IP-98: THERAPEUTIC IMMUNIZATION WITH AN ANTI-GLYCOSAMINOGLYCAN ANTIBODY REDUCES ATHEROSCLEROSIS IN MICE BY REGULATING OXIDATIVE STRESS AND INFLAMMATION Brito V, Delgado-Roche L, Acosta E, Pérez A, Fernández J, Hernández Y, Bécquer MA, Griñán T, Soto Y, León O.S, Marleau S, Vázquez AM. Center of Molecular Immunology, Havana, Cuba. IP-99: TARGETING ARTERIAL WALL SULFATED GLYCOSAMINOGLYCANS IN RABBIT ATHEROSCLEROSIS WITH A MOUSE/HUMAN CHIMERIC ANTIBODY Soto Y, Mesa N, Alfonso Y, Pérez A, Batlle F, Griñán T, Pino A, Viera J, Frómeta M, Brito V, Olivera A, Zayas F and Vázquez AM. Center of Molecular Immunology, Havana, Cuba. IP-100: HYPOCHOLESTEROLEMIC AND ANTI-ATHEROSCLEROTIC EFFECTS OF CRUDE LEAF EXTRACT OF MORINGA OLEIFERA IN APOE KO MICE Fuentes D, Fernández N, Díaz BL, León A, Blanco D, Gutiérrez M, García A, Ronda M, Prida Y, Torres Y, Cabezas L. National Center for Laboratory Animal Breeding (CENPALAB), Havana, Cuba. IP-101: MONOCLONAL ANTIBODIES WHICH DISCRIMINATE BETWEEN NATIVE AND OXIDIZED LOW DENSITY LIPOPROTEINS. Bebelagua Y, Rodríguez KM, Vázquez AM. Center of Molecular Immunology, Havana, Cuba. IP-102: USING PERSONALIZED BACH FLOWER THERAPY FOR DIABETIC PATIENTS WITH DYSLIPIDEMIA Mahía M, Diaz A, Quintela A, Hernández J, Arpajón Y, Llano Y. National Institute of Angiology and Vascular Surgery, Calzada del Cerro 1551, Cerro, Havana, Cuba. IP-103: PHYSIOLOGICAL AND PATHOLOGICAL COMPARISON BETWEEN 2, 8 AND 15 MONTH OLD APOE KO MICE FED WITH NORMAL DIET AS MODEL OF ATHEROSCLEROSIS. Fernández N, Beausoleil I, Jay D, Díaz BL, Brooks L, León A, García A, Ronda M, Gutiérrez M, Torres Y, Rodríguez M, Fuentes D National Center for Laboratory Animal Breeding (CENPALAB), Havana, Cuba. 69 IMMUNOPHARMACOLOGY - VACCIPHARMA 2015 IP-104: THE THERAPEUTIC IMMUNIZATION WITH AN ANTI-GLYCOSAMINOGLYCAN ANTIBODY ATTENUATES OXIDATIVE STRESS IN ATHEROSCLEROTIC RABBITS Hernández Y 1, Delgado-Roche L2, Dalia R. Álvarez 1, Vázquez AM 3. Center of Studies for Research and Biological Evaluations, Pharmacy and Food Sciences Institute, University of Havana, Havana, Cuba. Symposium of Inflammation and Pain Chairs: IP-105: ANTI-INFLAMMATORY EFFECT OF THE ETHANOLIC EXTRACT OF SOLANUM DIPLOCONOS FLOWERS IN MICE. Ivonilce Venturi, Livan Delgado-Roche, Ivones Hernández, Angela Malheiros, Idania Rodeiro. Department of Pharmacology, Center of Marine Bioproducts, Havana, Cuba. IP-106: ANTI-DIABETIC, ANTIOXIDANT AND ANTI-INFLAMMATORY EFFECTS OF MOMORDICA CHARANTIA L PLANT EXTRACT. Bellma A, Lagarto A, Menéndez R, Wong M , Aparicio G, Merino N, Valdés O, López O, Casanave D and Nogueiras A. Centro de Investigación y Desarrollo de Medicamentos (CIDEM). Havana, Cuba. IP-107: COMPARATION OF ANTI-INFLAMMATORY ACTIVITY OF 2-ALKYL AND 2-BENCYL-5NITROINDAZOLINONES Siverio-Mota D, Andújar I, Marrero-Ponce Y, Giner RM, Vicet-Muro L, Herrera-Pis Y, Cordero-Maldonado ML, de Witte PAM, Crawford AD, Sylla-Iyarreta-Veitía M, Arán VJ Unit of Computer-Aided Molecular «Biosilico» Discovery and Bioinformatic Research (CAMD-BIR Unit), Faculty of Chemistry-Pharmacy, Universidad Central «Marta Abreu» de Las Villas, Villa Clara, Cuba. IP-108: PERCUTANEOUS ASPIRATION AND OZONO APLICATION INTO LUMBAR FACET JOINT CYSTS Valdes-Llerena R. Garbey-Fernández R, Gómez-Monduy Y. Anaesthesiology Neurosurgery Service of International Center for Neurological Restoration (CIREN), Havana, Cuba. IP-109: ANTI-INFLAMMATORY EFFECT OF ONE EXTRACT FROM ULVA FASCIATA A MACRO ALGA IN MICE. Fernández M.D, Hernández I., Hernández Y., Cuellar C., del Vallin T., Rodeiro I. Department of Pharmacology, Center of Marine Bioproducts (CEBIMAR), Havana, Cuba. 70 IMMUNOPHARMACOLOGY - VACCIPHARMA 2015 Symposium on Pharmacology of Cytochrome P450, transporters and Omics Chairs: IP-110: IN VITRO MODULATION OF CYTOCHROME P450 ENZYMES BY CUBAN NATURAL PRODUCTS. Pérez C.L., Donato M.T., Herrera J.A., Marrero E., González K., Gómez-Lechón M.J., Rodeiro I. Institute for Basic and Preclinical Sciences ¨Victoria de Girón¨, Havana, Cuba. IP-111: IN VITRO AND IN VIVO REVERSAL OF P-GLYCOPROTEIN MEDIATED MULTIDRUG RESISTANCE BY THALASSIA TESTUDINUM EXTRACT, A NATURAL PRODUCT WITH ANTI-TUMOR PROPERTIES. Hernández I, Rodeiro I, Labrada M., Delgado L., Herrera J.A., Fernández MD, Carr A., Delgado R. , Vanden Bergue W., Lopes M.T. Center of Marine Bioproducts (CEBIMAR), Havana, Cuba. IP-112: ULVA FASCIATA EXTRACT MODULATES CYTOCHROME P450 ENZYMES ACTIVITY IN RAT HEPATOCYTES. Herrera M.E., Pérez C.L., Donato M.T., Hernández I., Herrera J.A., Hernández Y., Gómez-Lechón M. J., Rodeiro I. Department of Pharmacology, Center of Marine Bioactives, Havana, Cuba. IP-113: ULVA FASCIATA PROTECTS AGAINST GENETIC DAMAGE CAUSED BY BENZO(A)-PIRENE. Fernández G. 1, Pérez C.L. 1, Hernández Y. 2, Fernández M.D. 2, Rodeiro I.2. Institute for Basic and Preclinical Sciences ¨Victoria de Girón¨, Havana, Cuba. IP-114: EFFECTS OF THALASSIA TESTUDINUM EXTRACT ON P450 SYSTEM IN THE LIVER WISTAR RATS: IMPACT ON THE ELIMINATION OF THEOPHYLLINE AND BIOTRANSFORMATION OF BENZO(A)PIRENE. Rodeiro I.1, Hernández S.2, Hernández I.1, Padrón S.3, Herrera J.A.4, Olguín S.2, Camacho R.2, Ronquillo D.2, Menéndez R.3, Fernández M.D.1, Espinosa-Aguirre J.J.2. Departamento de Farmacología, Centro de Bioproductos Marinos (CEBIMAR), Havana, Cuba. IP-115: COMMON VARIANTS AT THE 9q22.23, 14q13.3 AND ATM LOCI, AND RISK OF DIFFERENTIATED THYROID CANCER IN THE CUBAN POPULATION Pereda C M, Lesueur F, Pertesi M , Robinot N, Lence J, Turcios SE, Velasco M, Chappe M, Infante I, Bustillo M, García A, Clero E, Xhaard C, Ren Y, MaillardS, Damiola F, Rubino C, Salazar S, Román G, Rodríguez R, Ortiz RM, De Vathaire F Institute of Oncology and Radiobiology, Havana, Cuba. IP-116: KNOWLEDGE ON PHARMACOGENETICS, GENOMICS AND MOLECULAR DIAGNOSTIC TECHNOLOGIES IN DOCTORS ENTERING MEDICAL RESIDENCIES. Hernández-Betancourt JC. Dr. Ernesto Guevara Hospital, Las Tunas, Cuba. 71 IMMUNOPHARMACOLOGY - VACCIPHARMA 2015 IP-117: NETWORK ANALYSIS REVEALS THE BENEFITS OF INTERFERON BETA AND C-PHYCOCYANIN TREATMENT IN AN EXPERIMENTAL MODEL OF AUTOIMMUNE ENCEPHALOMYELITIS IN C57BL6 MICE. Fernández-Masso JR, Nazabal-Gálvez M, Cervantes-Llanos M, Lagumersindez-Denis N, Llópiz Arzuaga A, Cintado- Benítez, Pentón-Arias E, Pentón-Rol G. Center for Genetic Engineering and Biotechnology,Havana,Cuba. IP-118: GENETIC FACTORS FOR MULTIPLE SCLEROSIS AND NEUROMYELITIS OPTICA IN CUBAN PATIENTS. Fernández-de-Cossío ME, Nazabal M, Cintado A, Díaz T, Hanlet C, Villarreal A, Ale M, Grass D, CervantesLlanos M, Pavón-Fuentes N, Benítez JV, Cabrera-Gómez JA, Pentón-Rol G. Center for Genetic Engineering and Biotechnology, Havana, Cuba. Symposium Hereditary Ataxias Chairs: IP-119: ALTERED REDOX STATUS IN CUBAN PATIENTS WITH SPINOCEREBELLAR ATAXIA TYPE 2 Guevara M, Gil L, Martínez G, Velásquez L. Biopharmaceutical and chemical Group (LABIOFAM), Havana, Cuba. Center for Research and Rehabilitation of Hereditary Ataxias (CIRAH), Holguín, Cuba. IP-120: ROLE OF GLUTATHIONE S-TRANSFERASES IN THE SPINOCEREBELLAR ATAXIA TYPE 2 CLINICAL PHENOTYPE. Almaguer-Gotay D1, Almaguer-Mederos LE, Aguilera-Rodríguez R, Estupiñán-Rodríguez A, GonzálezZaldívar Y, Cuello-Almarales D, Laffita-Mesa JM, Vázquez-Mojena Y. Center for the Research and Rehabilitation of Hereditary Ataxias (CIRAH). 72 IMMUNOPHARMACOLOGY - VACCIPHARMA 2015 NOTES 73 IMMUNOPHARMACOLOGY - VACCIPHARMA 2015 NOTES 74 IMMUNOPHARMACOLOGY - VACCIPHARMA 2015 NOTES 75 IMMUNOPHARMACOLOGY - VACCIPHARMA 2015 NOTES 76
© Copyright 2024